PD-1 binding proteins, VEGF and PD-1 bispecific binding proteins, compositions, and methods of use

Abstract

Bispecific antibodies that bind VEGF and PD-1, pharmaceutical compositions thereof, and methods of use thereof, including methods of inhibiting VEGF and PD-1 biological activities.

Description

Attorney Docket No. CRSN-001WO PD-1 BINDING PROTEINS, VEGF AND PD-1 BISPECIFIC BINDING PROTEINS, COMPOSITIONS, AND METHODS OF USE BACKGROUND

[0001] Vascular endothelial cell growth factor (VEGF) is a potent mitogen for vascular endothelial cells, has been reported as a pivotal regulator of both normal and abnormal angiogenesis. VEGF is a master regulator of angiogenesis during growth and development, as well as in disease states such as cancer, diabetes, and macular degeneration. It is also required for the cyclical blood vessel proliferation in the female reproductive tract and for bone growth and cartilage formation. Cancer is among the most common indications for current VEGF therapies, with FDA and EMA-approved therapies targeting various kinds of cancer. Some examples of current VEGF therapies to address these diseases and conditions include axitinib, bevacizumab, brolucizumab, cabozantinib, lapatinib, lenvatinib, pazopanib, ponatinib, ramucirumab, ranibizumab, regorafenib, sorafenib, sunitinib, and vandetanib.

[0002] Programmed death receptor 1 (PD-1) is an immunoinhibitory receptor primarily expressed on activated lymphocytes (e.g., peripheral CD4+ and CD8+ T cells, B cells and monocytes). Interaction with its ligands has been shown to attenuate T-cell responses both in vitro and in vivo.

[0003] The role of PD-1 in cancer is well established in the literature. The ligands for PD- 1 (Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2)) are constitutively expressed or can be induced in a variety of cell types, including non- hematopoietic tissues as well as various tumor types. Blockade of the interaction between PD-1 and PD-L1, for example, has been shown to enhance tumor-specific CD8+ T-cell immunity and may therefore be helpful in clearance of tumor cells by the immune system. Overall, the PD-1 / PD-L1 pathway is a well-validated target for the development of antibody therapeutics for cancer treatment. SUMMARY

[0004] The instant disclosure relates, in part, to PD-1 binding proteins and bispecific binding proteins that bind (1) VEGF and (2) PD-1.

[0005] In one aspect, provided are programmed death receptor 1 (PD-1) binding proteins comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions: CDR-H1 comprising the amino acid IPTS / 200128829.1 1Attorney Docket No. CRSN-001WO sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 456, 461, or 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 457 or 447; CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 458, 462, or 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 459 or 453; or CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 460, 463, or 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 457 or 447, provided that: if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 446, then CDR-H3 does not comprise the amino acid sequence of 447; if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 452, then CDR-H3 does not comprise the amino acid sequence of 453; and if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 455, then CDR- H3 does not comprise the amino acid sequence of 447.

[0006] In some embodiments, the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs 445, 456, and 457, respectively; SEQ ID NOs 451, 458, and 459, respectively; or SEQ ID NOs 443, 460, and 457, respectively. In some embodiments, the PD-1 binding protein further comprises an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450. In some embodiments, the anti-PD- 1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 302 and 335, respectively; SEQ ID NOs: 302 and 336, respectively; SEQ ID NOs: 302 and 340, respectively; SEQ ID NOs: 302 and 342, respectively; SEQ ID NOs: 302 and 343, respectively; SEQ ID NOs: 302 and 346, respectively; SEQ ID NOs: 306 and 337, respectively; SEQ ID NOs: 306 and 339, respectively; SEQ ID NOs: 306 and 341, respectively; SEQ ID NOs: 306 and 344, respectively; SEQ ID NOs: 306 and 345, respectively; SEQ ID NOs: 306 and 347, respectively; SEQ ID NOs: 308 and 340, respectively; SEQ ID NOs: 309 and 341, respectively; SEQ ID NOs: 310 and 336, respectively; SEQ ID NOs: 311 and 337, respectively; SEQ ID NOs: 313 and 336, IPTS / 200128829.1 2Attorney Docket No. CRSN-001WO respectively; SEQ ID NOs: 313 and 342, respectively; SEQ ID NOs: 313 and 343, respectively; SEQ ID NOs: 316 and 337, respectively; SEQ ID NOs: 316 and 344, respectively; SEQ ID NOs: 316 and 345, respectively; SEQ ID NOs: 318 and 336, respectively; SEQ ID NOs: 318 and 340, respectively; SEQ ID NOs: 318 and 346, respectively; SEQ ID NOs: 319 and 336, respectively; SEQ ID NOs: 319 and 340, respectively; SEQ ID NOs: 319 and 346, respectively; SEQ ID NOs: 320 and 337, respectively; SEQ ID NOs: 320 and 341, respectively; SEQ ID NOs: 320 and 347, respectively; SEQ ID NOs: 320 and 743, respectively; SEQ ID NOs: 321 and 337, respectively; SEQ ID NOs: 321 and 341, respectively; or SEQ ID NOs: 321 and 347, respectively. In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 302 and 335, respectively; SEQ ID NOs: 302 and 336, respectively; SEQ ID NOs: 302 and 340, respectively; SEQ ID NOs: 302 and 342, respectively; SEQ ID NOs: 302 and 343, respectively; SEQ ID NOs: 302 and 346, respectively; SEQ ID NOs: 306 and 337, respectively; SEQ ID NOs: 306 and 339, respectively; SEQ ID NOs: 306 and 341, respectively; SEQ ID NOs: 306 and 344, respectively; SEQ ID NOs: 306 and 345, respectively; SEQ ID NOs: 306 and 347, respectively; SEQ ID NOs: 308 and 340, respectively; SEQ ID NOs: 309 and 341, respectively; SEQ ID NOs: 310 and 336, respectively; SEQ ID NOs: 311 and 337, respectively; SEQ ID NOs: 313 and 336, respectively; SEQ ID NOs: 313 and 342, respectively; SEQ ID NOs: 313 and 343, respectively; SEQ ID NOs: 316 and 337, respectively; SEQ ID NOs: 316 and 344, respectively; SEQ ID NOs: 316 and 345, respectively; SEQ ID NOs: 318 and 336, respectively; SEQ ID NOs: 318 and 340, respectively; SEQ ID NOs: 318 and 346, respectively; SEQ ID NOs: 319 and 336, respectively; SEQ ID NOs: 319 and 340, respectively; SEQ ID NOs: 319 and 346, respectively; SEQ ID NOs: 320 and 337, respectively; SEQ ID NOs: 320 and 341, respectively; SEQ ID NOs: 320 and 347, respectively; SEQ ID NOs: 320 and 743, respectively; SEQ ID NOs: 321 and 337, respectively; SEQ ID NOs: 321 and 341, respectively; or SEQ ID NOs: 321 and 347, respectively.

[0007] In some embodiments, the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs 445, 456, and 447, respectively; SEQ ID NOs 451, 458, and 453, respectively; or SEQ ID NOs 443, 460, and 447, respectively. In some embodiments, the PD-1 binding protein further comprises an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: CDR-L1 IPTS / 200128829.1 3Attorney Docket No. CRSN-001WO comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450. In some embodiments, the anti-PD- 1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 303 and 336, respectively; SEQ ID NOs: 325 and 347, respectively; or SEQ ID NOs: 325 and 743, respectively. In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 303 and 336, respectively; SEQ ID NOs: 325 and 347, respectively; or SEQ ID NOs: 325 and 743, respectively.

[0008] In some embodiments, the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs 445, 461, and 447, respectively; SEQ ID NOs 451, 462, and 453, respectively; or SEQ ID NOs 443, 463, and 447, respectively. In some embodiments, the PD-1 binding protein further comprises an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450. In some embodiments, the anti-PD- 1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 326 and 347, respectively; or SEQ ID NOs: 326 and 743, respectively. In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 326 and 347, respectively; or SEQ ID NOs: 326 and 743, respectively.

[0009] In some embodiments, the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs 445, 446, and 457, respectively; SEQ ID NOs 451, 452, and 459, respectively; or SEQ ID NOs 443, 455, and 457, respectively. In some embodiments, the PD-1 binding protein further comprises an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: CDR-L1 IPTS / 200128829.1 4Attorney Docket No. CRSN-001WO comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450. In some embodiments, the anti-PD- 1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 327 and 347, respectively; or SEQ ID NOs: 327 and 743, respectively. In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 327 and 347, respectively; or SEQ ID NOs: 327 and 743, respectively.

[0010] In some embodiments, the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs 445, 461, and 457, respectively; SEQ ID NOs 451, 462, and 459, respectively; or SEQ ID NOs 443, 463, and 457, respectively. In some embodiments, the PD-1 binding protein further comprises an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450. In some embodiments, the anti-PD- 1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 303 and 335, respectively; SEQ ID NOs: 303 and 342, respectively; SEQ ID NOs: 303 and 343, respectively; SEQ ID NOs: 307 and 337, respectively; SEQ ID NOs: 307 and 344, respectively; SEQ ID NOs: 307 and 345, respectively; SEQ ID NOs: 314 and 336, respectively; SEQ ID NOs: 314 and 342, respectively; SEQ ID NOs: 314 and 343, respectively; SEQ ID NOs: 317 and 337, respectively; SEQ ID NOs: 317 and 344, respectively; SEQ ID NOs: 317 and 345, respectively; or SEQ ID NOs: 324 and 347, respectively. In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 303 and 335, respectively; SEQ ID NOs: 303 and 342, respectively; SEQ ID NOs: 303 and 343, respectively; SEQ ID NOs: 307 and 337, IPTS / 200128829.1 5Attorney Docket No. CRSN-001WO respectively; SEQ ID NOs: 307 and 344, respectively; SEQ ID NOs: 307 and 345, respectively; SEQ ID NOs: 314 and 336, respectively; SEQ ID NOs: 314 and 342, respectively; SEQ ID NOs: 314 and 343, respectively; SEQ ID NOs: 317 and 337, respectively; SEQ ID NOs: 317 and 344, respectively; SEQ ID NOs: 317 and 345, respectively; or SEQ ID NOs: 324 and 347, respectively.

[0011] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence at least 85% identical to that within any one of SEQ ID NO: 464-470 and the anti- PD-1 VL has a framework having an amino acid sequence at least 85% identical to that within any one of SEQ ID NO: 471-476.

[0012] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within any one of SEQ ID NO: 464-470 and the anti-PD-1 VL has a framework having an amino acid sequence of that within any one of SEQ ID NO: 471-476.

[0013] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471.

[0014] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472.

[0015] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471.

[0016] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473.

[0017] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472.

[0018] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473.

[0019] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474. IPTS / 200128829.1 6Attorney Docket No. CRSN-001WO

[0020] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475.

[0021] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471.

[0022] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474.

[0023] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475.

[0024] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471.

[0025] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474.

[0026] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475.

[0027] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 466 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471.

[0028] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 470 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474.

[0029] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 469 and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 476.

[0030] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti- PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 IPTS / 200128829.1 7Attorney Docket No. CRSN-001WO except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid IPTS / 200128829.1 8Attorney Docket No. CRSN-001WO sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 466 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; or the anti- PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 470 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, wherein the one amino acid substition in the VH is from a non-cysteine residue to a cysteine residue and the one amino acid substition in the VL is from a non-cysteine residue to a cysteine residue.

[0031] In some embodiments, the one amino acid substition in the anti-PD-1 VH is at residue H44 and the one amino acid substition in the anti-PD-1 VL is at residue L100, wherein numbering is according to Kabat.

[0032] In one aspect provided are PD-1 binding proteins comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 447, respectively; (2) SEQ ID NOs 451, 458, and 453, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and (b) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 325; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 325; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347. IPTS / 200128829.1 9Attorney Docket No. CRSN-001WO

[0033] In one aspect, provided are a PD-1 binding proteins comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 457, respectively; (2) SEQ ID NOs 451, 458, and 459, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and (b) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 320; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 320; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347.

[0034] In one aspect, provided are PD-1 binding proteins comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 457, respectively; (2) SEQ ID NOs 451, 462, and 459, respectively; or (3) SEQ ID NOs 443, 463, and 457, respectively, and (b) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 324; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 324; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347.

[0035] In one aspect, provided are PD-1 binding proteins comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 447, respectively; (2) SEQ ID NOs 451, 462, and 453, respectively; or (3) SEQ ID NOs 443, 463, and 447, respectively, and (b) an anti- IPTS / 200128829.1 10Attorney Docket No. CRSN-001WO PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 326; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 326; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347.

[0036]

[0037] In one aspect, provided are PD-1 binding proteins comprising an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of SEQ ID NOs 445, 446, and 457, respectively; SEQ ID NOs 451, 452, and 459, respectively; or SEQ ID NOs 443, 455, and 457, respectively, and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of SEQ ID NOs 448, 449, and 450, respectively; SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or SEQ ID NOs 448, 449, and 450 respectively.

[0038] In some embodiments, the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 327; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347.

[0039] In some embodiments, the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 327; and and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347.

[0040] In some embodiments, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for up to one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for up to one amino acid substitution.

[0041] In some embodiments, the one amino acid substitutions in the anti-PD-1 VH and the anti-PD-1 VL are collectively H44-L100 cysteine mutations.

[0042] In one aspect, provided are programmed death receptor 1 (PD-1) binding proteins comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein: the anti- IPTS / 200128829.1 11Attorney Docket No. CRSN-001WO PD-1 VH comprises complementary determining regions CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 453; or CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; the anti-PD-1 VL comprises complementary determining regions CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471, the anti- IPTS / 200128829.1 12Attorney Docket No. CRSN-001WO PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 466; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471, or the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 470; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474.

[0043] In one aspect, provided are programmed death receptor 1 (PD-1) binding proteins comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein the anti- PD-1 VH comprises complementary determining regions CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 453; or CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447, the anti-PD-1 VL comprises complementary determining regions CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 IPTS / 200128829.1 13Attorney Docket No. CRSN-001WO comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti- PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid IPTS / 200128829.1 14Attorney Docket No. CRSN-001WO sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution; the anti-PD- 1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 466 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution; or the anti- PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 470 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, wherein the one amino acid substition in the VH is from a non-cysteine residue to a cysteine residue and the one amino acid substition in the VL is from a non-cysteine residue to a cysteine residue.

[0044] In some embodiments, the one amino acid substition in the anti-PD-1 VH is at residue H44 and the one amino acid substition in the anti-PD-1 VL is at residue L100, wherein numbering is according to Kabat.

[0045] In one aspect, provided are programmed death receptor 1 (PD-1) binding proteins comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein: the anti- PD-1 VH comprises complementary determining regions CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of IPTS / 200128829.1 15Attorney Docket No. CRSN-001WO SEQ ID NO: 453; or CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; the anti-PD-1 VL comprises complementary determining regions CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 301 and 335, respectively; SEQ ID NOs: 301 and 336, respectively; SEQ ID NOs: 301 and 342, respectively; SEQ ID NOs: 301 and 343, respectively; SEQ ID NOs: 301 and 348, respectively; SEQ ID NOs: 305 and 337, respectively; SEQ ID NOs: 305 and 344, respectively; SEQ ID NOs: 305 and 345, respectively; SEQ ID NOs: 312 and 335, respectively; SEQ ID NOs: 312 and 336, respectively; SEQ ID NOs: 312 and 342, respectively; SEQ ID NOs: 312 and 343, respectively; SEQ ID NOs: 315 and 337, respectively; SEQ ID NOs: 315 and 344, respectively; SEQ ID NOs: 315 and 345, respectively; SEQ ID NOs: 322 and 346, respectively; SEQ ID NOs: 323 and 347, respectively; or SEQ ID NOs: 323 and 743, respectively.

[0046] In some embodiments, the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: SEQ ID NOs: 301 and 335, respectively; SEQ ID NOs: 301 and 336, respectively; SEQ ID NOs: 301 and 342, respectively; SEQ ID NOs: 301 and 343, respectively; SEQ ID NOs: 301 and 348, respectively; SEQ ID NOs: 305 and 337, respectively; SEQ ID NOs: 305 and 344, respectively; SEQ ID NOs: 305 and 345, respectively; SEQ ID NOs: 312 and 335, respectively; SEQ ID NOs: 312 and 336, respectively; SEQ ID NOs: 312 and 342, respectively; SEQ ID NOs: 312 and 343, respectively; SEQ ID NOs: 315 and 337, respectively; SEQ ID NOs: 315 and 344, respectively; SEQ ID NOs: 315 and 345, respectively; SEQ ID NOs: 322 and 346, respectively; SEQ ID NOs: 323 and 347, respectively; or SEQ ID NOs: 323 and 743, respectively.

[0047] In some embodiments, the PD-1 binding protein further comprises an Fc region. IPTS / 200128829.1 16Attorney Docket No. CRSN-001WO

[0048] In some embodiments, the Fc region comprises a means for extending the half-life of the PD-1 binding protein.

[0049] In some embodiments, the half-life extending means comprises an Fc modification.

[0050] In some embodiments, the Fc modification is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).

[0051] In some embodiments, the Fc modification is M252Y / S254T / T256E (YTE) or M428L / N434S (LS).

[0052] In some embodiments, the Fc modification is M428L / N434S (LS).

[0053] In some embodiments, the Fc region is an IgG1, IgG2, or IgG4 Fc region.

[0054] In some embodiments, the PD-1 binding protein is an antibody or antigen-binding fragment thereof.

[0055] In some embodiments, the PD-1 binding protein is a human or humanized antibody or antigen-binding fragment thereof.

[0056] In some embodiments, the antigen-binding fragment is a Fab, a F(ab’)2, a Fab’, a single-chain Fv (scFv), an Fv fragment, a Fd fragment, or a diabody.

[0057] In one aspect, provided are bispecific proteins comprising a PD-1 binding protein of any one of claims 1-48, further comprising a VEGF-binding region comprising an anti- VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1 comprising the amino acid sequence of SEQ ID NO: 433; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 434; and CDR- H3 comprising the amino acid sequence of SEQ ID NO: 435; CDR-H1 comprising the amino acid sequence of SEQ ID NO: 439; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 440; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 441; or CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 444; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 435.

[0058] In some embodiments, the bispecific protein further comprises an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementarity- determining regions: CDR-L1 comprising the amino acid sequence of SEQ ID NO: 436; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 437; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 438; CDR-L1 comprising the amino acid sequence IPTS / 200128829.1 17Attorney Docket No. CRSN-001WO of SEQ ID NO: 442; CDR-L2 comprising the amino acid sequence of FTS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 438; or CDR-L1 comprising the amino acid sequence of SEQ ID NO: 436; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 437; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 438.

[0059] In some embodiments, the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432.

[0060] In some embodiments, the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid of SEQ ID NO: 432.

[0061] In one aspect, provided are bispecific proteins comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 447, respectively; (2) SEQ ID NOs 451, 458, and 453, respectively; or (3) SEQ ID NOs 443, 460, and 447, respectively, and (ii) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 325; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432. In some embodiments, (a) the anti-PD-1 VH has an amino acid IPTS / 200128829.1 18Attorney Docket No. CRSN-001WO sequence of SEQ ID NO: 325; and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence of SEQ ID NO: 432.

[0062] In one aspect, provided are bispecific proteins comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 457, respectively; (2) SEQ ID NOs 451, 458, and 459, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and (b) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 320; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 320; and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence of SEQ ID NO: 432.

[0063] In one aspect, provided are bispecific proteins comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary IPTS / 200128829.1 19Attorney Docket No. CRSN-001WO determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 457, respectively; (2) SEQ ID NOs 451, 462, and 459, respectively; or (3) SEQ ID NOs 443, 463, and 457, respectively, and (ii) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (a) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 324; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 324; and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence of SEQ ID NO: 432.

[0064] In one aspect, provided are bispecific proteins comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 447, respectively; (2) SEQ ID NOs 451, 462, and 453, respectively; or (3) SEQ ID NOs 443, 463, and 447, respectively, and (ii) an anti- PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, IPTS / 200128829.1 20Attorney Docket No. CRSN-001WO and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (a) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 326; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432. In some embodiments, (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 326; and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence of SEQ ID NO: 432.

[0065] In one aspect, provided are bispecific proteins comprising a PD-1 binding region and a VEGF-binding region, wherein the PD-1 binding region comprises an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 446, and 457, respectively; (2) SEQ ID NOs 451, 452, and 459, respectively; or (3) SEQ ID NOs 443, 455, and 457, respectively, and (an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and the VEGF-binding region comprises an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions CDR-H1, CDR- H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and an anti-VEGF immunoglobulin light chain variable IPTS / 200128829.1 21Attorney Docket No. CRSN-001WO domain (anti-VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

[0066] In some embodiments, the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 327; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 432.

[0067] In some embodiments, the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 327; and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid sequence of SEQ ID NO: 432.

[0068] In some embodiments, the bispecific protein further comprises an Fc region.

[0069] In some embodiments, the Fc region comprises a means for extending the half-life of the PD-1 binding protein.

[0070] In some embodiments, the half-life extending means comprises an Fc modification.

[0071] In some embodiments, the Fc modification is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).

[0072] In some embodiments, the Fc modification is M252Y / S254T / T256E (YTE) or M428L / N434S (LS).

[0073] In some embodiments, the Fc modification is M428L / N434S (LS).

[0074] In some embodiments, the Fc region is an IgG1, IgG2, or IgG4 Fc region.

[0075] In some embodiments, the bispecific protein is an antibody or antigen-binding fragment thereof.

[0076] In some embodiments, the bispecific protein is a human or humanized antibody or antigen-binding fragment thereof.

[0077] In some embodiments, the antigen-binding fragment is a Fab, a F(ab’)2, a Fab’, a single-chain Fv (scFv), an Fv fragment, a Fd fragment, or a diabody.

[0078] In some embodiments, bispecific protein comprises two PD-1 binding regions and two VEGF binding regions. IPTS / 200128829.1 22Attorney Docket No. CRSN-001WO

[0079] In some embodiments, the bispecific protein comprises two PD-1 binding regions and one VEGF binding region.

[0080] In some embodiments, the bispecific protein comprises one PD-1 binding region and two VEGF binding regions.

[0081] In some embodiments, each PD-1 binding region is an scFv.

[0082] In some embodiments, each VEGF binding region comprises an anti-VEGF VH on a first polypeptide chain and an anti-VEGF VL on a second polypeptide chain, an anti- VEGF VH and an anti-VEGF VL within a Fab, or an anti-VEGF VH and an anti-VEGF VL within a CrossFab.

[0083] In some embodiments, each VEGF binding region is an scFv.

[0084] In some embodiments, each PD-1 binding region comprises an anti-PD1 VH on a first polypeptide chain and an anti-PD1 VL on a second polypeptide chain, an anti-PD1 VH and an anti-PD1 VL within a Fab, or an anti-PD1 VH and an anti-PD1 VL within a CrossFab.

[0085] In some embodiments, each PD-1 binding region is a VHH.

[0086] In some embodiments, each VEGF binding region comprises an anti-VEGF VH on a first polypeptide chain and an anti-VEGF VL on a second polypeptide chain, an anti- VEGF VH and an anti-VEGF VL within a Fab, or an anti-VEGF VH and an anti-VEGF VL within a CrossFab.

[0087] In one aspect, provided are bispecific proteins comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 92 and a second polypeptide chain having the sequence of SEQ ID NO: 239.

[0088] In one aspect, provided are bispecific proteins comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 73 and a second polypeptide chain having the sequence of SEQ ID NO: 220.

[0089] In one aspect, provided are bispecific proteins comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 91 and a second polypeptide chain having the sequence of SEQ ID NO: 238.

[0090] In one aspect, provided are bispecific proteins comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain IPTS / 200128829.1 23Attorney Docket No. CRSN-001WO having the sequence of SEQ ID NO: 94 and a second polypeptide chain having the sequence of SEQ ID NO: 241.

[0091]

[0092] In one aspect, provided are bispecific proteins comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 96 and a second polypeptide chain having the sequence of SEQ ID NO: 243.

[0093] In some embodiments, the bispecific protein forms a dimer.

[0094] In various aspects, provided are isolated nucleic acids encoding one or more chains of a PD-1 binding protein or a bispecific protein as disclosed herein, expression vectors comprising said isolated nucleic acids, and host cells comprising said isolated nucleic acids or expression vectors.

[0095] In various aspects, provided are sets of isolated nucleic acids collectively encoding a PD-1 binding protein or a bispecific protein as disclosed herein, sets of expression vectors collectively comprising said sets of isolated nucleic acids, and host cells comprising said sets of isolated nucleic acids or said sets of expression vectors.

[0096] In one aspect, provided are pharmaceutical compositions comprising a PD-1 binding protein or bispecific protein as disclosed herein and a pharmaceutically acceptable carrier.

[0097] In one aspect, provided are methods comprising a step of administering to a subject in need thereof an effective amount of a PD-1 binding protein, bispecific protein, or pharmaceutical composition as disclosed herein.

[0098] In some embodiments, the subject has or is at risk of having a disease or condition associated with aberrant PD-1 and / or VEGF expression or signaling.

[0099] In some embodiments, the disease or condition is a cancer.

[0100] In some embodiments, the cancer is a lung cancer.

[0101] In some embodiments, the lung cancer is non-small cell lung cancer.

[0102] In some embodiments, the cancer is a gastrointestinal cancer.

[0103] In some embodiments, the gastrointestinal cancer is colorectal cancer, biliary cancer, gastric cancer, or hepatocellular cancer.

[0104] In some embodiments, the cancer is a reproductive cancer.

[0105] In some embodiments, the reproductive cancer is cervical cancer, endometrial cancer, or ovarian cancer. IPTS / 200128829.1 24Attorney Docket No. CRSN-001WO

[0106] In some embodiments, the step of administering comprises systemic administration of the PD-1 binding protein, bispecific protein, or pharmaceutical composition.

[0107] In some embodiments, systemic administration comprises intravenous administration of the PD-1 binding protein, bispecific protein, or pharmaceutical composition.

[0108] In some embodiments, systemic administration comprises subcutaneous administration of the PD-1 binding protein, bispecific protein, or pharmaceutical composition. BRIEF DESCRIPTION OF THE DRAWINGS

[0109] These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawing, where:

[0110] FIGs.1A-1CC depict binding activity of the indicated antibodies to PD-1 expressing cells.

[0111] FIGs.2A-2D depict the surface plasmon resonance (SPR) curves (FIGs.2A-2C) and PD-1 / PD-L1 blockade assay results (FIG.2D) for the indicated antibodies.

[0112] FIG.3A depicts binding activity of the indicated antibodies to human VEGF determined by ELISA.

[0113] FIG.3B depicts binding activity of the indicated antibodies to human PD-1 determined by ELISA.

[0114] FIG.3C depicts binding activity of the indicated antibodies to cynomolgus PD-1 determined by ELISA.

[0115] FIGs.4A-4D depict the SPR curves for binding of the indicated antibodies to human VEGF.

[0116] FIGs.5A-5D depict the SPR curves for binding of the indicated antibodies to human PD-1.

[0117] FIGs.6A-6D depict the SPR curves for binding of the indicated antibodies to cynomolgus PD-1.

[0118] FIGs.7A-7F depict SEC-MALS complex profiles for the indicated antibodies. IPTS / 200128829.1 25Attorney Docket No. CRSN-001WO

[0119] FIG.8 depicts the heavy and light chain sequences (SEQ ID NOs: 128 and 275, respectively) and format for ivonescimab (“AK112”). The variable domains from penpulimab (“AK105”) are underlined.

[0120] FIGs.9 demonstrates that bispecific antibodies can enhance PD-1 binding through VEGF daisy chaining.

[0121] FIGs.10A-10KK depict the PD-1 reporter assay results for the indicated antibodies.

[0122] FIGs.11A-11V depict VEGF reporter assay results for the indicated antibodies.

[0123] FIGs.12A-12O depict inhibition of VEGF-mediated proliferation of human umbilical vein endothelial cells (HUVECs) by the indicated antibodies.

[0124] FIGs.13A-13S depict PD-1 internalization results for the indicated antibodies.

[0125] FIG.14A depicts a PD-1-VEGF (scFv) bispecific reverse construct.

[0126] FIGs.14B-14E depict results of PD-1 binding (FIG.14B), PD-1 internalization (FIG.14D), PD-1 reporter (FIG.14C), and VEGF reporter (FIG.14E) assays for the PD-1- VEGF (scFv) bispecific reverse construct.

[0127] FIGs.15A-15R depict data from T cell activation assessed in human PBMC and hepatocellular carcinoma co-culture assays with the indicated antibodies.

[0128] FIGs.16A-16F depict data from T cell activation assessed in human monocyte derived dendritic cell and CD4+ T cell mixed lymphocyte reaction assays with the indicated antibodies.

[0129] FIG.17A depicts a graph of viscosity at varying protein concentrations at constant pH of 6.0.

[0130] FIG.17B depicts a graph of percent monomer by analytical size exclusion chromatography (SEC) at varying protein concentrations.

[0131] FIGs.17C-17D depict stability data at 40 °C (FIG.17C) and 25 °C (FIG.17D).

[0132] FIGs.18A-18C depict pharmacokinetic data of the indicated antibodies.

[0133] FIG.19 depicts anti-tumor activity of the indicated antibodies. DETAILED DESCRIPTION Definitions

[0134] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art. In some cases, terms with commonly understood meanings are defined herein IPTS / 200128829.1 26Attorney Docket No. CRSN-001WO for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.

[0135] As used herein, the singular form “a,” “an,” and “the” includes plural references unless indicated otherwise.

[0136] It is understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

[0137] For all compositions described herein, and all methods using a composition described herein, the compositions can either comprise the listed components or steps, or can “consist essentially of” the listed components or steps. When a composition is described as “consisting essentially of” the listed components, the composition contains the components listed, and may contain other components which do not substantially affect the condition being treated, but do not contain any other components which substantially affect the condition being treated other than those components expressly listed; or, if the composition does contain extra components other than those listed which substantially affect the condition being treated, the composition does not contain a sufficient concentration or amount of the extra components to substantially affect the condition being treated. When a method is described as “consisting essentially of” the listed steps, the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed. As a non-limiting specific example, when a composition is described as “consisting essentially of” a component, the composition may additionally contain any amount of pharmaceutically acceptable carriers, vehicles, or diluents and other such components which do not substantially affect the condition being treated.

[0138] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host IPTS / 200128829.1 27Attorney Docket No. CRSN-001WO cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

[0139] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which an exogenous nucleic acid has been introduced, and the progeny of such cells. Host cells include “transformants” (or “transformed cells”) and “transfectants” (or “transfected cells”), which each include the primary transformed or transfected cell and progeny derived therefrom. Such progeny may not be completely identical in nucleic acid content to a parent cell, and may contain mutations. A “recombinant host cell” or “host cell” refers to a cell that includes an exogenous polynucleotide, regardless of the method used for insertion, for example, direct uptake, transduction, f-mating, or other methods known in the art to create recombinant host cells.

[0140] An “effective amount” or “therapeutically effective amount” as used herein refers to an amount of therapeutic compound, such as an anti-VEGF antibody, administered to an individual, either as a single dose or as part of a series of doses, which is effective to produce or contribute to a desired therapeutic effect, either alone or in combination with another therapeutic modality. Examples of a desired therapeutic effect is enhancing an immune response, slowing or delaying tumor development; stabilization of disease; amelioration of one or more symptoms. An effective amount may be given in one or more dosages.

[0141] The term “treating” (and variations thereof such as “treat” or “treatment”) refers to clinical intervention in an attempt to alter the natural course of a disease or condition in a subject in need thereof. Treatment can be performed during the course of clinical pathology. Desirable effects of treatment include preventing recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.

[0142] The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate an immune response in a subject.

[0143] The terms “recipient”, “individual”, “subject”, “host”, and “patient”, are used interchangeably herein and in some embodiments, refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and laboratory, zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, IPTS / 200128829.1 28Attorney Docket No. CRSN-001WO goats, pigs, mice, rats, rabbits, guinea pigs, monkeys etc. In some embodiments, the mammal is human. None of these terms require the supervision of medical personnel. As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compound of the present disclosure) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating, slowing or preventing a symptom thereof. As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0144] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA (1975).

[0145] The terms “modulate” and “modulation” refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.

[0146] The terms “increase” and “activate” refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

[0147] The terms “reduce” and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

[0148] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ± 10%, ± 5%, or ± 1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ± one standard deviation of that value(s).

[0149] The term “optionally” is meant, when used sequentially, to include from one to all of the enumerated combinations and contemplates all sub-combinations. IPTS / 200128829.1 29Attorney Docket No. CRSN-001WO

[0150] The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0151] The term “affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or epitope). Unless indicated otherwise, as used herein, “affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen or epitope).

[0152] The term “kd” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.

[0153] The term “ka” (M-1×sec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.

[0154] The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD = kd / ka. In some embodiments, the affinity of an antibody is described in terms of the KD for an interaction between such antibody and its antigen. For clarity, as known in the art, a smaller KDvalue indicates a higher affinity interaction, while a larger KD value indicates a lower affinity interaction.

[0155] The term “KA” (M-1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA = ka / kd.

[0156] As used herein, unless otherwise indicated, the term “antibody” is understood to mean an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof, such as a Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody), or an antigen- binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including an intact antibody, antigen-binding fragment, or Fc fragment that has been modified, engineered, or chemically conjugated. In general, antibodies are multimeric proteins that contain four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A light chain consists of one variable region (VL) and one IPTS / 200128829.1 30Attorney Docket No. CRSN-001WO constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CH1, CH2 and CH3). The variable regions determine the binding specificity of the antibody. Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The extent of the FRs and CDRs has been defined (Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242; and Chothia, C. et al. (1987) J. Mol. Biol.196:901-917). The three CDRs, referred to as CDR1, CDR2, and CDR3, contribute to the antibody binding specificity. Naturally occurring antibodies have been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies. Examples of antibody-based antigen-binding fragments include Fab, Fab’, (Fab’)2, Fv, single chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). An example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.

[0157] A “VEGF antibody” or “VEGF specific antibody” is an antibody, as provided herein, which specifically binds to VEGF. A “VEGF binder” or “VEGF specific binder” is a binder, as provided herein, which specifically binds to VEGF.

[0158] A “PD-1 antibody,” “PD1 antibody” or “PD1 specific antibody” is an antibody, as provided herein, which specifically binds to PD1. A “PD-1 binder,” “PD1 binder” or “PD1 specific binder” is an binder, as provided herein, which specifically binds to PD1.

[0159] The term “epitope” means a portion of an antigen that specifically binds to an antibody.

[0160] The term “hypervariable region” or “HVR,” as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and / or form structurally defined loops (“hypervariable loops”).

[0161] The term “antigen-binding domain” means the portion of an antibody that is capable of specifically binding to an antigen or epitope.

[0162] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0163] The term “human antibody” refers to an antibody which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or IPTS / 200128829.1 31Attorney Docket No. CRSN-001WO derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

[0164] The term “humanized antibody” refers to a protein having a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to induce an immune response, and / or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject.

[0165] The term “multispecific antibody” refers to an antibody that comprises two or more different antigen-binding domains that collectively specifically bind two or more different epitopes.

[0166] A “bispecific antibody” is an antibody that comprises two different antigen binding domains that each bind different epitopes.

[0167] A “monospecific antibody” is an antibody that comprises one or more binding sites that specifically bind to a single epitope. An example of a monospecific antibody is a naturally occurring IgG molecule which, while divalent (i.e., having two antigen-binding domains), recognizes the same epitope at each of the two antigen-binding domains. The binding specificity may be present in any suitable valency.

[0168] The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0169] The term “single-chain” refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In a particular such embodiment, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab heavy chain in the single-chain Fab molecule. As described in more detail herein, an scFv has a variable domain of light chain IPTS / 200128829.1 32Attorney Docket No. CRSN-001WO (VL) connected from its C-terminus to the N-terminal end of a variable domain of heavy chain (VH) by a polypeptide chain. Alternately the scFv comprises of polypeptide chain where in the C-terminal end of the VH is connected to the N-terminal end of VL by a polypeptide chain.

[0170] The “Fab fragment” (also referred to as fragment antigen-binding) contains the constant domain (CL) of the light chain and the first constant domain (CH1) of the heavy chain along with the variable domains VL and VH on the light and heavy chains respectively. The variable domains comprise the complementarity determining loops (CDR, also referred to as hypervariable region) that are involved in antigen-binding. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.

[0171] “F(ab’)2” fragments contain two Fab’ fragments joined, near the hinge region, by disulfide bonds. F(ab’)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab’) fragments can be dissociated, for example, by treatment with ß-mercaptoethanol.

[0172] “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.

[0173] “Single-chain Fv” or “sFv” or “scFv” includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen-binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., Springer-Verlag, New York, pp.269-315 (1994). HER2 antibody scFv fragments are described in WO93 / 16185; U.S. Pat. No.5,571,894; and U.S. Pat. No. 5,587,458.

[0174] “scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminal of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL- VH ). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG4 Fc domain.

[0175] The term “single domain antibody” or “sdAb” refers to a molecule in which one variable domain of an antibody specifically binds to an antigen without the presence of the other variable domain. Single domain antibodies, and fragments thereof, are described in IPTS / 200128829.1 33Attorney Docket No. CRSN-001WO Arabi Ghahroudi et al. (1998) FEBS Letters 414:521-526 and Muyldermans et al. (2001) Trends in Biochem. Sci.26:230-245, each of which is incorporated by reference in its entirety. Single domain antibodies are also known as sdAbs, VHH, or nanobodies. sdAbs are fairly stable and easy to express as fusion partner with the Fc chain of an antibody (Harmsen MM, De Haard HJ (2007) “Properties, production, and applications of camelid single-domain antibody fragments” Appl. Microbiol Biotechnol.77(1): 13-22).

[0176] The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a naturally occurring antibody structure and having heavy chains that comprise an Fc region. For example, when used to refer to an IgG molecule, a “full length antibody” is an antibody that comprises two heavy chains and two light chains.

[0177] The term “antibody fragment” refers to an antibody that comprises a portion of an intact antibody, such as the antigen-binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2fragments, Fab’ fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0178] The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions.

[0179] The term “substantially purified” refers to a construct described herein, or variant thereof that may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e. a native cell, or host cell in the case of recombinantly produced antibody that in certain embodiments, is substantially free of cellular material includes preparations of protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating protein.

[0180] The term “percent identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., using publicly available computer software such as BLAST, BLASTP, BLASTN, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software or other algorithms available to persons of skill) IPTS / 200128829.1 34Attorney Docket No. CRSN-001WO or by visual inspection. Software for performing BLAST analyses (Altschul et al. (1990) J. Mol. Biol.215:403-410) is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.

[0181] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0182] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman (1981) Adv. Appl. Math.2:482, by the homology alignment algorithm of Needleman & Wunsch (1970) J. Mol. Biol.48:443, by the search for similarity method of Pearson & Lipman (1988) Proc. Nat’l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).

[0183] Ranges recited herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.

[0184] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. PD-1 Antibodies and Bispecific Anti-VEGF / PD-1 Antibodies Basic Antibody Structure

[0185] The recognized immunoglobulin (antibody) genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad IPTS / 200128829.1 35Attorney Docket No. CRSN-001WO immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. The “class” of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0186] An exemplary immunoglobulin structural unit is composed of two pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminal domain of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chain domains respectively. The IgG1 heavy chain comprises of the VH, CH1, CH2, and CH3 domains respectively from the N- to C-terminus. The light chain comprises of the VL and CL domains from N- to C-terminus. The IgG1 heavy chain comprises a hinge between the CH1 and CH2 domains. In certain embodiments, the immunoglobulin constructs comprise at least one immunoglobulin domain from IgG, IgM, IgA, IgD, or IgE connected to a therapeutic polypeptide. In some embodiments, the immunoglobulin domain found in an antibody provided herein, is from or derived from an immunoglobulin based construct such as a diabody or a nanobody. In certain embodiments, the immunoglobulin constructs described herein comprise at least one immunoglobulin domain from a heavy chain antibody such as a camelid antibody. In certain embodiments, the immunoglobulin constructs provided herein comprise at least one immunoglobulin domain from a mammalian antibody such as a bovine antibody, a human antibody, a camelid antibody, a mouse antibody, or any chimeric antibody.

[0187] In some embodiments, the antibodies provided herein comprise a heavy chain. In one embodiment, the heavy chain is an IgA. In one embodiment, the heavy chain is an IgD. In one embodiment, the heavy chain is an IgE. In one embodiment, the heavy chain is an IgG. In one embodiment, the heavy chain is an IgM. In one embodiment, the heavy chain is an IgG1. In one embodiment, the heavy chain is an IgG2. In one embodiment, the heavy chain is an IgG3. In one embodiment, the heavy chain is an IgG4. In one embodiment, the heavy chain is an IgA1. In one embodiment, the heavy chain is an IgA2. IPTS / 200128829.1 36Attorney Docket No. CRSN-001WO

[0188] In some embodiments, an antibody is an IgG1 antibody. In some embodiments, an antibody is an IgG3 antibody. In some embodiments, an antibody is an IgG2 antibody. In some embodiments, an antibody is an IgG4 antibody.

[0189] Generally, native four-chain antibodies comprise six hypervariable regions (HVRs); three in the VH (H1, H2, and H3), and three in the VL (L1, L2, and L3). HVRs generally comprise amino acid residues from the hypervariable loops and / or from the complementarity determining regions (CDRs), the latter being of highest sequence variability and / or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. HVRs are also referred to as CDRs, and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen-binding regions. This particular region has been described by Kabat et al. (1983) U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest and by Chothia et al. (1987) J Mol Biol 196:901-917, where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0190] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al. (1997) J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al. (1996) J. Mol. Biol.262:732- 745 (“Contact” numbering scheme); Lefranc et al. (2003) Dev. Comp. Immunol.27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun (2001) J. Mol. Biol.309:657-70 (“AHo” numbering scheme); each of which is incorporated by reference in its entirety.

[0191] Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR- H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

[0192] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin (2008) Immunology, 45:3832-3839, incorporated by reference in its entirety. IPTS / 200128829.1 37Attorney Docket No. CRSN-001WO Table 1. Residues in CDRs according to Kabat and Chothia numbering schemes. Table 1 CDR Kabat Chothia * T , varies bet, .

[0193] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0194] One example of an antigen-binding domain is an antigen-binding domain formed by a VH-VL dimer of an antibody. Another example of an antigen-binding domain is an antigen-binding domain formed by diversification of certain loops from the tenth fibronectin type III domain of an Adnectin. An antigen-binding domain can include CDRs 1, 2, and 3 from a heavy chain in that order; and CDRs 1, 2, and 3 from a light chain in that order.

[0195] Epitopes frequently consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter may be lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to VEGF variants with different point-mutations or to chimeric VEGF variants. IPTS / 200128829.1 38Attorney Docket No. CRSN-001WO

[0196] To screen for antibodies which bind to an epitope on a target antigen bound by an antibody of interest (e.g., VEGF or PD-1), a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art.

[0197] Chimeric antibodies are antibodies in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0198] Human antibodies are antibodies which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

[0199] A humanized antibody has a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to induce an immune response, and / or induces a less severe immune response, as compared to the non- human species antibody, when it is administered to a human subject. In one embodiment, certain amino acids in the framework and constant domains of the heavy and / or light chains of the non-human species antibody are mutated to produce the humanized antibody. In another embodiment, the constant domain(s) from a human antibody are fused to the variable domain(s) of a non-human species. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody are changed to reduce the likely immunogenicity of the non-human antibody when it is administered to a human subject, wherein the changed amino acid residues either are not critical for immunospecific binding of the antibody to its antigen, or the changes to the amino acid sequence that are made are conservative changes, such that the binding of the humanized antibody to the antigen is not significantly worse than the binding of the non-human antibody to the antigen. Examples of how to make humanized antibodies can be found in U.S. Pat. Nos.6,054,297, 5,886,152 and 5,877,293. For further details, see Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-329; and Presta (1992) Curr. Op. Struct. Biol.2:593-596, each of which is incorporated by reference in its entirety. IPTS / 200128829.1 39Attorney Docket No. CRSN-001WO

[0200] The two or more different epitopes may be epitopes on the same antigen (e.g., a single VEGF) or on different antigens (e.g., different VEGF molecules, or a VEGF molecule and a non-VEGF molecule). In some embodiments, a multi-specific antibody binds two different epitopes (i.e., a “bispecific antibody”). In some embodiments, a multi-specific antibody binds three different epitopes (i.e., a “trispecific antibody”).

[0201] Anti-VEGF or PD-1 antibodies can include those described herein such as the clones set forth in the drawings and / or tables. In some embodiments, the binding protein comprises an alternative scaffold. In some embodiments, the binding protein consists of an alternative scaffold. In some embodiments, the binding protein consists essentially of an alternative scaffold. In some embodiments, the binding protein comprises an antibody fragment. In some embodiments, the binding protein consists of an antibody fragment. In some embodiments, the binding protein consists essentially of an antibody fragment.

[0202] In some embodiments the bispecific antibodies are monoclonal antibodies.

[0203] In some embodiments the bispecific antibodies are polyclonal antibodies.

[0204] In some embodiments the bispecific antibodies are produced by hybridomas. In other embodiments, the bispecific antibodies are produced by recombinant cells engineered to express the desired variable and constant domains.

[0205] In some embodiments the bispecific antibodies may be single chain antibodies or other antibody derivatives retaining the antigen specificity and the lower hinge region or a variant thereof.

[0206] In some embodiments the bispecific antibodies may be polyfunctional antibodies, recombinant antibodies, human antibodies, humanized antibodies, fragments or variants thereof. In particular embodiments, the antibody fragment or a derivative thereof is selected from a Fab fragment, a Fab′2 fragment, a CDR, and scFv.

[0207] In some embodiments, the bispecific antibodies are capable of forming an immune complex. For example, an immune complex can be a tumor cell covered by bispecific antibodies.

[0208] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. IPTS / 200128829.1 40Attorney Docket No. CRSN-001WO Bispecific Antibody Structure

[0209] The present application provides proteins that bind VEGF and PD-1, as well as compositions (e.g., pharmaceutical compositions thereof). Bispecific antibodies disclosed herein can be of any structure known in the art.

[0210] Disclosed bispecific binding proteisn can take any format, including but not limited to those described herein.

[0211] In one exemplary bispecific format, the bispecific binding protein comprises (a) two immunoglobulin heavy chains which each comprise, from N- to C- terminus: (1) a heavy chain variable domain, (2) an Fc (hinge-CH2-CH3) domain, which immunoglobulin heavy chains are each linked at their C-termini to an scFv; and (b) two immunoglobulin light chains which each comprise, from N- to C- terminus: (1) a light chain variable domain and (2) a light chain constant domain. Linkers (e.g., amino acid linkers) may be used between any of the aforementioned domains within a given immunoglobulin chain, within an scFv, and / or between the immunoglobulin heavy chain and the scFv. In this format, a heavy chain variable domain and a light chain variable domain together form a first binding region, and the scFv comprises a second binding region. In som embodiments, the first binding region is a VEGF binding region and the second binding region is a PD-1 binding region. In some embodiments, the first binding region is a PD-1 binding region and the second binding region is a VEGF binding region. Thus, for example, in this format, the bispecific binding protein comprises two VEGF binding regions and two PD-1 binding regions per construct.

[0212] However, additional formats, such as formats comprising different numbers of each binding region, are also contemplated, e.g., two VEGF binding regions and one PD-1 binding region, one VEGF binding region and two PD-1 binding reigons, or one VEGF binding region and one PD-1 binding region.

[0213] Another format is a bispecific binding protein that includes a first immunoglobulin heavy chain, a second immunoglobulin heavy chain and an immunoglobulin light chain. In this format, (1) the first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain, a first variable heavy chain domain and an optional first CH1 heavy chain domain, (2) the immunoglobulin light chain includes a variable light chain domain and a constant light chain domain; and (3) together with the first immunoglobulin heavy chain, the immunoglobulin light chain forms an antigen-binding site that binds VEGF. In this format, the second immunoglobulin heavy chain comprises a second Fc (hinge-CH2- IPTS / 200128829.1 41Attorney Docket No. CRSN-001WO CH3) domain, a second variable heavy chain domain and a second CH1 heavy chain domain that may pair with an immunoglobulin light chain identical to the one that pairs with the first immunoglobulin heavy chain, except that when immunoglobulin light chain is paired with the second immunoglobulin heavy chain, the resulting antigen binding site binds to PD-1.

[0214] In some embodiments, the bispecific binding protein is in the Triomab form, which is a trifunctional, bispecific binding protein that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from two parental antibodies.

[0215] In some embodiments, the bispecific binding protein is the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHs) technology. The KIH involves engineering CH3 domains to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization. The concept behind the “Knobs-into-Holes (KiH)” Fc technology was to introduce a “knob” in one CH3 domain (CH3A) by substitution of a small residue with a bulky one (e.g., T366WCH3Ain EU numbering). To accommodate the “knob,” a complementary “hole” surface was created on the other CH3 domain (CH3B) by replacing the closest neighboring residues to the knob with smaller ones (e.g., T366S / L368A / Y407VCH3B). The “hole” mutation was optimized by structured-guided phage library screening (Atwell et al. (1997) “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” J. Mol. Biol.270(1):26–35). X-ray crystal structures of KiH Fc variants (Elliott et al. (2014) “Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction,” J. Mol. Biol.426(9):1947–57; Mimoto et al. (2014) “Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgammaRs,” Mol. Immunol.58(1):132–8) demonstrated that heterodimerization is thermodynamically favored by hydrophobic interactions driven by steric complementarity at the inter-CH3 domain core interface, whereas the knob–knob and the hole–hole interfaces do not favor homodimerization owing to steric hindrance and disruption of the favorable interactions, respectively.

[0216] In some embodiments, the bispecific binding protein is in the Orthogonal Fab interface (Ortho-Fab) form. In the ortho-Fab IgG approach (Lewis et al. (2014) “Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface,” Nat. Biotechnol.32(2):191–8), structure-based regional design introduces complementary IPTS / 200128829.1 42Attorney Docket No. CRSN-001WO mutations at the LC and HCVH-CH1 interface in only one Fab, without any changes being made to the other Fab.

[0217] In some embodiments, the bispecific binding protein is in the 2-in-1 Ig format. In some embodiments, the bispecific binding protein is in the ES form, which is a heterodimeric construct containing two different Fabs binding to targets 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc. In some embodiments, the bispecific binding protein is in the ĸλ-Body form, which is an heterodimeric constructs with two different Fabs fused to Fc stabilized by heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC.

[0218] In some embodiments, the bispecific binding protein is in Fab Arm Exchange form (antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, which results in bispecific antibodies). In some embodiments, the bispecific binding protein is in the SEED Body form. The strand-exchange engineered domain (SEED) platform was designed to generate asymmetric and bispecific binding protein-like molecules, a capability that expands therapeutic applications of natural antibodies. This protein engineered platform is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. The SEED design allows efficient generation of AG / GA heterodimers, while disfavoring homodimerization of AG and GA SEED CH3 domains. (Muda M. et al. (2011) Protein Eng. Des. Sel.24(5):447-54). In some embodiments, the bispecific binding protein is in the LuZ-Y form, in which a leucine zipper is used to induce heterodimerization of two different HCs. (Wranik et al. (2012) J. Biol. Chem.287:43331-9).

[0219] In some embodiments, the bispecific binding protein is in the Cov-X-Body form. In bispecific CovX-Bodies, two different peptides are joined together using a branched azetidinone linker and fused to the scaffold binding protein under mild conditions in a site- specific manner. Whereas the pharmacophores are responsible for functional activities, the binding protein scaffold imparts long half-life and Ig-like distribution. The pharmacophores can be chemically optimized or replaced with other pharmacophores to generate optimized or unique bispecific antibodies. (Doppalapudi et al. (2010) PNAS 107(52): 22611-22616).

[0220] In some embodiments, the bispecific binding protein is is in an Oasc-Fab heterodimeric form that includes Fab binding to target 1, and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations in the Fc. IPTS / 200128829.1 43Attorney Docket No. CRSN-001WO

[0221] In some embodiments, the bispecific binding protein is in a DuetMab form, which is an heterodimeric construct containing two different Fabs binding to antigens 1 and 2, and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S-S bridges that ensure correct LC and HC pairing.

[0222] In some embodiments, the bispecific binding protein is in a CrossmAb form, which is an heterodimeric construct with two different Fabs binding to targets 1 and 2, fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, e.g., CH1 is fused in-line with VL, while CL is fused in-line with VH.

[0223] In some embodiments, the bispecific binding protein is n a Fit-Ig form, which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1. The construct contains wild-type Fc.

[0224] Tables 2A-2B lists sequences of heavy chains and light chains that, in combination, can bind to VEGF and / or PD-1. Sequences of PD-1 Antibodies and Bispecific Anti-VEGF / PD-1 Binding Proteins

[0225] Provided herein are binding proteins that bind programmed death receptor 1 (PD- 1). PD-1 binding proteins generally comoprise one or more PD-1 binding regions, as further discussed herein.

[0226] Also provided herein are bispecific binding proteins that bind vascular endothelial growth factor (VEGF) and programmed death receptor 1 (PD-1). Provided bispecific binding proteins generally comprise one or more VEGF binding regions and one or more PD-1 binding regions. Exemplary characteristic sequences of VEGF binding regions

[0227] VEGF binding regions are capable of binding to VEGF. In some embodiments, VEGF binding regions are capable of binding to an epitope of human VEGF, such as a human VEGF-A isoform. In some embodiments, VEGF binding regions are capable of binding to all human VEGF-A isoforms. In some embodiments, VEGF binding regions antagonize VEGF, e.g., by blocking binding of VEGF to its receptor.

[0228] In some embodiments, VEGF binding regions comprise a heavy chain variable domain comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 with sequences as shown in Table 2. In some embodiments, VEGF binding regions further IPTS / 200128829.1 44Attorney Docket No. CRSN-001WO comprise a light chain variable domain comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 with sequences as shown in Table 2.

[0229] In some embodiments, VEGF binding regions comprise a heavy chain variable domain with a heavy chain variable domain sequence as shown in Table 2. In some embodiments, VEGF binding regions comprise a heavy chain variable domain which is a variant of the heavy chain variable sequence shown in Table 2, in that the heavy chain variable domain has (1) CDR-H1, CDR-H2, and CDR-H3 with sequences as shown in Table 2 and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the heavy chain variable domain sequence shown in Table 2.

[0230] In some embodiments, VEGF binding regions comprise a heavy chain variable domain as described herein in Table 2 (or a variant thereof, as described herein) and further comprise a light chain variable region which has (1) CDR-L1, CDR-L2, and CDR-L3 with sequences as shown in Table 2 and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the light chain variable domain sequence shown in Table 2. Table 2: Characteristic sequences of exemplary VEGF binding regions Heavy chain Light chain Variable domain Variable domain Y G WIPTS / 200128829.1Attorney Docket No. CRSN-001WO IMGT CDRs IMGT CDRs CDR-H1: GYTFTNYG CDR-L1: QDISNY SE ID NO 439 SE ID NO 442, domain comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 with sequences within a heavy chain variable domain sequence shown in Table 5A. In some embodiments, VEGF binding regions further comprise a light chain variable domain comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 with sequences as shown within a light chain variable domain sequence in Table 6A.

[0232] In some embodiments, VEGF binding regions comprise a heavy chain variable domain with a heavy chain variable sequence as shown in Table 5A. In some embodiments, VEGF binding regions comprise a heavy chain variable domain which is a variant of the heavy chain variable sequence shown in Table 5A, in that the heavy chain variable domain has (1) CDR-H1, CDR-H2, and CDR-H3 with sequences within a given heavy chain variable domain sequence shown in Table 5A and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the same heavy chain variable domain sequence shown in Table 5A.

[0233] In some embodiments, VEGF binding regions comprise a heavy chain variable domain as described herein in Table 5A (or a variant thereof, as described herein) and further comprise a light chain variable region which has (1) CDR-L1, CDR-L2, and CDR-L3 within IPTS / 200128829.1 46Attorney Docket No. CRSN-001WO a light chain variable domain sequence as shown in Table 6A and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the same light chain variable domain sequence shown in Table 6A. Exemplary characteristic sequences of PD-1-binding regions

[0234] PD-1 binding regions are capable of binding to PD-1. In some embodiments, PD-1 binding regions are capable of binding to an epitope of human PD-1. In some embodiments, PD-1 binding regions antagonize PD-1, e.g., by blocking binding of PD-1 to PD-L1.

[0235] In some embodiments, PD-1 binding regions comprise a heavy chain variable domain comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 with sequences as shown for a given set in Table 3A. In some embodiments, PD-1 binding regions further comprise a light chain variable domain comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 with sequences as shown in the same set in Table 3A. Table 3A. Exemplary sequences of complementarity-determining regions within PD-1 binding regions Heavy chain Light chainIPTS / 200128829.1Attorney Docket No. CRSN-001WO CDR-H3: ARRDYRFDMGFDY (SEQ ID NO: 450) (SEQ ID NO: 453)IPTS / 200128829.1Attorney Docket No. CRSN-001WO (SEQ ID NO: 445) (SEQ ID NO: 448) CDR-H2: GINPS GGTNFNEKFKN CDR-L2: LASYLESIPTS / 200128829.1Attorney Docket No. CRSN-001WO (SEQ ID NO: 453) Chthi CDR Chthi CDRIPTS / 200128829.1Attorney Docket No. CRSN-001WO CDR-H2: GINPSRGGTNFNEKFKN CDR-L2: LASYLES (SEQ ID NO: 461) (SEQ ID NO: 449)

[0036] n some embod men s, - bnd ng regons compr se a eavy c a n var ab e domain comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 with sequences within a heavy chain variable domain sequence shown in Table 5B. In some embodiments, PD-1 binding regions further comprise a light chain variable domain comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 with sequences as shown within a light chain variable domain sequence in Table 6B.

[0237] In some embodiments, PD-1 binding regions comprise a heavy chain variable domain with a heavy chain variable sequence as shown in Table 5B. In some embodiments, PD-1 binding regions comprise a heavy chain variable domain which is a variant of the heavy chain variable sequence shown in Table 5B, in that the heavy chain variable domain has (1) CDR-H1, CDR-H2, and CDR-H3 with sequences within a given heavy chain variable domain sequence shown in Table 5B and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the same heavy chain variable domain sequence shown in Table 5B. IPTS / 200128829.1 51Attorney Docket No. CRSN-001WO

[0238] In some embodiments, PD-1 binding regions comprise a heavy chain variable domain as described herein in Table 5B (or a variant thereof, as described herein) and further comprise a light chain variable region which has (1) CDR-L1, CDR-L2, and CDR-L3 within a light chain variable domain sequence as shown in Table 6B and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the same light chain variable domain sequence shown in Table 6B.

[0239] Tables 3B and 3C depict exemplary VH and VL sequences, respectively, of PD-1 binding regions, which illustrate representative heavy chain variable domain and light chain variable domain framework sequences within PD-1 binding regions of the present disclosure. Exemplary CDR sequences (as defined by Kabat) within these VH and VL sequences are shown within boxes. However, it is understood by those of ordinary skill in the art that the exact borders between CDRs and framework regions may vary depending on the antibody annotation system used. For example, CDRs may be defined as described by Kabat et al., U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Other CDR definitions, such as according to IMGT, Chothia, Contact residues, may also be used. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0240] In some embodiments, PD-1 binding regions comprise: (1) a set of CDRs as described herein for PD-1 binding regions, (2) a heavy chain variable domain having a sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 92.5%, at least 95%, at least 97.5%, at least 98%, or at least 99% amino acid sequence identity with the sequence of a VH sequence shown in Table 3B, and (3) a light chain variable domain having a sequence that has at least 75%, at least 80%, at least 85%, at least 90%, at least 92.5%, at least 95%, at least 97.5%, at least 98%, or at least 99% amino acid sequence identity with the sequence of a VL sequence shown in Table 3C.

[0241] In some embodiments, PD-1 binding regions comprise a heavy chain variable domain framework sequence as shown within a VH sequence shown in Table 3B and a light IPTS / 200128829.1 52Attorney Docket No. CRSN-001WO chain variable domain framework sequence as shown within a VL sequence as shown in Table 3C.

[0242] In some embodiments, PD-1 binding regions comprise a heavy chain variable domain framework sequence as shown within a VH sequence shown in Table 3B and a variant of a light chain variable domain framework sequence as shown within a VL sequence as shown in Table 3C. In some embodiments, PD-1 binding regions comprise a variant of a heavy chain variable domain framework sequence as shown within a VH sequence shown in Table 3B and a light chain variable domain framework sequence as shown within a VL sequence as shown in Table 3C. In some embodiments, PD-1 binding regions comprise a variant of a heavy chain variable domain framework sequence as shown within a VH sequence shown in Table 3B and a variant of a light chain variable domain framework sequence as shown within a VL sequence as shown in Table 3C.

[0243] Examples of variants of disclosed framework sequences include, but are not limited to: (1) sequences that have at least 75%, at least 80%, at least 85%, at least 90%, at least 92.5%, at least 95%, at least 97.5%, at least 98%, or at least 99% amino acid sequence identity across framework region residues (not including CDR residues, according to any definition of CDRs used by those of skill in the art) with a disclosed framework sequence and (2) sequences that are nearly identical to a disclosed framework sequence except for a specific framework mutation or set of framework mutations (e.g., up to four, three, two, or one amino acid substitutions, deletions, or insertions within a given immunoglobulin framework region) as discussed herein. Non-limiting examples of specific framework mutations include stabilizing mutations and / or cysteine mutations (e.g., at H44 and / or L100).

[0244] Any combination of the heavy chain framework sequences and light chain framework sequences disclosed herein may be used in PD-1 binding regions of the present disclosure. Non-limiting examples of pairs of heavy chain and light chain framework sequences that can be used within PD-1 binding regions include:

[0245] (1) VH0 and VL0 framework regions (within SEQ ID NOs: 464 and 471, respectively), or variants thereof;

[0246] (2) VH1 and VL1 framework regions (within SEQ ID NOs: 465 and 472, respectively), or variants thereof;

[0247] (3) VH1 and VL0 framework regions (within SEQ ID NOs: 465 and 471, respectively), or variants thereof; IPTS / 200128829.1 53Attorney Docket No. CRSN-001WO

[0248] (4) VH1 and VL2 framework regions (within SEQ ID NOs: 465 and 473, respectively), or variants thereof;

[0249] (5) VH0 and VL1 framework regions (within SEQ ID NOs: 464 and 472, respectively), or variants thereof;

[0250] (6) VH0 and VL2 framework regions (within SEQ ID NOs: 464 and 473, respectively), or variants thereof;

[0251] (7) VH0 and VL3 framework regions (within SEQ ID NOs: 464 and 474, respectively), or variants thereof;

[0252] (8) VH0 and VL4 framework regions (within SEQ ID NOs: 464 and 475, respectively), or variants thereof;

[0253] (9) VH3 and VL0 framework regions (within SEQ ID NOs: 467 and 471, respectively), or variants thereof;

[0254] (10) VH3 and VL3 framework regions (within SEQ ID NOs: 467 and 474, respectively), or variants thereof;

[0255] (11) VH3 and VL4 framework regions (within SEQ ID NOs: 467 and 475, respectively), or variants thereof;

[0256] (12) VH4 and VL0 framework regions (within SEQ ID NOs: 468 and 471, respectively), or variants thereof;

[0257] (13) VH4 and VL3 framework regions (within SEQ ID NOs: 468 and 474, respectively), or variants thereof;

[0258] (14) VH4 and VL4 framework regions (within SEQ ID NOs: 468 and 475, respectively), or variants thereof;

[0259] (15) VH2 and VL0 framework regions (within SEQ ID NOs: 466 and 471, respectively), or variants thereof;

[0260] (16) VH6 and VL3 framework regions (within SEQ ID NOs: 470 and 474, respectively), or variants thereof; and

[0261] (17) VH5 and VL5 framework regions (within SEQ ID NOs: 469 and 476, respectively), or variants thereof;

[0262] Any of the framework sequences disclosed herein may be combined with any set of CDRs for PD-1 binding regions as described herein, or any of the CDRs within the VH and VL sequences shown with Tables 5B and 6B. Table 3B. Exemplary VH sequences of PD-1 binding regions IPTS / 200128829.1 54Attorney Docket No. CRSN-001WO VH SEQ Sequence ID NO N D N D N D N D N D N D N DTable 3C. Exemplary VL sequences of PD-1 binding regions VL SEQ Sequence ID I G I G IIPTS / 200128829.1Attorney Docket No. CRSN-001WO YLASYLESGVPARFSGSGSGTDFTLTISGLEPEDFAVYYCQHSRDLPLTFGG GTKVEIKR I G I G Y G

[0263] In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 85% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148- 194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 96% IPTS / 200128829.1 56Attorney Docket No. CRSN-001WO sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 97% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 98% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148- 194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having at least 99% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. In some embodiments, the binding protein comprises a heavy chain comprising an amino acid sequence having 100% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 1-147, 656-678, and 702-713; and a light chain sequence comprising a sequence having 100% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737.

[0264] Provided herein, in certain embodiments, are bispecific binding proteins that bind vascular endothelial growth factor (VEGF) and programmed death receptor 1 (PD-1), comprising: a) a heavy chain sequence comprising a sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 22-23, 60, 62, 65-67, 70-72, 75-77, 142-143, 667-678, and 702-713; and b) a light chain sequence comprising a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737.

[0265] Further provid hereing, in certain embodiments, are bispecific binding proteins that bind vascular endothelial growth factor (VEGF) and programmed death receptor 1 (PD- 1), comprising: a) a heavy chain sequence comprising a sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-21, 24-57, 58, 59, 61, 63, 64, 68, 69, 73, 74, 78-97, 130-141, 144-147, and 656-666; and b) a light chain IPTS / 200128829.1 57Attorney Docket No. CRSN-001WO sequence comprising a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737.

[0266] Further provid hereing, in certain embodiments, are bispecific binding proteins that bind vascular endothelial growth factor (VEGF) and programmed death receptor 1 (PD- 1), comprising: a) a heavy chain sequence comprising the amino acid sequence of any one of SEQ ID NOs: 98-127 and 129; and b) a light chain sequence comprising a sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 148-194, 679-701, and 714-737. IPTS / 200128829.1 58NO L GS TG LL DK PS NW Y G Q C S S L G Y S T G G L Q L D C KS1N0S S I G G S F V T V D S Q L N S G V E GQ SI GS FT V DQS E0D F W A T H D F W A T- Q R P T V T Q R P T VNSRC.oNtekcoDyenrottAL LK S H K S T C C E N E N N G V G E T Q H G F K S H KtG G T S S T Q P T R S D E G S S G M G T L S T G G T S ShngG GP D S S L T P V P V R P Q G A M Y Q L Y G L P D S SiiaG GA L G P A G C E K K S Q Q G G W A G V S S P A L G PLhS SQ S Y A G L T P T C P G W G P E T W I Y F L Q S Y AdE ER F Y L S S H T K K P N R G K L T Y E G R D R F Y LCnV VV T H P N S T R A Y L S S K K G T D S S A R V T H Py aL LW F P F W S K S N E T E K G V Q S F G T P S W F P FvsaQ QN R Y V S P D I H K Y W D P E G S G G S V H N R Y VneV VM R K S V V C M V G V E V S V P D M G V G Q M R K SiaH E G K A P T T S L E N Q V T L G A T D G G S C E G K A PhCy Dv IaeQOH Ef S 1 2Nose1.c 9an 2e8e L L8u 112m . .1qa 1 10e 00 0 2 N S / 1 1S.t 0 0Tc - -PAIu 4 44 r 5 5te0 0slL Lnb oa A ATCP PP O S NL G Y S TG L L G Q L DK PW S N S G C S SS1G S G F VV D0Q LG0-NSRC.oNtekcoDyenrottAT Q P T R S D E G S S G M G Q L T P V P V R T L S T GG G T S S T Q P T R S D E G A G C E K K S PQ QQ GG AG MW YA QG LV YS GS LP G PA DL SG SP LA TG PC VE PK VK RS PQ Q GS LS TH PE TK CK PP GN WR GG PK EL TT WY IE YG FR LD SE QR S Y A G L T P T C P G QWF Y L S S H T K K P N RVN S T R A Y L S S K K G T D S S A R V T H P N S T R A Y L S SLW S K T N E T E K G V Q S F G T P S W F P F W S K S N E T E KQS P D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W DVV V C Y V G V E V S V P D M G V G Q M R K S V V C M V G V E VT T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T 3 1.9b 28L812.11000 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASG SA GM MY G Q Q TL LY SG TL GG GP TD S S T Q P T R S D E G S S G M G QT L S T GG G W A G V S S P G A L SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PT TK CK P G W G P E T W I Y F LP N R G K L T Y E G R DVK K G T D S S A R V T H P N S T R A Y L S S K K G T D S S A RLG V Q S F G T P S W F P F W S K S N E T E K G V Q S F G T P SQP E G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HVS V P D M G V G Q M R K S V V C M V G V E V S V P D L G V G QL G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C 4 1.928L812.12000 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAG G T S S T Q P T R S D E G S S G M G QT L S T G G T SGG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV Y G L G S T Q P T G P D S S L T P VS S P A L G P A G C ES SQ S Y A G L T P T C P G W G P E T W I Y F L Q S Y A G L T PE ER F Y L S S H E K K P N R G K L T Y E G R D R F Y L S S H TV VV T H P N S T R A Y L S S K K G T D S S A R V T H P N S T RL LW F P F W S K T N E T E K G V Q S F G T P S W F P F W S K SQ QN R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D IV VM R K S V V C Y V G V E V S V P D L G V G Q M R K S V V C ME G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L 561.9a b 28L L81 12. .12 2000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAR S D E G S S G M G Q P V R P Q G A M Y Q TL LY S T GG G T S S T Q P T R S D E G S S G MG L P D S S L T P V P V R P Q G A M YGK K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G G W AST C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E TEK K P N R G K L T Y E G R D R F Y L S S H T K K P N R G K L TVA Y L S S K K G T D S S A R V T H P N S T R A Y L S S K K G TLN E T E K G V Q S F G T P S W F P F W S K S N E T E K G V Q SQH K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G SVV G V E V S V P D L G V G Q M R K S V V C M V G V E V S V P DE N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T 7 1.928L812.13000 2 / 1S0T-PI450LAPNL GS T G G LL DK P C S NO S S L G Y S T Q Y G LLW NS SG GF VV D L N G S S Q G G C10Q G F VV0-NSRC.oNtekcoDyenrottAG QT L S T G G T S S T Q P T R S D E G S S G M G QT L S T G G T SQG LV YS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA Q WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK C P G W G P E T G L W V Y I S G Y S L F P GG P D S L S A L E Q S GYK P N R G K L T Y E G R D R F YV VD S S A R V T H P N S T R A Y L S S K K G T D S S A R V T HL LF G T P S W F P F W S K T N E T E K G V Q S F G T P S W F PQ QG G S V H N R Y V S P D I H K Y W D P E G S G G S V H N R YV VL G V G Q M R K S V V C Y V G V E V S V P D L G V G Q M R KD G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A 891.9a b 28L L81 12. .13 3000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PDK PS NL G W S S T G G L S L D Q C K PO D L Y S SS1Q G NS SG GF VV DQ L0G0-NSRC.oNtekcoDyenrottAS T Q P T R S D E G S S Q S L T P V P G M G T L S T GG G T S S T Q P T R S D E P A G C E K VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PA DL SG SP LA TG PC VE PK VK RS P AL GS LS TH PT TK CK PP GN WR GG PK EL TT WY IE YG FR LD SE QR SF Y A G L T P T C P QGY L S S H T K K P NVP N S T R A Y L S S K K G T D S S A R V T H P N S T R A Y L SLF W S K S N E T E K G V Q S F G T P S W F P F W S K S N E T EQV S P D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y WVS V V C M V G V E V S V P D L G V G Q M R K S V V C M V G V EP T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V 011.928L812.14000 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGQ SG SA GM MY G Q Q TL LY SG TL GG GP T S S T Q P T R S D E G S S G M G QT L S QW G G W A G V S S P G A DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS R GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK C P G W G P E T W I Y FK P N R G K L T Y E G RVS K K C T D S S A R V T H P N S T R A Y L S S K K C T D S S ALK G V Q S F G T P S W F P F W S K T N E T E K G V Q S F G T PQD P E G S G G S V H N R Y V S P D I H K Y W D P E G S G G S VVV S V P D M G V G Q M R K S V V C Y V G V E V S V P D M G V GT L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S 111.9a 28L812.14000 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottATL G G T S S T Q P T R S D E G S S G M G QT L S T G G T P GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG L Y G L G S S T Q G P D S S L T PP LD SE QR SF YY AL GS LS TH PT TK CK PP GN W G P E T W VI SY SF PL S A L G P A G E Q S Y A G L CTR G K L T Y E G R D R F Y L S S HV VR V T H P N S T R A Y L S S K K C T D S S A R V T H P N S TL LS W F P F W S K S N E T E K G V Q S F G T P S W F P F W S KQ QH N R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P DV VQ M R K S V V C M V G V E V S V P D M G V G Q M R K S V V CC E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S 231 11.9b 28L L81 12. .14 5000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAT R S D E G S S G M G Q V P V R P Q G A M Y Q TL L S T GG G T S S T Q P T R S D E G S S GY G L P D S S L T P V P V R P Q G A MGE K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G G WSP T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P EET K K P N R G K L T Y E G R D R F Y L S S H E K K P N R G K LVR A Y L S S K K C T D S S A R V T H P N S T R A Y L S S K K CLS N E T E K G V Q S F G T P S W F P F W S K T N E T E K G V QQI H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E GVM V G V E V S V P D L G V G Q M R K S V V C Y V G V E V S V PL E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A 411.9a 28L812.15000 2 / 1S0T-PI450LAPNL GS T G G LO L D C K P Y S N Q S L GW S Y S T G G1NS SG GF VV DQ L Q0G NS SG GF0-NSRC.oNtekcoDyenrottAM G Q Y Q TL L S T GG G T S S T Q P T R S D E G S S G M G QT L S T GG G T A G V YS GS LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS L TT WY IE YG FR LD SE QR SF YY AL GS LS TH PT TK CK PP GN WR G P E T W I Y F P G P D L S A E Q LSG K L T Y E G R D R FV VT D S S A R V T H P N S T R A Y L S S K K C T D S S A R V TL LS F G T P S W F P F W S K S N E T E K G V Q S F G T P S W FQ QS G G S V H N R Y V S P D I H K Y W D P E G S G G S V H N RV VD L G V G Q M R K S V V C M V G V E V S V P D L G V G Q M RT D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K 561 11.9b 28L L81 12. .15 6000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PLL DK P S S NO L G Y S T C G L S Q L D G C K P S S W1VV DQ LG NS SG GF V D S V Q L0G0-NSRC.oNtekcoDyenrottASS S T Q P T R S D E G S S G M G QT L S T GG G T S S T Q P T R S D G S L T P V P V R P Q G A M Y Q L Y G L P D S S L T P V P V R Y PA AG GL CT EP KT KC SP QG QW GG GP WE AT GW VI SY SF PL GS AQ L G P A G C E K K SS Y A G L T P T C PEY L S S H T K K P N R G K L T Y E G R D R F Y L S S H E K K PVH P N S T R A Y L S S K K C T D S S A R V T H P N S T R A Y LLP F W S K S N E T E K G V Q S F G T P S W F P F W S K T N E TQY V S P D I H K Y W D P E G S G G S V H N R Y V S P D I H K YVK S V V C M V G V E V S V P D L G V G Q M R K S V V C Y V G VA P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q 711.9a 28L812.16000 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAEP GQ SG SA GM MY G Q Q TL LY SG TL GG G T S S T Q P T R S D E G S S G M G QT L QG Q G G W A G V S S P G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS N WR GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PT T C P G W G P E T W I YK K P N R G K L T Y E GVS S K K C T D S S A R V T H P N S T R A Y L S S K K C T D S SLE K G V Q S F G T P S W F P F W S K S N E T E K G V Q S F G TQW D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G G SVE V S V P D L G V G Q M R K S V V C M V G V E V S V P D L G VV T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G 811.9b 28L812.16000 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAS T G G T S S T Q P T R S D E G S E R S S K G T D G G T S S T QGS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GP PA SI SK VE QG SS FG GG P D S S L T FR LD SE QR SF YY AL GS LS TH PT TK CK PP GN WR GG SL QG T I V P D L S A L G P A E Q S Y A G G A R V V T H P N S T R A Y L S S L E G A T D V R F Y L S LSK S P T V S Q T F V T H P N SL LP S W F P F W S K S N E T E K G L K F K Q R L R W F P F W SQ QV H N R Y V S P D I H K Y W D P T Q D T V V T Y N R Y V S PV VG Q M R K S V V C M V G V E V S A Q T G L W V D M R K S V VS C E G K A P T T S L E N Q V T L P Y G G Q Y R R E G K A P T T 901 21.9a 28L L8112. .17 7000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAPP TV RP SV DR EP GQ SG EG RP SS SS KV GQ TS DF GG GP TD SS SS TL QT PP TV RP S D E G S E CT EP KT KC SP QG QW GG PS AQ IT KI EV G S G GS A L G P A G C E K VK RS PQ QQ GG GP HT E K K P N R G L G L E G PA DT LD E Q S Y A G L T P T C P G W G S V R F Y L S S H E K K P N R G LR A Y L S S K S P T V S Q T F V T H P N S T R A Y L S S K SLK T N E T E K G L K F K Q R L R W F P F W S K T N E T E K G LQD I H K Y W D P T Q D T V V T Y N R Y V S P D I H K Y W D P TVC Y V G V E V S A Q T G L W V D M R K S V V C Y V G V E V S AS L E N Q V T L P Y G G Q Y R R E G K A P T T S L E N Q V T L P 121.9a 28L812.18000 2 / 1S0T-PI450LAPNL GS TG L W G L D C K P Y S N S S L GO N S QG Y SG1S G F VV DQ LG NS S0G0-NSRC.oNtekcoDyenrottARP SS GG PK EL TT WY GG GP T S S T Q P T R S D E G S S G QL G QT L S T GG G AQ I K K C T D G D S S L T P V P V R P Q G G M Y Q L Y G L S A L G P A G C E K K S Q Q G G W L G V S S P G P G TL IE VE QG SS FG E QR SF YY AL GS LS TH PE TK CK PP GN WR GG PQ EL TN WY IE Y F L S A E Q PK TF VK VG PA DT LD VL VW TF HP PF NW SS TK RT AN YE LT S S K V G K D S GS RA DR V R QQ DT TG SQ QR TL FR QV NM RR YK V S P D I H K Y EW KD GP LG KG SN FG GG TS PI S L V H Q W V NS V V C Y V G V E V S G P D L G V G Q MY G C V V T Y E G K A P T T S L E N Q V T L G A R D G G S C E G 232 21.9a a 28L L81 12. .19 0000 1 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PTG LL D C K PS NL G S S TO Y G G L Q L D S Q K PSW GF VV DQ LG N S G C F V S V D S10S G Q LG0-NSRC.oNtekcoDyenrottAT S S T Q P T R S D E G S S G QL G QT L S T G G T S S T Q P T R SDL SG SP LA TG PC VE PK VK RS PQ QQ GG GG MW YL QG LV YS GS LP GG PA DL S S L T P V P V SF YY AL GS LS TH PE TK CK PP GN WR GG PQ EL T W I Y F L S G P A G C E K K E Q S Y A G L T P T CN Y E G R D R F Y L S S H E K KVT H P N S T R A Y L S S K V C K D S S A R V T H P N S T R A YLF P F W S K T N E T E K G L K S F G T P S W F P F W S K T N EQR Y V S P D I H K Y W D P G G N G G S I H N R Y V S P D I H KVR K S V V C Y V G V E V S G P D L G V G Q M R K S V V C Y V GK A P T T S L E N Q V T L G A R D G G S C E G K A P T T S L E N 421.9a 28L812.11001 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottADR EP GQ SG SA GM MY G Q Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G QT SP Q Q G G W A G V S S LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV P GN WR GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH P T C P G W G P E T W IE K K P N R G K L T Y EVL S S K K G T D S S A R V T H P N S T R A Y L S S K K C T D SLT E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S F GQY W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G GVV E V S V P D L G V G Q M R K S V V C Y V G V E V S V P D L GQ V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G 521.9a 28L812.12001 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAL S T G G T S S T Q P T R S D E G S S G M G QT L S T GYS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW Y Q L Y G L G G T S S G P D S S T YG FR LD SE QR SF YY AL GS LS TH PE TK CK P G W G P E AT GW VI SY SF PL S A L G P L E Q S Y A AGP N R G K L T Y E G R D R F Y L SV VS A R V T H P N S T R A Y L S S K K G T D S S A R V T H P NL LT P S W F P F W S K T N E T E K G V Q S F G T P S W F P F WQ QS V H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V SV VV G Q M R K S V V C Y V G V E V S V P D M G V G Q M R K S VG S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T 672 21.9a 28L L81 12. .13 4001 1 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAQ P T R S D E G S S G M G Q T P V P V R P Q G A M Y T L S T GG G T S S T Q P T R S D E G SQ L Y G L P D S S L T P V P V R P Q GGG C E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q GSL T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W GES H T K K P N R G K L T Y E G R D R F Y L S S H E K K P N R GVS T R A Y L S S K K G T D S S A R V T H P N S T R A Y L S S KLS K S N E T E K G V Q S F G T P S W F P F W S K T N E T E K GQP D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D PVV C M V G V E V S V P D M G V G Q M R K S V V C Y V G V E V ST S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L 821.9a 28L812.14001 2 / 1S0T-PI450LAPN O L GS T G G LL D N Q C K PS NW Y S G V SD S LY10S G F V Q LG NS0-NSRC.oNtekcoDyenrottASA GM MY GQ TL LY SG TL GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG SA GM MY G T L S T GGGP W K E AT GW VI SY SF PL GS AQ LS GY PA AG GL CT E K K S Q Q G G W A QG LV YS GS LP GS K LG TT YD ES G R D EV R F Y L S S H PE TK CK PP GN WR GG PK EL TT WY IE YG FR LD EVS A R V T H P N S T R A Y L S S K K G T D S S A RL LV Q S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQ QE G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HV VV P D M G V G Q M R K S V V C Y V G V E V S V P D M G V G QG A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E 902 31.9a 28L L81 12. .15 6001 1 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PGS TG L O Q L DK PS N S L GS TG L C L D G S K PS W1SG G VV D L YN G G S Q F G G C Q F V S S V D S Q L0G0-NSRC.oNtekcoDyenrottAG T S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T RPA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP GG PA D S S L T P V P QR SF YY AL GS LS TH PT TK CK PP GN WR GG PK E T W I Y F L S L G P A G C E K E Q S Y A G L T P TL T Y E G R D R F Y L S S H E KVV T H P N S T R A Y L S S K K G T D S S A R V T H P N S T R ALW F P F W S K S N E T E K G V Q S F G T P S W F P F W S K T NQN R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D I HVM R K S V V C M V G V E V S V P D M G V G Q M R K S V V C Y VG K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E 131.9a 28L812.16001 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASV D E G S S G M G Q R P Q G A M Y Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G K S Q Q G G W A G V S S LP G P D S S L T P V P V R P Q G A M Y Q S A L G P A G C E K K S Q Q G G W A GC P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E T WEK P N R G K L T Y E G R D R F Y L S S H E K K P N R G K L T YVY L S S K K G T D S S A R V T H P N S T R A Y L S S K K G T DLE T E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S FQK Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S GVG V E V S V P D M G V G Q M R K S V V C Y V G V E V S V P D MN Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D 231.9a 28L812.17001 2 / 1S0T-PI450LAPNL GS T O G G LL DK P C S N S L GS T Q G L Y S L DK W1NS SG G VV D L Y G N G F S Q Q G G C0S F V S V DQ0-NSRC.oNtekcoDyenrottAQT L S T G G T S S T Q P T R S D E G S S G M G QT L S T G G T S SLV YS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS G IE YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG P E T W I Y S L F P GG P L S A DL SG S E Q S Y PAK L T Y E G R D R F Y LV VS S A R V T H P N S T R A Y L S S K K G T D S S A R V T H PL LG T P S W F P F W S K T N E T E K G V Q S F G T P S W F P FQ QG S V H N R Y V S P D I H K Y W D P E G S G G S V H N R Y VV VG V G Q M R K S V V C Y V G V E V S V P D L G V G Q M R K SG G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P 343 31.9a a 28L L81 12. .18 9001 1 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PP O S NL G Y S TG L L G Q L DK PW S N S G CV S SS10G S G F V DQ LG0-NSRC.oNtekcoDyenrottAT Q P T R S D E G S S G M G Q L T P V P V R P Q G A T L S T GG G T S S T Q P T R S D E GM Y Q L Y G L P D S S L T P V P V R P QGA G C E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q QSG L T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G WES S H E K K P N R G K L T Y E G R D R F Y L S S H E K K P N RVN S T R A Y L S S K K G T D S S A R V T H P N S T R A Y L S SLW S K T N E T E K G V Q S F G T P S W F P F W S K T N E T E KQS P D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W DVV V C Y V G V E V S V P D L G V G Q M R K S V V C Y V G V E VT T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T 531.9a 28L812.10002 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASG SA GM MY G Q Q TL LY SG TL GG GP TD S S T Q P T R S D E G S S G M G QT L S T GG G W A G V S S P G A L SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK CK P G W G P E T W I Y F LP N R G K L T Y E G R DVK K G T D S S A R V T H P N S T R A Y L S S K K G T D S S A RLG V Q S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQP E G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HVS V P D L G V G Q M R K S V V C Y V G V E V S V P D L G V G QL G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C 631.9a 28L812.11002 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAG G T S S T Q P T R S D E G S S G M G QT L S T G G T SGG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV Y G L G S T Q P T G P D S S L T P VS S P A L G P A G C ES SQ S Y A G L T P T C P G W G P E T W I Y F L Q S Y A G L T PE ER F Y L S S H E K K P N R G K L T Y E G R D R F Y L S S H EV VV T H P N S T R A Y L S S K K G T D S S A R V T H P N S T RL LW F P F W S K T N E T E K G V Q S F G T P S W F P F W S K TQ QN R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D IV VM R K S V V C Y V G V E V S V P D L G V G Q M R K S V V C YE G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L 783 31.9a a 28L L81 12. .12 3002 2 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAR S D E G S S G M G Q P V R P Q G A M Y Q TL LY S T GG G T S S T Q P T R S D E G S S G MG L P D S S L T P V P V R P Q G A M YGK K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G G W AST C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E TEK K P N R G K L T Y E G R D R F Y L S S H E K K P N R G K L TVA Y L S S K K G T D S S A R V T H P N S T R A Y L S S K K G TLN E T E K G V Q S F G T P S W F P F W S K T N E T E K G V Q SQH K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G SVV G V E V S V P D L G V G Q M R K S V V C Y V G V E V S V P DE N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T 931.9a 28L812.14002 2 / 1S0T-PI450LAPNL GS T G G LL DK P C S NO S S L G Y S T Q Y G G LL W1NS SG GF V0V D LG N S Q G G C Q S F VV0-NSRC.oNtekcoDyenrottAG Q Q TL L S T GG G T S S T Q P T R S D E G S S G M G QT L S T GG G T S G V YS GS LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PA D S WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG PK EL TT W I Y F L S L E Q S GY DF SG ST AP RS VL VW TF HP PF NW SS TK RT AN YE LT S S K K G T YD ES GS RA DR V R F L V T Y GL GG SV VG HQ QV NM RR YK VS SV P D I H K Y EW KD GP VE QG SS FG GG TS PV S H H Q W F V N R PYV C Y V G V E V S V P D L G V G Q M R KD G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A 014 41.9a a 28L L81 12. .15 6002 2 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PDK PS NL G W S S T G G L S L D Q C K PO D L Y S SS1Q G NS SG GF VV DQ L0G0-NSRC.oNtekcoDyenrottAS T Q P T R S D E G S S Q S L T P V P G M G T L S T GG G T S S T Q P T R S D E P A G C E K VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PA DL SG SP LA TG PC VE PK VK RS P AL GS LS TH PE TK CK PP GN WR GG PK EL TT WY IE YG FR LD SE QR SF Y A G L T P T C P QGY L S S H E K K P NVP N S T R A Y L S S K K G T D S S A R V T H P N S T R A Y L SLF W S K T N E T E K G V Q S F G T P S W F P F W S K T N E T EQV S P D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y WVS V V C Y V G V E V S V P D L G V G Q M R K S V V C Y V G V EP T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V 241.9a 28L812.17002 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGQ SG SA GM MY G Q Q TL LY SG TL GG GP T S S T Q P T R S D E G S S G M G QT L S QW G G W A G V S S P G A DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS R GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK C P G W G P E T W I Y FK P N R G K L T Y E G RVS K K G T D S S A R V T H P N S T R A Y L S S K K C T D S S ALK G V Q S F G T P S W F P F W S K T N E T E K G V Q S F G T PQD P E G S G G S V H N R Y V S P D I H K Y W D P E G S G G S VVV S V P D L G V G Q M R K S V V C Y V G V E V S V P D M G V GT L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S 341.9a 28L812.18002 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottATL G G T S S T Q P T R S D E G S S G M G QT L S T G G T P GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG L Y G L G S S T Q G P D S S L T PP LD SE QR SF YY AL GS LS TH PE TK CK PP GN W G P E T W VI SY SF PL S A L G P A G E Q S Y A G L CTR G K L T Y E G R D R F Y L S S HV VR V T H P N S T R A Y L S S K K C T D S S A R V T H P N S TL LS W F P F W S K T N E T E K G V Q S F G T P S W F P F W S KQ QH N R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P DV VQ M R K S V V C Y V G V E V S V P D M G V G Q M R K S V V CC E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S 454 41.9a a 28L L81 12. .19 0002 3 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAT R S D E G S S G M G Q V P V R P Q G A M Y Q TL L S T GG G T S S T Q P T R S D E G S S GY G L P D S S L T P V P V R P Q G A MGE K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G G WSP T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P EEE K K P N R G K L T Y E G R D R F Y L S S H E K K P N R G K LVR A Y L S S K K C T D S S A R V T H P N S T R A Y L S S K K CLT N E T E K G V Q S F G T P S W F P F W S K T N E T E K G V QQI H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E GVY V G V E V S V P D M G V G Q M R K S V V C Y V G V E V S V PL E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A 641.9a 28L812.11003 2 / 1S0T-PI450LAPNL GS T G G LO L D C K P Y S N Q S L GW S Y S T G G1NS SG GF VV DQ L Q0G NS SG GF0-NSRC.oNtekcoDyenrottAM G Q Y Q TL L S T GG G T S S T Q P T R S D E G S S G M G QT L S T GG G T A G V YS GS LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS L TT WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR G P E T W I Y F P G P D L S A E Q LSG K L T Y E G R D R FV VT D S S A R V T H P N S T R A Y L S S K K C T D S S A R V TL LS F G T P S W F P F W S K T N E T E K G V Q S F G T P S W FQ QS G G S V H N R Y V S P D I H K Y W D P E G S G G S V H N RV VD M G V G Q M R K S V V C Y V G V E V S V P D M G V G Q M RT D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K 784 41.9a a 28L L81 12. .12 3003 3 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PLL DK P S S NO L G Y S T C G L S Q L D G C K P S S W1VV DQ LG NS SG GF V D S V Q L0G0-NSRC.oNtekcoDyenrottASS S T Q P T R S D E G S S G M G QT L S T GG G T S S T Q P T R S D G S L T P V P V R P Q G A M Y Q L Y G L P D S S L T P V P V R Y PA AG GL CT EP KT KC SP QG QW GG GP WE AT GW VI SY SF PL GS AQ L G P A G C E K K SS Y A G L T P T C PEY L S S H E K K P N R G K L T Y E G R D R F Y L S S H E K K PVH P N S T R A Y L S S K K C T D S S A R V T H P N S T R A Y LLP F W S K T N E T E K G V Q S F G T P S W F P F W S K T N E TQY V S P D I H K Y W D P E G S G G S V H N R Y V S P D I H K YVK S V V C Y V G V E V S V P D L G V G Q M R K S V V C Y V G VA P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q 941.9a 28L812.14003 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAEP GQ SG SA GM MY G Q Q TL LY SG TL GG G T S S T Q P T R S D E G S S G M G QT L QG Q G G W A G V S S P G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS N WR GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH PE T C P G W G P E T W I YK K P N R G K L T Y E GVS S K K C T D S S A R V T H P N S T R A Y L S S K K C T D S SLE K G V Q S F G T P S W F P F W S K T N E T E K G V Q S F G TQW D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G G SVE V S V P D L G V G Q M R K S V V C Y V G V E V S V P D L G VV T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G 051.9a 28L812.15003 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAS T G G T S S T Q P T R S D E G S S G M G QT L S T G GGS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA Q L Y G L G T S S T G P D S S L Q FR LD SE QR SF YY AL GS LS TH PE TK CK PP G W G P E T GW VI SY SF PL S A L G P A T E Q S Y A G GLN R G K L T Y E G R D R F Y L S SV VA R V T H P N S T R A Y L S S K K C T D S S A R V T H P N SL LP S W F P F W S K T N E T E K G V Q S F G T P S W F P F W SQ QV H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V S PV VG Q M R K S V V C Y V G V E V S V P D L G V G Q M R K S V VS C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T 125 51.9a a 28L L81 12. .16 7003 3 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAP T R S D E G S S G M G Q P V P V R P Q G A M Y Q T L S T GG G T S S T Q P T R S D E G S SL Y G L P D S S L T P V P V R P Q G AGC E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G GST P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G PEH E K K P N R G K L T Y E G R D R F Y L S S H E K K P N R G KVT R A Y L S S K K C T D S S A R V T H P N S T R A Y L S S K KLK T N E T E K G V Q S F G T P S W F P F W S K T N E T E K G VQD I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P EVC Y V G V E V S V P D L G V G Q M R K S V V C Y V G V E V S VS L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G 351.9a 28L812.18003 2 / 1S0T-PI450LAPNL GS TG L W G L D C K P Y S N S S L GO N S QG Y SG1S G F VV DQ LG NS S0G0-NSRC.oNtekcoDyenrottAG M G Q M Y Q TL LY SG TL GG GP T S S T Q P T R S D E G S S G M G QT L S T GG G WE A G V S S P G D S S L T P V P V R P Q G A M Y Q L Y G L S A L G P A G C E K K S Q Q G G W A G V S S P G P L TT WY IE YG FR LD E QR SF YY AL GS LS TH PE TK CK PP GN WR GG PK EL TT WY IE Y F L S A E Q CQ TS DF SG ST AP RS VL VW TF HP PF NW SS TK RT AN YE LT S S K K C T D S GS RA DR V R GP SD GL GG SV VG HQ QV NM RR YK V S P D I H K Y EW KD GP VE QG SS FG GG TS PV S L V H Q W V NS V V C Y V G V E V S V P D L G V G Q MA T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G 455 51.9a a 28L L81 12. .19 0003 4 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PTG LL D C K PS NL G S S TO Y G G L Q L D S K PSW G V0V D LG N S Q G G C Q V S F V D S1F S Q LG0-NSRC.oNtekcoDyenrottAT S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T R SDL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP GG P D S S L T P V P V SF YY AL GS LS TH PE TK CK PP GN W G P E T W I Y F L S A L G P A G C E K K E Q S Y A G L T P T CR G K L T Y E G R D R F Y L S S H E K KVT H P N S T R A Y L S S K K C T D S S A R V T H P N S T R A YLF P F W S K T N E T E K G V Q S F G T P S W F P F W S K T N EQR Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D I H KVR K S V V C Y V G V E V S V P D L G V G Q M R K S V V C Y V GK A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N 651.9a 28L812.11004 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottADR EP GQ SG SA GM MY G Q Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G QT SP Q Q G G W A G V S S LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV P GN WR GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH P T C P G W G P E T W IE K K P N R G K L T Y EVL S S K K C T D S S A R V T H P N S T R A Y L S S K K C T D SLT E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S F GQY W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G GVV E V S V P D L G V G Q M R K S V V C Y V G V E V S V P D L GQ V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G 751.9a 28L812.12004 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAL S T G G T S S T Q P T R S D E G S S G M G QT L S T GYS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW Y Q L Y G L G G T S S G P D S S T YG FR LD SE QR SF YY AL GS LS TH PE TK CK P G W G P E AT GW VI SY SF PL S A L G P L E Q S Y A AGP N R G K L T Y E G R D R F Y L SV VS A R V T H P N S T R A Y L S S K K G T D S S A R V T H P NL LT P S W F P F W S K T N E T E K G V Q S F G T P S W F P F WQ QS V H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V SV VV G Q M R K S V V C Y V G V E V S V P D L G V G Q M R K S VG S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T 895 51.9a a 28L L81 12. .13 4004 4 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAQ P T R S D E G S S G M G Q T P V P V R P Q G A M Y T L S T GG G T S S T Q P T R S D E G SQ L Y G L P D S S L T P V P V R P Q GGG C E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q GSL T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W GES H E K K P N R G K L T Y E G R D R F Y L S S H E K K P N R GVS T R A Y L S S K K G T D S S A R V T H P N S T R A Y L S S KLS K T N E T E K G V Q S F G T P S W F P F W S K T N E T E K GQP D I H K Y W D P E G S G G S I H N R Y V S P D I H K Y W D PVV C Y V G V E V S V P D L G V G Q M R K S V V C Y V G V E V ST S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L 061.9a 28L812.15004 2 / 1S0T-PI450LAPN O L GS T G G LL D N Q C K PS NW Y S G V SD S L L Y10S G F V Q G NS0-NSRC.oNtekcoDyenrottASA GM MY GQ TL LY SG TL GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG SA GM MY GQ T L S T GGGP W K E AT GW QI SY SF PL GS AQ LS GY PA AG GL CT EP KT KC S Q Q G G W A G LV YS GS LP GS K LG TT YD DS GS RS DR EV RV FT Y L S S H E K K PP GN WR GG PK EL TS WY IE YG FR LD EVH P N S T R A Y L S S K K G T D S S A RL LV Q S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQ QE G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HV VV P D L G V G Q M R K S V V C Y V G V E V S A P D L G V G QG A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E 126 61.9a a 28L L81 12. .16 7004 4 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PGS TG L O Q L DK PS N S L GS TG L C L D G S K PS W1SG G VV D L YN G G S Q F G G C Q F V S S V D S Q L0G0-NSRC.oNtekcoDyenrottAG T S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T RPA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP GG PA D S S L T P V P QR SF YY AL GS LS TH PE TK CK PP GN WR GG PK E T W I Y F L S L G P A G C E K E Q S Y A G L T P TL S Y E G R D R F Y L S S H T KVV T H P N S T R A Y L S S K K G T D S S A R V T H P N S T R ALW F P F W S K T N E T E K G V Q S F G T P S W F P F W S K S NQN R Y V S P D I H K Y W D P E G S G G S I H N R Y V S P D I HVM R K S V V C Y V G V E V S A P D L G V G Q M R K S V V C M VG K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E 361.928L812.18004 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASV D E G S S G M G Q R P Q G A M Y Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G K S Q Q G G W A G Q S S LP G P D S S L T P V P V R P Q G A M Y Q S A L G P A G C E K K S Q Q G G W A GC P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E T WEK P N R G K L S Y D G R D R F Y L S S H E K K P N R G K L S YVY L S S K K G T D S S S R V T H P N S T R A Y L S S K K G T DLE T E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S FQK Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S GVG V E V S A P D L G V G Q M R K S V V C Y V G V E V S A P D LN Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D 461.9a 28L812.18004 2 / 1S0T-PI450LAPNL GS T O G G LL DK P C S N S L GS T Q G L Y S L DK W1NS SG G VV D L Y G N G F S Q Q G G C0S F V S V DQ0-NSRC.oNtekcoDyenrottAQT L S T G G T S S T Q P T R S D E G S S G QL G QT L S T G G T S SLQ YS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GG MW YA QG LV YS G ID YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG P E T W I Y S L F P GG P L S A DL SG S E Q S Y PAQ L N Y E G R D R F Y LV VS S S R V T H P N S T R A Y L S S K V G K D S S A R V T H PL LG T P S W F P F W S K T N E T E K G L K S F G T P S W F P FQ QG S V H N R Y V S P D I H K Y W D P G G S G G S V H N R Y VV VG V G Q M R K S V V C Y V G V E V S G P D L G V G Q M R K SG G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P 566 61.9a a 28L L81 12. .19 0004 5 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PP O S NL G Y S TG L L G Q L DK PW S N S G CV S SS10G S G F V DQ LG0-NSRC.oNtekcoDyenrottAT Q P T R S D E G S S G QL G Q L T P V P V R P Q G T L S T GG G T S S T Q P T R S D E GG M Y Q L Y G L P D S S L T P V P V R P QGA G C E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q QSG L T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G WES S H E K K P N R G Q L N Y E G R D R F Y L S S H E K K P N RVN S T R A Y L S S K V G K D S S A R V T H P N S T R A Y L S SLW S K T N E T E K G L K S F G T P S W F P F W S K T N E T E KQS P D I H K Y W D P G G S G G S I H N R Y V S P D I H K Y W DVV V C Y V G V E V S G P D L G V G Q M R K S V V C Y V G V E VT T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T 761.9a 28L812.11005 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASG SG G Q M LY G Q Q TL LY SG TL GG GP T S S T Q P T R S D E G S S G M G QT L S T G G W A G Q S S P G A DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS L GG PQ EL TN WY ID YG FR LD SE QR SF YY AL GS LS TH PE TK CK P G W G P E T W I Y F PLP N R G K L T Y E G R DVK V G K D S S S R V T H P N S T R A Y L S S K K C T D S S A RLG L K S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQP G G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HVS G P D L G V G Q M R K S V V C Y V G V E V S V P D L G V G QL G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C 861.9a 28L812.12005 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAG G T S S T Q P T R S D E G S S G M G QT L S T G G T SGG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV Y G L G S T Q P T G P D S S L T P VS S P A L G P A G C ES SQ S Y A G L T P T C P G W G P E T W I Y F L Q S Y A G L T PE ER F Y L S S H E K K P N R G K L T Y E G R D R F Y L S S H EV VV T H P N S T R A Y L S S K K C T D S S A R V T H P N S T RL LW F P F W S K T N E T E K G V Q S F G T P S W F P F W S K TQ QN R Y V S P D I H K Y W D P E G S G G S I H N R Y V S P D IV VM R K S V V C Y V G V E V S V P D L G V G Q M R K S V V C YE G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L 906 71.9a a 28L L81 12. .13 4005 5 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAR S D E G S S G M G Q P V R P Q G A M Y Q TL LY S T GG G T S S T Q P T R S D E G S S G MG L P D S S L T P V P V R P Q G A M YGK K S Q Q G G W A G Q S S P A L G P A G C E K K S Q Q G G W AST C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E TEK K P N R G K L T Y D G R D R F Y L S S H E K K P N R G K L SVA Y L S S K K C T D S S S R V T H P N S T R A Y L S S K K C TLN E T E K G V Q S F G T P S W F P F W S K T N E T E K G V Q SQH K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G SVV G V E V S V P D L G V G Q M R K S V V C Y V G V E V S A P DE N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T 171.9a 28L812.15005 2 / 1S0T-PI450LAPNL GS T G G LL DK P C S NO S S L G Y S T Q Y G G LL W1NS SG GF V0V D LG N S Q G G C Q S F VV0-NSRC.oNtekcoDyenrottAG Q Q TL L S T GG G T S S T Q P T R S D E G S S G M G QT L S T GG G T S G V YS GS LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP G PA D S WY IE YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG PK EL TS W I Y F L S L E Q S GY DF SG ST AP RS VL VW TF HP PF NW SS TK RT AN YE LT S S K K C T YD ES GS RA DR V R F L V T Y GL GG SV VG HQ QV NM RR YK VS SV P D I H K Y EW KD GP VE QG SS FG GG TS PI S H H Q W F V N R PYV C Y V G V E V S A P D L G V G Q M R KD G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A 237 71.9a 28L L81 12. .16 7005 5 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PDK PS NL G W S S T G G L S L D Q C K PO D L Y S SS1Q G NS SG GF VV DQ L0G0-NSRC.oNtekcoDyenrottAS T Q P T R S D E G S S Q S L T P V P G M G T L S T GG G T S S T Q P T R S D E P A G C E K VK RS PQ QQ GG AG MW YA QG LQ YS GS LP G PA DL SG SP LA TG PC VE PK VK RS P AL GS LS TH PT TK CK PP GN WR GG PK EL TS WY ID YG FR LD SE QR SF Y A G L T P T C P QGY L S S H E K K P NVP N S T R A Y L S S K K C T D S S S R V T H P N S T R A Y L SLF W S K S N E T E K G V Q S F G T P S W F P F W S K T N E T EQV S P D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y WVS V V C M V G V E V S A P D L G V G Q M R K S V V C Y V G V EP T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V 471.9a 28L812.17005 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGQ SG SA GM MY G Q Q TL LY SG TL GG G T S S T Q P T R S D E G S S G QL G QT L S Q G G W A G Q S S P G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GG MW YA QG LV YS G WR GG PK EL TS WY ID YG FR LD SE QR SF YY AL GS LS TH PE TK C P G W G P E T W I Y SFK P N R G Q L N Y E G RVS K K C T D S S S R V T H P N S T R A Y L S S K V C K D S S ALK G V Q S F G T P S W F P F W S K T N E T E K G L K S F G T PQD P E G S G G S V H N R Y V S P D I H K Y W D P G G S G G S VVV S A P D L G V G Q M R K S V V C Y V G V E V S G P D L G V GT L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S 571.9a 28L812.18005 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottATL G G T S S T Q P T R S D E G S S G QL G QT L S T G G P GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GG MW YA Q L Y G L G T S S T Q G P D S S L T PP LD SE QR SF YY AL GS LS TH PE TK CK PP G W G P E T GW VI SY SF PL S A L G P A G E Q S Y A G L CTN R G Q L N Y E G R D R F Y L S S HV VR V T H P N S T R A Y L S S K V C K D S S A R V T H P N S TL LS W F P F W S K T N E T E K G L K S F G T P S W F P F W S KQ QH N R Y V S P D I H K Y W D P G G S G G S I H N R Y V S P DV VQ M R K S V V C Y V G V E V S G P D L G V G Q M R K S V V CC E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S 677 71.9a a 28L L81 12. .19 0005 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAT R S D E G S S G QL G Q V P V R P Q G G M Y Q T L S T GG G T S S T Q P T R S D E G S E RL Y G L P D S S L T P V P V R P Q G G PGE K K S Q Q G G W A G Q S S P A L G P A G C E K K S Q Q G P ASP T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G S QEE K K P N R G Q L N Y D G R D R F Y L S S H T K K P N R G L GVR A Y L S S K V C K D S S S R V T H P N S T R A Y L S S K S PLT N E T E K G L K S F G T P S W F P F W S K S N E T E K G L KQI H K Y W D P G G S G G S V H N R Y V S P D I H K Y W D P T QVY V G V E V S G P D L G V G Q M R K S V V C M V G V E V S A QL E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L P Y 871.928L812.11006 2 / 1S0T-PI450LAPNL GS T G G LO L D C K P Y S N Q S L GW S Y S T G G1NS SG GF VV DQ L Q0G NS SG GF0-NSRC.oNtekcoDyenrottASS GG PK EL TT WY GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG EG RP SS GG PK EL T W GG G T IT KI KV GQ TS DF GS AQ LS GY PA AG GL CT EP KT KC SP QG Q G P A I K K G TT YD G P S A D LT EV EV GP SD GM EV RV FT YH LP S S H E K K P N WR GG SL QG TL IE VE QG SS F L G E Q V R SFN S T R A Y L S S K S P T V V P D M V TL LF K G A T D W F P F W S K T N E T E K G L K F K G A T D W FQ QD T S Q T F N R Y V S P D I H K Y W D P T Q D T S Q T F N RV VT G Q R L R M R K S V V C Y V G V E V S A Q T G Q R L R M RG G V V T Y E G K A P T T S L E N Q V T L P Y G G V V T Y E G K 907 81.9a 28L L81 12. .11 2006 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PLL DK P S S NO L G Y S T C G L S Q L D G C K P S S W1VV DQ LG NS SG GF V D S V Q L0G0-NSRC.oNtekcoDyenrottASS SS TL QT PP TV RP SV DR EP GQ SG EG RP SS GG PK EL TT WY GG GP TD SS SS TL QT P T R S D GY PA AG GL CT EP KT KC SP QG QW GG PS AQ IT KI K G T D GS A L G P A G PC VE PK VK RS YH LP SN SS HT TR K K P N R G L G L E VE QG SS FG E Q S Y A G L T P T C P V R F Y L S S H E K K PA Y L S S K S P T V V P D L V T H P N S T R A Y LLP F W S K S N E T E K G L K F K G A T D W F P F W S K T N E TQY V S P D I H K Y W D P T Q D T S Q T F N R Y V S P D I H K YVK S V V C M V G V E V S A Q T G Q R L R M R K S V V C Y V G VA P T T S L E N Q V T L P Y G G V V T Y E G K A P T T S L E N Q 181.9a 28L812.12006 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAEP GQ SG EG RP SS GG PK EL TT WY GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG E R S G P E QG QW GG PS AQ IT KI KV GQ TS DF GS AQ LS G P A G C E K K S Q Q G GP PA SI GK KK LG NS R G L G L E E G S G E Y A G L T P T C P G W G S Q T I V Q V R F Y L S S H T K K P N R G L G L E E GS K S P T V V P D L V T H P N S T R A Y L S S K S P T V V PLE K G L K F K G A T D W F P F W S K S N E T E K G L K F K G AQW D P T Q D T S Q T F N R Y V S P D I H K Y W D P T Q D T S QVE V S A Q T G Q R L R M R K S V V C M V G V E V S A Q T G Q RV T L P Y G G V V T Y E G K A P T T S L E N Q V T L P Y G G V V 281.928L812.13006 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAT W G G T S S T Q P T R S D E G S E R S G P E T W G G T S S T QTT YD GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GP PA SI GK KK LG TT YD GG P D S S L T SS FG SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG SL QG T I V Q S F S A L G P A E Q S Y A G G D M V V T H P N S T R A Y L S S L E E G S G V R F Y L S LSK S P T V V P D M V T H P N SL LT D W F P F W S K T N E T E K G L K F K G A T D W F P F W SQ QT F N R Y V S P D I H K Y W D P T Q D T S Q T F N R Y V S PV VL R M R K S V V C Y V G V E V S A Q T G Q R L R M R K S V VT Y E G K A P T T S L E N Q V T L P Y G G V V T Y E G K A P T T 348 81.9a 28L L81 12. .13 4006 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAPP TV RP SV DR EP GQ SG EG RP SS GG PK EL TT WY GG GP TD SS SS TL QT PP TV RP S D E G S E CT EP KT KC SP QG QW GG PS AQ IT KI KV G T D GS A L G P A G C E K VK RS PQ QQ GG GP HT T K K P N R G L G L E E QG SS FG E Q S Y A G L T P T C P G W G S V R F Y L S S H E K K P N R G LR A Y L S S K S P T V V P D M V T H P N S T R A Y L S S K SLK S N E T E K G L K F K G A T D W F P F W S K T N E T E K G LQD I H K Y W D P T Q D T S Q T F N R Y V S P D I H K Y W D P TVC M V G V E V S S Q T G Q R L R M R K S V V C Y V G V E V S SS L E N Q V T L P Y G G V V T Y E G K A P T T S L E N Q V T L P 581.9a 28L812.14006 2 / 1S0T-PI450LAPNL GS TG L W G L D C K P Y S N S S L GO N S QG Y SG1S G F VV DQ LG NS S0G0-NSRC.oNtekcoDyenrottARP SS GG PK EL TT WY GG GP TD S S T Q P T R S D E G S S G M G QT L S T GG G AQ I K K G T D GS A L SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LQ YS GS LP G P S A G TL IE VE QG SS FG E QR SF YY AL GS LS TH PT TK CK PP GN WR GG PK EL TS WY ID Y F L E Q PK TF VK VG PA DT MD VL VW TF HP PF NW SS TK RS AN YE LT S S K K G T D S GS RS DR V R QQ DT TG SQ QR TL FR QV NM RR YK V S P D I H K Y EW KD GP VE QG SS FG GG TS PV S L V H Q W V NS V V C M V G V E V S A P D M G V G Q MY G G V V T Y E G K A P T T S L E N Q V T L G A T D G G S C E G 678 81.9a 28L L8112. .15 5006 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PTG LL D C K PS NL G S S TO Y G G L Q L D S K PSW G V0V D LG N S Q G G C Q V S F V D S1F S Q LG0-NSRC.oNtekcoDyenrottAT S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T R SDL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LQ YS GS LP GG P D S S L T P V P V SF YY AL GS LS TH PE TK CK PP GN W G P E T W I Y F L S A L G P A G C E K K E Q S Y A G L T P T CR G K L S Y D G R D R F Y L S S H T K KVT H P N S T R A Y L S S K K G T D S S S R V T H P N S T R A YLF P F W S K T N E T E K G V Q S F G T P S W F P F W S K S N EQR Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D I H KVR K S V V C Y V G V E V S A P D M G V G Q M R K S V V C M V GK A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N 881.928L812.16006 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottADR EP GQ SG SA GM MY G Q Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G QT SP Q Q G G W A G Q S S LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LQ P GN WR GG PK EL TS WY ID YG FR LD SE QR SF YY AL GS LS TH P T C P G W G P E T W IE K K P N R G K L S Y DVL S S K K C T D S S S R V T H P N S T R A Y L S S K K C T D SLT E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S F GQY W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G GVV E V S A P D M G V G Q M R K S V V C Y V G V E V S A P D M GQ V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G 981.9a 28L812.16006 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAL S T G G T S S T Q P T R S D E G S S G M G QT L S T GYS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW Y Q L Y G L G G T S S G P D S S T YG FR LD SE QR SF YY AL GS LS TH PT TK CK P G W G P E AT GW QI SY SF PL S A L G P L E Q S Y A AGP N R G K L S Y D G R D R F Y L SV VS S R V T H P N S T R A Y L S S K K C T D S S S R V T H P NL LT P S W F P F W S K S N E T E K G V Q S F G T P S W F P F WQ QS V H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V SV VV G Q M R K S V V C M V G V E V S A P D L G V G Q M R K S VG S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T 019 91.9a 28L L8112. .17 7006 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAQ P T R S D E G S S G M G Q T P V P V R P Q G A M Y T L S T GG G T S S T Q P T R S D E G SQ L Y G L P D S S L T P V P V R P Q GGG C E K K S Q Q G G W A G Q S S P A L G P A G C E K K S Q Q GSL T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W GES H E K K P N R G K L S Y D G R D R F Y L S S H T K K P N R GVS T R A Y L S S K K C T D S S S R V T H P N S T R A Y L S S KLS K T N E T E K G V Q S F G T P S W F P F W S K S N E T E K GQP D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D PVV C Y V G V E V S A P D L G V G Q M R K S V V C M V G V E V ST S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L 291.928L812.18006 2 / 1S0T-PI450LAPN O L GS T G G LL D N Q C K PS NW Y S G V SD S LY10S G F V Q LG NS0-NSRC.oNtekcoDyenrottASA GM MY GQ TL LY SG TL GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG SA GM MY G T L S T GGGP W K E AT GW QI SY SF PL GS AQ LS GY PA AG GL CT E K K S Q Q G G W A QG LQ YS GS LP GS K LC ST YD DS G R D EV R F Y L S S H PE TK CK PP GN WR GG PK EL TS WY ID YG FR LD EVS S R V T H P N S T R A Y L S S K K C T D S S S RL LV Q S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQ QE G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HV VA P D M G V G Q M R K S V V C Y V G V E V S A P D M G V G QG A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E 349 91.9a 28L L81 12. .18 9006 6 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PGS TG L O Q L DK PS N S L GS TG L C L D G S K PS W1SG G VV D L YN G G S Q F G G C Q F V S S V D S Q L0G0-NSRC.oNtekcoDyenrottAG T S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T RPA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LQ YS GS LP GG PA D S S L T P V P QR SF YY AL GS LS TH PT TK CK PP GN WR GG PK E T W I Y F L S L G P A G C E K E Q S Y A G L T P TL S Y D G R D R F Y L S S H E KVV T H P N S T R A Y L S S K K C T D S S S R V T H P N S T R ALW F P F W S K S N E T E K G V Q S F G T P S W F P F W S K T NQN R Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D I HVM R K S V V C M V G V E V S A P D M G V G Q M R K S V V C Y VG K A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E 591.9a 28L812.19006 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASV D E G S S G M G Q R P Q G A M Y Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G K S Q Q G G W A G Q S S LP G P D S S L T P V P V R P Q G A M Y Q S A L G P A G C E K K S Q Q G G W A GC P G W G P E T W I Y F L Q S Y A G L T P T C P G W G P E T WEK P N R G K L S Y D G R D R F Y L S S H T K K P N R G K L S YVY L S S K K C T D S S S R V T H P N S T R A Y L S S K K C T DLE T E K G V Q S F G T P S W F P F W S K S N E T E K G V Q S FQK Y W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S GVG V E V S A P D M G V G Q M R K S V V C M V G V E V S A P D LN Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D 691.928L812.10007 2 / 1S0T-PI450LAPNL GS T O G G LL DK P C S Y S G GS F Q T V Y S S QE W1NS SG G VV D L S G T F F R L Q A P A0S L T T G VS0-NSRC.oNtekcoDyenrottAQT L S T G G T S S T Q P T R S D E G S S G M G QT L S T E QG S G TLQ YS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LQ YS G ID YG FR LD SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG P E T W I Y S L F P VG P L S A DT MD S Q Q T F KSK L S Y D G R D R L R SV VS S S R V T H P N S T R A Y L S S K K C T D S S S R V T Y PL LG T P S W F P F W S K T N E T E K G V Q S F G T P S W V D AQ QG S V H N R Y V S P D I H K Y W D P E G S G G S V H Y R R LV VG V G Q M R K S V V C Y V G V E V S A P D L G V G Q M N R PG G S C E G K A P T T S L E N Q V T L G A T D G G S C Q Y K A F 789 91.9a 28L L81 12. .10 1007 0 2 / 1 2S0 0T- -PI4 45 50 0L LA AP PG O Q YG G S S FT V T F L S QE GW H T R P AT T QH10V S A L G VS TV0-NSRC.oNtekcoDyenrottAV I A V Q A T Y F G L N N G QT Q G Y P V E K L N V Q T G E Q V G S G T V I A V Q A T Y FG R I M Q M Y G Q P D M S G Y P V E K L N VGS T C C E N E N N G L W Q G Q W S G A T D K S T C C E N E N NST Q P T R S D E G S S G L W I N G F Q T F S T Q P T R S D E GQL T P V P V R P Q G G V Y V D L S T R L R S L T P V P V R P QVA G C E K K S Q Q G G W A D S Y G W V T Y P A G C E K K S Q QLG L T P T C P G W G P E T F G N S P W V D A G L T P T C P G WQS S H T K K P N R G Q L S Y G S F V Y R R L S S H E K K P N RVN S T R A Y L S S K V G K W G I R T M N R P N S T R A Y L S SW S K S N E T E K G L K S H G D S S Q Y K A F W S K T N E T E K 991.9a 28L812.11000 2 / 2S0T-PI450LAPYG GS F F T VS QOW S A E G R L1T T Q TS P V H0A L G S TV0-NSRC.oNtekcoDyenrottAGG LR NI NM G Q Q T Q M QY TG GQ E Q V GP SD GM T V I A V Q A T Y F G L N N G QT QQ T G GS LS W Q G Q W S G G S G Y P V E K L N V G R I M Q M Y G Q S A T D K S T C C E N E N N G L W Q G Q W S GG L W I N G F Q T F S T Q P T R S D E G S S G L W I N G FQG G V Y V D L S T R L R S L T P V P V R P Q G G V Y V D L S TVG G W A D S Y G W V T Y P A G C E K K S Q Q G G W A D S Y G WLG P E T F G N S P W V D A G L T P T C P G W G P E T F G N S PQG Q L S Y G S F V Y R R L S S H T K K P N R G Q L S Y G S F VVK V G K W G I R T M N R P N S T R A Y L S S K V G K W G I R TG L K S H G D S S Q Y K A F W S K S N E T E K G L K S H G D S S 0011.9b 28L812.11000 2 / 2S0T-PI450LAPYG GS FT VS Q A E GQ Y F G GS FT V S S QO L E GQ W1T R P T T G V H S T S A V T FR L A P A S T T L S V H0L G S TV0-NSRC.oNtekcoDyenrottAE QG S G T V I A V Q A T Y F G L N N G QT QQ T G E Q VG PA DT LD SK GS YT PC VC EE KN LE NN VN GG RL IW M Q M Y G Q V G S G T V I A V G P D L S G Y P VQ G Q W S G A T D K S T C CS SQ T F S T Q P T R S D E G S S G L W I N G F Q T F S T Q P TQ QR L R S L T P V P V R P Q G G V Y V D L S T R L R S L T P VV VV T Y P A G C E K K S Q Q G G W A D S Y G W V T Y P A G C EL LW V D A G L T P T C P G W G P E T F G N S P W V D A G L T PQ QY R R L S S H T K K P N R G Q L S Y G S F V Y R R L S S H EV VM N R P N S T R A Y L S S K V G K W G I R T M N R P N S T RQ Y K A F W S K S N E T E K G L K S H G D S S Q Y K A F W S K T 120 01 11.9a 28L L8112. .12 2000 0 2 / 2 2S0 0T- -PI4 45 50 0L LA AP PYG GS F F T VS QOW S A E G R L1T T Q T P V H0S A L G S TV0-NSRC.oNtekcoDyenrottAQ A T Y F G L N N G QT QQ T G E Q E K L N V G R I M Q V G S G T V I A V Q A T Y F G L N NM Y G Q P D L S G Y P V E K L N V G R I MGE N E N N G L W Q G Q W S G A T D K S T C C E N E N N G L W QSR S D E G S S G L W I N G F Q T F S T Q P T R S D E G S S G LQP V R P Q G G V Y V D L S T R L R S L T P V P V R P Q G G V YVK K S Q Q G G W A D S Y G W V T Y P A G C E K K S Q Q G G W ALT C P G W G P E T F G N S P W V D A G L T P T C P G W G P E TQK K P N R G Q L S Y G S F V Y R R L S S H T K K P N R G Q L SVA Y L S S K V G K W G I R T M N R P N S T R A Y L S S K V G KN E T E K G L K S H G D S S Q Y K A F W S K S N E T E K G L K S 3011.9b 28L812.12000 2 / 2S0T-PI450LAPYG GS F F T VS QE G A Q YO T H G G S S F L S F T VS W1TS RA PL T0G V TV T R L A P A S S L TG0-NSRC.oNtekcoDyenrottAG QT Q Q Q T G E QG S G T V I A V Q A T Y F G L N N G QT QQ T G E QG S G G MQ YW GS QG VG PA DT LD SK GS YT PC VC EE KN LE NN VN GG RL IW MQ QG MQ Y G Q VG P D L WV ID NL GS FT SQ QR TL FR SS TL QT PP TV RP SV DR EP GQ S S G L W I WN SG GF S A T Q Q T DFG G V Y V D L S T R L RV VD S Y G W V T Y P A G C E K K S Q Q G G W A D S Y G W V T YL LF G N S P W V D A G L T P T C P G W G P E T F G N S P W V DQ QY G S F V Y R R L S S H T K K P N R G Q L S Y G S F V Y R RV VW G I R T M N R P N S T R A Y L S S K V G K W G I R T M N RH G D S S Q Y K A F W S K S N E T E K G L K S H G D S S Q Y K A 450 01 11.9a 28L L8112. .13 3000 0 2 / 2 2S0 0T- -PI4 45 50 0L LA AP PQE GQ YG G W H S F F T V T S Q L A E GO V T S T QH1S V TS RA PL TG VS T0V0-NSRC.oNtekcoDyenrottATS VG IY AP V Q A T Y F G L N N G QT QQ T G E Q V G S G T V I A V Q A T Y K S T C VC EE KN LE NN VN GG RL IW MQ QG MQ YW GS QG G PA DT LD SK GS YT PC V SS TL QT PP TV RP SV DR EP GQ SG SG GV LY WV ID N G F SQ Q T F S T Q P C E T E K R N L S E N D NEL S T R L R S L T P V P V R PVP A G C E K K S Q Q G G W A D S Y G W V T Y P A G C E K K S QLA G L T P T C P G W G P E T F G N S P W V D A G L T P T C P GQL S S H E K K P N R G Q L S Y G S F V Y R R L S S H T K K P NVP N S T R A Y L S S K V G K W G I R T M N R P N S T R A Y L SF W S K T N E T E K G L K S H G D S S Q Y K A F W S K S N E T E 6011.9b 28L812.13000 2 / 2S0T-PI450LAPYG GS F F T VS QOW S A E G R L1T T Q T P V H0S A L G S TV0-NSRC.oNtekcoDyenrottAFV GG LR NI NM G Q Q T Q M QY T G E Q V G S G T V I A V Q A T Y F G L N N G QT QQ T N G L W Q G Q W GS QG G PA DT MD SK GS YT PC VC EE KN LE NN VN GG RL IW MQ QG MQ YW G GQ SG SG GV LY WV ID NL GS FT SQ QR TL FR SS TL QT PP TV RP S D E G S S G L W I N SGV R P Q G G V Y V D L SVQ G G W A D S Y G W V T Y P A G C E K K S Q Q G G W A D S Y GLW G P E T F G N S P W V D A G L T P T C P G W G P E T F G N SQR G Q L S Y G S F V Y R R L S S H T K K P N R G Q L S Y G S FVS K V G K W G I R T M N R P N S T R A Y L S S K V C K W G I RK G L K S H G D S S Q Y K A F W S K S N E T E K G L K S H G D S 7011.928L812.14000 2 / 2S0T-PI450LAPYG GS FT VS Q A E GQ Y F G GS FT V S S QO L E GQ W1T R P T T G V H S T S A V T FR L A P A S T T L S V H0L G S TV0-NSRC.oNtekcoDyenrottAG E QG S G T V I A V Q A T Y F G L N N G QT QQ T G Q CG VG PA DT MD SK GS YT PC VC EE KN LE NN VN GG RL I M Q M Y G C EV G S G T V I A G P D M S G Y PW Q G Q W S G A T D K S T CS SF Q T F S T Q P T R S D E G S S G L W I N G F Q T F S T Q PQ QT R L R S L T P V P V R P Q G G V Y V D L S T R L R S L T PV VW V T Y P A G C E K K S Q Q G G W A D S Y G W V T Y P A G CL LP W V D A G L T P T C P G W G P E T F G N S P W V D A G L TQ QV Y R R L S S H E K K P N R G Q L S Y G S F V Y R R L S S HV VT M N R P N S T R A Y L S S K V C K W G I R T M N R P N S TS Q Y K A F W S K T N E T E K G L K S H G D S S Q Y K A F W S K 890 01 11.9a b 28L L81 12. .14 4000 0 2 / 2 2S0 0T- -PI4 45 50 0L LA AP PYG GS F F T VS QOW S A E G R L1T T Q T P V H0S A L G S TV0-NSRC.oNtekcoDyenrottAV Q A T Y F G L N N G QT QQ T G E Q V E K L N V G R I M V G S G T V I A V Q A T Y F G L NQ M Y G C P D L S G Y P V E K L N V G R IGC E N E N N G L W Q G Q W S G A T D K S T C C E N E N N G L WST R S D E G S S G L W I N G F Q T F S T Q P T R S D E G S S GQV P V R P Q G G V Y V D L S T R L R S L T P V P V R P Q G G VVE K K S Q Q G G W A D S Y G W V T Y P A G C E K K S Q Q G G WLP T C P G W G P E T F G N S P W V D A G L T P T C P G W G P EQT K K P N R G Q L S Y G S F V Y R R L S S H T K K P N R G Q LVR A Y L S S K V C K W G I R T M N R P N S T R A Y L S S K V CS N E T E K G L K S H G D S S Q Y K A F W S K S N E T E K G L K 0111.928L812.15000 2 / 2S0T-PI450LAPYG GS F F T VO S Q A E G S Q YW T L H G G T S S F F T1S RA P L L TG VS T0V TS RA PL0-NSRC.oNtekcoDyenrottAN G QT Q M Q M Q T G E Q V G S G T V I A V Q A T Y F G L N N G QT QQ T G E Q V G S Q G Q YW GS CG G PA DT LD SK GS YT PC VC EE KN LE NN VN GG RL IW MQ QG MQ YW GS CG G PA D LY WV ID NL GS FT SQ QR TL FR SS TL QT PP TV RP SV DR EP GQ SG SG GV LY WV I N G F SQ Q TTD L S T R LV VA D S Y G W V T Y P A G C E K K S Q Q G G W A D S Y G W V TL LT F G N S P W V D A G L T P T C P G W G P E T F G N S P W VQ QS Y G S F V Y R R L S S H E K K P N R G Q L S Y G S F V Y RV VK W G I R T M N R P N S T R A Y L S S K V C K W G I R T M NS H G D S S Q Y K A F W S K T N E T E K G L K S H G D S S Q Y K 121 11 11.9a b 28L L81 12. .15 5000 0 2 / 2 2S0 0T- -PI4 45 50 0L LA AP PVS QE G T Q YO G G S S F A T V H L S Q F A E G T Q W1TG VS TV TS RA PL T V H G S T0V0-NSRC.oNtekcoDyenrottAG T V I A V Q A T Y F G L N N G QT QQ T G E QG S G T V I A V Q A TLD SK GS YT PC VC EE KN LE NN VN GG RL IW MQ QG MQ YW GS CG VG PA D L S G Y P V E K L FR SS TL QT PP TV RP SV DR EP GQ S S G L W I N G F S T D K S T C C E N E Q Q T F S T Q P T R S DG G V Y V D L S T R L R S L T P V P V RVY P A G C E K K S Q Q G G W A D S Y G W V T Y P A G C E K K SLD A G L T P T C P G W G P E T F G N S P W V D A G L T P T C PQR L S S H T K K P N R G Q L S Y G S F V Y R R L S S H T K K PVR P N S T R A Y L S S K V C K W G I R T M N R P N S T R A Y LA F W S K S N E T E K G L K S H G D S S Q Y K A F W S K S N E T 3111.928L812.16000 2 / 2S0T-PI450LAPYG GS F F T VS QOW S A E G R L1T T Q TS P V H0A L G S TV0-NSRC.oNtekcoDyenrottAYN FV GG LR NI NM G Q Q T Q M QY TG GC E Q V GP S G T V I A V Q A T Y F G L N N G QT QQ NE NG G L W Q G Q W S G G D L S G Y P V E K L N V G R I M Q M Y S A T D K S T C C E N E N N G L W Q G Q WS S G L W I N G F Q T F S T Q P T R S D E G S S G L W I NQP Q G G V Y V D L S T R L R S L T P V P V R P Q G G V Y V D LVQ Q G G W A D S Y G W V T Y P A G C E K K S Q Q G G W A D S YLG W G P E T F G N S P W V D A G L T P T C P G W G P E T F G NQN R G Q L S Y G S F V Y R R L S S H E K K P N R G Q L S Y G SVS S K V C K W G I R T M N R P N S T R A Y L S S K V C K W G IE K G L K S H G D S S Q Y K A F W S K T N E T E K G L K S H G D 4111.9a 28L812.16000 2 / 2S0T-PI450LAPYG GS FT VS Q A E GQ N F L GS TG L S L DO L K PS W1T R P T T G V H S T Y A V N GS Q G G C S V S L S D S0F V Q LG0-NSRC.oNtekcoDyenrottAT G E QG S G T V I A V Q A T Y F G L N N G QT QQ T GGS CG VG PA DT LD SK GS YT PC VC EE KN LE NN VN GG RL I M Q M Y G C GG G T S S T G P D S S L Q GS FT SQ QR TL FR SS TL QT PP TV RP S D E G S S WG QL GW QI WN SG GF S A L G P A T E Q S Y A G GLV R P Q G G V Y V D L S T R F Y L S SV VG W V T Y P A G C E K K S Q Q G G W A D S Y G W V T H P N SL LS P W V D A G L T P T C P G W G P E T F G N S P W F P F W SQ QF V Y R R L S S H T K K P N R G Q L S Y G S F V N R Y V S PV VR T M N R P N S T R A Y L S S K V C K W G I R T M R K S V VS S Q Y K A F W S K S N E T E K G L K S H G D S S E G K A P T T 561 11 11.9b 28L L81 12. .16 1000 0 2 / 2 3S0 0T- -PI4 45 50 0L LA AP PN O L GS T G G LL D N Q C K PS NW Y S G V SD S L L Y10S G F V Q G NS0-NSRC.oNtekcoDyenrottAPP TV RP SV DR EP GQ SG SG SV LY TG GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG S S L T GGCT E H P KT KC SP QG QW GG GP WE LT QG GS AQ LS GY PA AG GL C E K K S Q Q G GG VW YL GQ GS T TR KA KY PL NS RS GK QV RE N W EV R F Y L S S TH PE TK CK PP GN WR GG PQ ER TN GW EVK Y V T H P N S T R A Y L S S K V E K YL LK S N E T E K G L K S D W F P F W S K T N E T E K G L K S DQ QD I H K Y W D P G G N Y N R Y V S P D I H K Y W D P G G N YV VC M V G V E V S G P D W M R K S V V C Y V G V E V S G P D WS L E N Q V T L G A R S E G K A P T T S L E N Q V T L G A R S E 781 11 11.9a 28L L81 12. .11 2000 0 2 / 3 3S0 0T- -PI4 45 50 0L LA AP PGS TG L O Q L DK PS N S L GS TG L C L D G S K PS W1SG G VV D L YN G G S Q F G G C Q F V S S V D S Q L0G0-NSRC.oNtekcoDyenrottAG T S S T Q P T R S D E G S S S QL T G G T S S T Q P T R S D E GPA D Q L SG SP LA TG PC VE PK VK RS PQ QQ GG GG VW YV GQ GG PA DL SG SP LA T P V P V R P Q R SF YY AL GS LS TH PT TK CK PP GN WR GG PQ E T G SE Q S Y A G GL CT EP KT KC SP QG QWR N W R F Y L S S H E K K P N RVV T H P N S T R A Y L S S K V E K Y V T H P N S T R A Y L S SLW F P F W S K S N E T E K G L K S D W F P F W S K T N E T E KQN R Y V S P D I H K Y W D P G G N Y N R Y V S P D I H K Y W DVM R K S V V C M V G V E V S G P D W M R K S V V C Y V G V E VG K A P T T S L E N Q V T L G A R S E G K A P T T S L E N Q V T 9111.9a 28L812.12000 2 / 3S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottASG S S QL T G G T S S T Q P T R S D E G S S S QL T G G G GG VW YV GQ GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ G G V Y G G T S S T Q G P D S S L T PP GG PQ ER TN GW SE QR SF YY AL GS LS TH P T C P G W GG GP FE LT QG S A L G P A G E Q S Y A G L CTT K K P N R G Q R N W R F Y L S S HV VK V E K Y V T H P N S T R A Y L S S K V E K Y V T H P N S TL LG L K S D W F P F W S K S N E T E K G L K S D W F P F W S KQ QP G G N Y N R Y V S P D I H K Y W D P G G N Y N R Y V S P DV VS G P D W M R K S V V C M V G V E V S G P D W M R K S V V CL G A R S E G K A P T T S L E N Q V T L G A R S E G K A P T T S 012 21 11.9a 28L L8112. .13 3000 0 2 / 3 3S0 0T- -PI4 45 50 0L LA AP PNL GS TG L W G L D C K P Y S N S S L GO N S QG Y SG1S G F VV DQ LG NS S0G0-NSRC.oNtekcoDyenrottATV RP SV DR EP GQ SG SG S QL T GG G T S S T Q P T R S D E G S S S QL T GG G E K K S Q Q G G VF YL GQ G P D S S L T P V P V R P Q G G V Y G G P S A L G P A G C E K K S Q Q G G F V Q S AP T C P G W G P E T G Q S Y A G L T P T C P G W G P E T G QE EE K K P N R G Q R N W R F Y L S S H T K K P N R G Q R N W RV VR A Y L S S K V E K Y V T H P N S T R A Y L S S K V E K Y VL LT N E T E K G L K S D W F P F W S K S N E T E K G L K S D WQ QI H K Y W D P G G N Y N R Y V S P D I H K Y W D P G G N Y NV VY V G V E V S G P D W M R K S V V C M V G V E V S G P D W ML E N Q V T L G A R S E G K A P T T S L E N Q V T L G A R S E G 232 21 11.9a 28L L8112. .14 4000 0 2 / 3 3S0 0T- -PI4 45 50 0L LA AP PTG LL D C K PS NL G S S TO Y G G L Q L D S K PSW G V0V D LG N S Q G G C Q V S F V D S1F S Q LG0-NSRC.oNtekcoDyenrottAT S S T Q P T R S D E G S S S QL T G G T S S T Q P T R S D E G SDL SG SP LA TG PC VE PK VK RS PQ QQ GG GG VF YV GQ GG PA DL SG SP L T P V P V R P Q G SF YY AL GS LS TH PE TK CK PP GN W G P E T G S A G C E K K S Q Q G E Q S Y A G L T P T C P G W GR G Q R N W R F Y L S S H T K K P N R GVT H P N S T R A Y L S S K V E K Y V T H P N S T R A Y L S S KLF P F W S K T N E T E K G L K S D W F P F W S K S N E T E K GQR Y V S P D I H K Y W D P G G N Y N R Y V S P D I H K Y W D PVR K S V V C Y V G V E V S G P D W M R K S V V C M V G V E V SK A P T T S L E N Q V T L G A R S E G K A P T T S L E N Q V T L 4211.928L812.15000 2 / 3S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAS A QL T G G T S S T Q P T R S D E G S S A QL T G G TGG VF YV GQ GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG G V Y G G S S T Q P G P D S S L T P TV PQ ER TN GW SE QR SF YY AL GS LS TH PE T C P G W G GP FE VT QG S A L G P A G C E E Q S Y A G L T PK K P N R G Q R N W R F Y L S S H TV VV E K Y V T H P N S T R A Y L S S K V E K Y V T H P N S T RL LL K S D W F P F W S K T N E T E K G L K S D W F P F W S K SQ QG G N Y N R Y V S P D I H K Y W D P G G N Y N R Y V S P D IV VG P D W M R K S V V C Y V G V E V S G P D W M R K S V V C MG A R S E G K A P T T S L E N Q V T L G A R S E G K A P T T S L 562 21 11.9a 28L L81 12. .15 6000 0 2 / 3 3S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LO L D C K P Y S N Q S L GW S Y S T G G1NS SG GF VV DQ L Q0G NS SG GF0-NSRC.oNtekcoDyenrottARP SV DR E G S S A QL T GG G T S S T Q P T R S D E G S S A QL T GG G T K K S PQ QQ GG GG VW YV GQ G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GG VW YV G TK CK PP GN WR GG PQ ER TN GW SE QR SF YY AL GS LS TH PE TK C P G W G P E T Q G P D G S A E Q LSK P N R G Q R N W R FV VA Y L S S K V E K Y V T H P N S T R A Y L S S K V E K Y V TL LN E T E K G L K S D W F P F W S K T N E T E K G L K S D W FQ QH K Y W D P G G N Y N R Y V S P D I H K Y W D P G G N Y N RV VV G V E V S G P D W M R K S V V C Y V G V E V S G P D W M RE N Q V T L G A R S E G K A P T T S L E N Q V T L G A R S E G K 782 21 11.9a 28L L81 12. .16 1000 0 2 / 3 0S0 0T- -PI4 45 50 0L LA AP PLL DK P S S NO L G Y S T C G L S Q L D G C K P S S W1VV DQ LG NS SG GF V D S V Q L0G0-NSRC.oNtekcoDyenrottASS S T Q P T R S D E G S S A QL L S K Y K GG G T S S T Q P T R S D G S L T P V P V R P Q G G V Y T Q Q D T P D S S L T P V P V R Y PA AG GL CT EP KT KC SP QG QW GG GP WD LN GQ TM QF QG GA GS AQ L G P A G C E K K SS Y A G L T P T C PEY L S S H T K K P N R G Q L N G Q W S G R F Y L S S H E K K PVH P N S T R A Y L S S K V G K W I S G F V T H P N S T R A Y LLP F W S K S N E T E K G L K S Y D L S T W F P F W S K T N E TQY V S P D I H K Y W D P G G N A S Y G L N R Y V S P D I H K YVK S V V C M V G V E V S G P D F G T S P M R K S V V C Y V G VA P T T S L E N Q V T L G A R W G N F F E G K A P T T S L E N Q 9211.9a 28L812.11000 2 / 0S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAEP GQ SG SG A Q V LY LT SQ KQ YD KT GG G T S S T Q P T R S D E G S S G M G QT L QG Q G G W L G T Q Q G G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS N WR GG PQ DL NN QG MQ FW GS AG SE QR SF YY AL GS LS TH PT T C P G W G P E T W I YK K P N R G K L T Y E GVS S K V G K W I S G F V T H P N S T R A Y L S S K K G T D S SLE K G L K S Y D L S T W F P F W S K S N E T E K G V Q S F G TQW D P G G N A S Y G L N R Y V S P D I H K Y W D P E G S G G SVE V S G P D F G T S P M R K S V V C M V G V E V S V P D M G VV T L G A R W G N F F E G K A P T T S L E N Q V T L G A T D G G 0311.928L812.11000 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAS T G G T S S T Q P T R S D E G S S G M G QT L S T G GGS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA Q L Y G L G T S S T G P D S S L Q FR LD SE QR SF YY AL GS LS TH PE TK CK PP G W G P E T GW VI SY SF PL S A L G P A T E Q S Y A G GLN R G K L T Y E G R D R F Y L S SV VA R V T H P N S T R A Y L S S K K G T D S S A R V T H P N SL LP S W F P F W S K T N E T E K G V Q S F G T P S W F P F W SQ QV H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V S PV VG Q M R K S V V C Y V G V E V S V P D M G V G Q M R K S V VS C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T T 123 31 11.9a 28L L81 12. .11 2000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAP T R S D E G S S G M G Q P V P V R P Q G A M Y Q T L S T GG G T S S T Q P T R S D E G S SL Y G L P D S S L T P V P V R P Q G AGC E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q G GST P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W G PEH T K K P N R G K L T Y E G R D R F Y L S S H E K K P N R G KVT R A Y L S S K K G T D S S A R V T H P N S T R A Y L S S K KLK S N E T E K G V Q S F G T P S W F P F W S K T N E T E K G VQD I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D P EVC M V G V E V S V P D L G V G Q M R K S V V C Y V G V E V S VS L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L G 3311.9a 28L812.12000 2 / 1S0T-PI450LAPNL GS TG L W G L D C K P Y S N S S L GO N S QG Y SG1S G F VV DQ LG NS S0G0-NSRC.oNtekcoDyenrottAG M G Q M Y Q TL LY SG TL GG GP T S S T Q P T R S D E G S S G M G QT L S T GG G WE A G V S S P G D S S L T P V P V R P Q G A M Y Q L Y G L S A L G P A G C E K K S Q Q G G W A G V S S P G P L TT WY IE YG FR LD E QR SF YY AL GS LS TH PT TK CK PP GN WR GG PK EL TT WY IE Y F L S A E Q GQ TS DF SG ST AP RS VL VW TF HP PF NW SS TK RS AN YE LT S S K K G T D S GS RA DR V R GP SD GL GG SV VG HQ QV NM RR YK V S P D I H K Y EW KD GP VE QG SS FG GG TS PV S L V H Q W V NS V V C M V G V E V S V P D L G V G Q MA T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E G 453 31 11.9a 28L L8112. .13 3000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PTG LL D C K PS NL G S S TO Y G G L Q L D S K PSW G V0V D LG N S Q G G C Q V S F V D S1F S Q LG0-NSRC.oNtekcoDyenrottAT S S T Q P T R S D E G S S G M G QT L S T G G T S S T Q P T R SDL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV YS GS LP GG P D S S L T P V P V SF YY AL GS LS TH PE TK CK PP GN W G P E T W I Y F L S A L G P A G C E K K E Q S Y A G L T P T CR G K L T Y E G R D R F Y L S S H T K KVT H P N S T R A Y L S S K K G T D S S A R V T H P N S T R A YLF P F W S K T N E T E K G V Q S F G T P S W F P F W S K S N EQR Y V S P D I H K Y W D P E G S G G S V H N R Y V S P D I H KVR K S V V C Y V G V E V S V P D L G V G Q M R K S V V C M V GK A P T T S L E N Q V T L G A T D G G S C E G K A P T T S L E N 6311.928L812.14000 2 / 1S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottADR EP GQ SG SA GM MY G Q Q TL LY SG T GG G T S S T Q P T R S D E G S S G M G QT SP Q Q G G W A G V S S LP G PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW YA QG LV P GN WR GG PK EL TT WY IE YG FR LD SE QR SF YY AL GS LS TH P T C P G W G P E T W IE K K P N R G K L T Y EVL S S K K C T D S S A R V T H P N S T R A Y L S S K K C T D SLT E K G V Q S F G T P S W F P F W S K T N E T E K G V Q S F GQY W D P E G S G G S V H N R Y V S P D I H K Y W D P E G S G GVV E V S V P D M G V G Q M R K S V V C Y V G V E V S V P D M GQ V T L G A T D G G S C E G K A P T T S L E N Q V T L G A T D G 7311.9a 28L812.14000 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAL S T G G T S S T Q P T R S D E G S S G M G QT L S T GYS GS LP GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ GG AG MW Y Q L Y G L G G T S S G P D S S T YG FR LD SE QR SF YY AL GS LS TH PT TK CK P G W G P E AT GW VI SY SF PL S A L G P L E Q S Y A AGP N R G K L T Y E G R D R F Y L SV VS A R V T H P N S T R A Y L S S K K C T D S S A R V T H P NL LT P S W F P F W S K S N E T E K G V Q S F G T P S W F P F WQ QS V H N R Y V S P D I H K Y W D P E G S G G S V H N R Y V SV VV G Q M R K S V V C M V G V E V S V P D L G V G Q M R K S VG S C E G K A P T T S L E N Q V T L G A T D G G S C E G K A P T 893 31 11.9a 28L L8112. .15 5000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAQ P T R S D E G S S G M G Q T P V P V R P Q G A M Y T L S T GG G T S S T Q P T R S D E G SQ L Y G L P D S S L T P V P V R P Q GGG C E K K S Q Q G G W A G V S S P A L G P A G C E K K S Q Q GSL T P T C P G W G P E T W I Y F L Q S Y A G L T P T C P G W GES H E K K P N R G K L T Y E G R D R F Y L S S H T K K P N R GVS T R A Y L S S K K C T D S S A R V T H P N S T R A Y L S S KLS K T N E T E K G V Q S F G T P S W F P F W S K S N E T E K GQP D I H K Y W D P E G S G G S V H N R Y V S P D I H K Y W D PVV C Y V G V E V S V P D L G V G Q M R K S V V C M V G V E V ST S L E N Q V T L G A T D G G S C E G K A P T T S L E N Q V T L 0411.928L812.16000 2 / 1S0T-PI450LAPN O L GS T G G LL D N Q C K PS NW Y S G V SD S L L Y10S G F V Q G NS0-NSRC.oNtekcoDyenrottASA GM MY GQ TL LY SG TL GG GP TD SS SS TL QT PP TV RP SV DR EP GQ SG SA GM MY GQ T L S T GGGP W K E AT GW VI SY SF PL GS AQ LS GY PA AG GL CT EP KT KC S Q Q G G W A G LV YS GS LP GS K LC TT YD ES GS RA DR EV RV FT Y L S S H E K K PP GN WR GG PK EL TT WY IE YG FR LD EVH P N S T R A Y L S S K K C T D S S A RL LV Q S F G T P S W F P F W S K T N E T E K G V Q S F G T P SQ QE G S G G S V H N R Y V S P D I H K Y W D P E G S G G S V HV VV P D L G V G Q M R K S V V C Y V G V E V S V P D L G V G QG A T D G G S C E G K A P T T S L E N Q V T L G A T D G G S C E 124 41 11.9a a 28L L81 12. .16 9000 0 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PGS TG L O Q L DK PS N S L GS TG L C L D G S K PS W1SG G VV D L YN G G S Q F G G C Q F V S S V D S Q L0G0-NSRC.oNtekcoDyenrottAG T S S T Q P T R S D E G S S G QL G QT L S T G G T S SPA DL SG SP LA TG PC VE PK VK RS PQ QQ GG GG MW YL QG L Y G L G T Q P T R G P D S S L T P V PV S S P A L G P A G C E KSQ S Y A G L T P T C P G W G P E T W I Y F L Q S Y A G L T P TER F Y L S S H E K K P N R G Q L N Y E G R D R F Y L S S H E KVV T H P N S T R A Y L S S K V G K D S S A R V T H P N S T R ALW F P F W S K T N E T E K G L K S F G T P S W F P F W S K T NQN R Y V S P D I H K Y W D P G G N G G S I H N R Y V S P D I HVM R K S V V C Y V G V E V S G P D L G V G Q M R K S V V C Y VG K A P T T S L E N Q V T L G A R D G G S C E G K A P T T S L E 3411.9a 28L812.10001 2 / 1S0T-PI450LAPYG GS F F T VS QOW S A E G R L1T T Q T P V H0S A L G S TV0-NSRC.oNtekcoDyenrottAS D E G S S G QL G QT L S T E Q V R P Q G G M Y Q L V G S G T V I A V Q A T Y F G L N N GY G L P D L S G Y P V E K L N V G R I M QGK S Q Q G G W L G V S S P A T D K S T C C E N E N N G L W Q GSC P G W G P E T W I Y F L Q T F S T Q P T R S D E G S S G L WQK P N R G Q L N Y E G R D R L R S L T P V P V R P Q G G V Y VVY L S S K V C K D S S A R V T Y P A G C E K K S Q Q G G W A DLE T E K G L K S F G T P S W V D A G L T P T C P G W G P E T FQK Y W D P G G N G G S I H Y R R L S S H E K K P N R G Q L S YVG V E V S G P D L G V G Q M N R P N S T R A Y L S S K V G K WN Q V T L G A R D G G S C Q Y K A F W S K T N E T E K G L K S H 4411.9a 28L812.12000 2 / 2S0T-PI450LAPYG GS F O F T VS QE G A Q Y H G GS F L T V S T S QE W1TS RA P TG V T S V T F L R L S A P A0S L T T G VS0-NSRC.oNtekcoDyenrottAQT QQ T G E QG S G T V I A V Q A T Y F G L N N G QT QQ T G E QG S G TMQ YW GS QG VG PA DT LD SK GS YT PC VC EE KN LE NN VN GG RL IW MQ QG MQ YW G ID NL GS FT SQ QR TL FR SS TL QT PP TV RP SV DR EP GQ SG S G L W I N S Q G G VG P F S A DT LD S Q Q T F KSG V Y V D L S T R L R SV VS Y G W V T Y P A G C E K K S Q Q G G W A D S Y G W V T Y PL LG N S P W V D A G L T P T C P G W G P E T F G N S P W V D AQ QG S F V Y R R L S S H E K K P N R G Q L S Y G S F V Y R R LV VG I R T M N R P N S T R A Y L S S K V G K W G I R T M N R PG D S S Q Y K A F W S K T N E T E K G L K S H G D S S Q Y K A F 564 41 11.9a a 28L L81 12. .13 5000 0 2 / 2 2S0 0T- -PI4 45 50 0L LA AP PG O Q YG G S S FT V T F L S QE GW H T R P AT T QH10V S A L G VS TV0-NSRC.oNtekcoDyenrottAV I A V Q A T Y F G L N N G QT Q G Y P V E K L N V Q T G E Q V G S G T V I A V Q A T Y FG R I M Q M Y G C P D L S G Y P V E K L N VGS T C C E N E N N G L W Q G Q W S G A T D K S T C C E N E N NST Q P T R S D E G S S G L W I N G F Q T F S T Q P T R S D E GQL T P V P V R P Q G G V Y V D L S T R L R S L T P V P V R P QVA G C E K K S Q Q G G W A D S Y G W V T Y P A G C E K K S Q QLG L T P T C P G W G P E T F G N S P W V D A G L T P T C P G WQS S H E K K P N R G Q L S Y G S F V Y R R L S S H E K K P N RVN S T R A Y L S S K V C K W G I R T M N R P N S T R A Y L S SW S K T N E T E K G L K S H G D S S Q Y K A F W S K T N E T E K 7411.9a 28L812.16000 2 / 2S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGG L N N G QT Q R I M Q M QY TG GC GG GP TD S S T Q P T R S D E G G V G E T Q H G F GS L W Q G Q W S G G A L SG SP LA TG PC VE PK VK RS PQ QQ SG SA GM MY GQ TL LY SG TL G SG GV LY WV ID NL GS FT SE QR SF YY AL GS LS TH PT TK CK P G W G G W A G Q S S PP N R G P E T W I Y F LVG G W A D S Y G W V T H P N S T R A Y L S S G K L S Y D G R DLG P E T F G N S P W F P F W S K S N E T E K G K C T D S S S RQG Q L S Y G S F V N R Y V S P D I H K Y W D P V Q S F G T P SVK V C K W G I R T M R K S V V C M V G V E V S E G S G G S V HG L K S H G D S S E G K A P T T S L E N Q V T L A P D L G V G Q 6561.928L812.11007 2 / 1S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAG G T S S T Q P T R S D E G G V G E T Q H G F G G T S S T Q P TGG PA DL SG SP LA TG PC VE PK VK RS PQ QQ SG SA GM MY GQ TL LY SG TL GG PA DL S S L T P V SE QR SF YY AL GS LS TH PE TK CK PP GN WR GG GP WE AT GW Q S S P S G P A G C E Q S Y A G L T E V V T H P N S T R A Y L S S G K I Y F L V R F Y L S S H PTL S Y D G R D V T H P N S T RL LW F P F W S K T N E T E K G K C T D S S S R W F P F W S K SQ QN R Y V S P D I H K Y W D P V Q S F G T P S N R Y V S P D IV VM R K S V V C Y V G V E V S E G S G G S V H M R K S V V C ME G K A P T T S L E N Q V T L A P D L G V G Q E G K A P T T S L 785 56 61.9a 28L L81 12. .11 2007 7 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottARP SV DR EP GQ GS VS GG EM TG QT HL GS FT GG GP TD SS SS TL QT PP TV RP SV DR E G G V G E KT KC SP QG QW GG AG MW YA QG LQ YS GS L GS A L G P A G C E K K S PQ QQ SG SA GM MY KA K P N R G P E T W I Y F PL E Q S Y A G L T P T C P G W G G W A V R F Y L S S H E K K P N R G P E TY L S S G K L S Y D G R D V T H P N S T R A Y L S S G K L SLN E T E K G K C T D S S S R W F P F W S K T N E T E K G K C TQH K Y W D P V Q S F G T P S N R Y V S P D I H K Y W D P V Q SVV G V E V S E G S G G S V H M R K S V V C Y V G V E V S E G SE N Q V T L A P D M G V G Q E G K A P T T S L E N Q V T L A P D 9561.9a 28L812.12007 2 / 1S0T-PI450LAPNL GS T G G LL DK P C S NO S S L G Y S T Q Y G LLW NS SG GF VV D L N G S S Q G G C10Q G F VV0-NSRC.oNtekcoDyenrottATG QT HL GS FT GG GP TD SS SS TL QT PP TV RP SV DR EP GQ GS VS GG EM TG QT HL GS F GG G T S QG LQ YS GS LP GS AQ LS GY PA AG GL CT EP KT KC SP QG QW G A M Y Q L Y G TL G P D S A L S WY ID YG FR LD EV RV FT YH LP SN S H T K K P N R GG GP WE AT GW QI SY SF P G L E Q S V R F YYS T R A Y L S S G K L S Y D G R D V T HL LD S S S R W F P F W S K S N E T E K G K C T D S S S R W F PQ QF G T P S N R Y V S P D I H K Y W D P V Q S F G T P S N R YV VG G S V H M R K S V V C M V G V E V S E G S G G S V H M R KM G V G Q E G K A P T T S L E N Q V T L A P D M G V G Q E G K A 016 66 61.928L L81 12. .13 4007 7 2 / 1 1S0 0T- -PI4 45 50 0L LA AP PDK PS NL G W S S T G G L S L D Q C K PO D L Y S SS1Q G NS SG GF VV DQ L0G0-NSRC.oNtekcoDyenrottASS TL QT PP TV RP SV DR EP GQ GS VS GG EM TG QT HL GS FT GG GP TD SS SS TL QT PP T R S D E PA AG GL CT EP KT KC SP QG QW GG AG MW YA QG LQ Y G L GS A L G P A G C VE PK VK RS PQ LP SN SS HT TR KA K P N R G P E T W I SY SF PL E Q S Y A G L T P T C P G V R F Y L S S H T K K P NY L S S G K L S Y D G R D V T H P N S T R A Y L SLF W S K S N E T E K G K C T D S S S R W F P F W S K S N E T EQV S P D I H K Y W D P V Q S F G T P S N R Y V S P D I H K Y WVS V V C M V G V E V S E G S G G S V H M R K S V V C M V G V EP T T S L E N Q V T L A P D M G V G Q E G K A P T T S L E N Q V 2661.928L812.15007 2 / 1S0T-PI450LAPNL GS T G G LO L D C K P Y S N Q S L GW S Y S T G G1NS SG GF VV DQ L Q0G NS SG GF0-NSRC.oNtekcoDyenrottAGQ GS VS GG EM TG QT HL GS FT GG GP TD SS SS TL QT PP TV RP SV DR EP GQ GS LS VA Q L GG G T QW GG AG MW YA QG LQ YS GS LP GS AQ LS GY PA AG GL CT EP K K S Q Q G G V LY TG G P S A D RS GG PK EL TS WY ID YG FR LD EV R F Y L S S H T TK CK PP GN WR GG GP FE VT Q L G E Q V R SFV T H P N S T R A Y L S S G Q R N W V TL LK G K C T D S S S R W F P F W S K S N E T E K G V E K Y W FQ QD P V Q S F G T P S N R Y V S P D I H K Y W D P L K S D N RV VV S E G S G G S V H M R K S V V C M V G V E V S G G N Y M RT L A P D L G V G Q E G K A P T T S L E N Q V T L G P D W E G K 346 66 61.928L L81 12. .17 8000 0 2 / 3 3S0 0T- -PI4 45 50 0L LA AP PLL DK P S S NO L G Y S T C G L S Q L D G C K P S S W1VV DQ LG NS SG GF V D S V Q L0G0-NSRC.oNtekcoDyenrottASS SS TL QT PP TV RP SV DR EP GQ GS LS VA QL LT GG GP TD SS SS TL QT PP TV RP SV D E G G L GY PA AG GL CT EP KT KC SP QG QW GG GG VF YV GQ GS A L G P A G C E K K RS PQ QQ SG SG YH LP SN SS HT TR K K P N R G P E T G E Q S Y A G L T P T C P G W G G V R F Y L S S H T K K P N R G PA Y L S S G Q R N W V T H P N S T R A Y L S S G QLP F W S K S N E T E K G V E K Y W F P F W S K S N E T E K G VQY V S P D I H K Y W D P L K S D N R Y V S P D I H K Y W D P LVK S V V C M V G V E V S G G N Y M R K S V V C M V G V E V S GA P T T S L E N Q V T L G P D W E G K A P T T S L E N Q V T L G 5661.928L812.19000 2 / 3S0T-PI450LAPNL GS TG LL D C K PS N G L GS TG L Y L DO Q K PS W1N S G V S V D S S L Y G G N GS Q G G C Q V S F S D S0F V Q LG0-NSRC.oNtekcoDyenrottAV Q L G G T S S T Q P T R S D E G G L V Q L G G T S S T Q P T RAV LY TG GG PA DL SG SP LA TG PC VE PK VK RS PQ QQ SG SG AV LY TG GG PA DL SG S L T P V P FE VT QG SE QR SF YY AL GS LS TH PT TK CK PP GN WR GG GP F V Q S P A G C E K E Q S Y A G L T P TE T G R F Y L S S H T KV VR N W V T H P N S T R A Y L S S G Q R N W V T H P N S T R AL LE K Y W F P F W S K S N E T E K G V E K Y W F P F W S K S NQ QK S D N R Y V S P D I H K Y W D P L K S D N R Y V S P D I HV VG N Y M R K S V V C M V G V E V S G G N Y M R K S V V C M VP D W E G K A P T T S L E N Q V T L G P D W E G K A P T T S L E 676 66 61.928L L81 12. .10 1001 0 2 / 3 5S0 0T- -PI4 45 50 0L LA AP PNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASV DR EP GQ GG TA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS T Q P T R S KC SP QG QW GS RE LR LS VT RP SY TV TG A T F A K P V P G L T P V P S A L G P A G C E K VK KY P N R G G P S R Y T P A GA YG NT TD TS EP SS EV E Q S Y A G L T P T C V R F Y L S S H E K KL S S G P A I K F S S S T S G D A F L K V T H P N S T R A YLE T E K G S Q T I N D S T A A G F S Y S K W F P F W S K T N EQK Y W D P L G L E N K L G T K N Q S D Y D N R Y V S P D I H KVG V E V S S P T V L S G T G C S L V K L V M R K S V V C Y V GN Q V T L L K F K L D Q G G S P S T V G K E G K A P T T S L E N 8661.9a 28L812.11000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottADR EP GQ GG TA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL Q P T R S D SP QG QW GS RE LR LS VT RP SY TV TG AG T F A K P V P G T P V P V S A L G P A G C E K K RS PL N R G G P S R Y T P A A YG NT TD TS EP SS EV E Q S Y A G L T P T C P V R F Y L S S H T K K PS S G P A I K F S S S T S G D A F L K V T H P N S T R A Y LLT E K G S Q T I N D S T A A G F S Y S K W F P F W S K S N E TQY W D P L G L E N K L G T K N Q S D Y D N R Y V S P D I H K YVV E V S S P T V L S G T G C S L V K L V M R K S V V C M V G VQ V T L L K F K L D Q G G S P S T V G K E G K A P T T S L E N Q 9661.928L812.12000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAEP GQ GG TA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT P T R S D E QG QW GS RE LR LS VT RP SY TV TG AG TY F A K P V P G P V P V R P S A L G P A G C E K K S QN T T E S E Q S Y A G L T P T C P GEN R G G P S R Y T P A A G T D S P S V R F Y L S S H E K K P NVS S G P A I K F S S S T S G D A F L K V T H P N S T R A Y L SLE K G S Q T I N D S T A A G F S Y S K W F P F W S K T N E T EQW D P L G L E N K L G T K Q Q S D Y D N R Y V S P D I H K Y WVE V S S P T V L S G T G C S L V K L V M R K S V V C Y V G V EV T L L K F K L D Q G G S P S T V G K E G K A P T T S L E N Q V 0761.9a 28L812.12000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGQ GG TA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP T R S D E G QW GS RE LR LS VT RP SY TV TG AG TY FN A K P V P GS A L G P A G C VE PK VK RS PQ QQ RS G G P S R Y T P A A G T TD TS EP SS EV E Q S Y A G L T P T C P G W V R F Y L S S H T K K P N RG P A I K F S S S T S G D A F L K V T H P N S T R A Y L S SLK G S Q T I N D S T A A G F S Y S K W F P F W S K S N E T E KQD P L G L E N K L G T K Q Q S D Y D N R Y V S P D I H K Y W DVV S S P T V L S G T G C S L V K L V M R K S V V C M V G V E VT L L K F K L D Q G G S P S T V G K E G K A P T T S L E N Q V T 1761.928L812.13000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAGG TA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV R S D E G G GS RE LR LS VT RP SY TV TG AG TY FN AT K P V P GS A L G P A G C E PK VK RS PQ QQ GG GG G P S R Y T P A A G T D TS EP SS EV E Q S Y A G L T P T C P G W S V R F Y L S S H E K K P N R GP A I K F S S S T S G D A F L K V T H P N S T R A Y L S S GLG S Q T I N D S T A A G F S Y S K W F P F W S K T N E T E K GQP L G L E N K L G T K R Q S D Y D N R Y V S P D I H K Y W D PVS S P T V L S G T G C S L V K L V M R K S V V C Y V G V E V SL L K F K L D Q G G S P S T V G K E G K A P T T S L E N Q V T L 2761.9a 28L812.13000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottATA IL PE AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV RP S D E G G T RE LR LS VT RP SY TV TG AG TY FN AT KT P V P GS A L G P A G C E K VK RS PQ QQ GG VR GP P S R Y T P A A G T D S EP SS EV E Q S Y A G L T P T C P G W S D V R F Y L S S H T K K P N R G GA I K F S S S T S G D A F L K V T H P N S T R A Y L S S G VLS Q T I N D S T A A G F S Y S K W F P F W S K S N E T E K G SQL G L E N K L G T K R Q S D Y D N R Y V S P D I H K Y W D P AVS P T V L S G T G C S L V K L V M R K S V V C M V G V E V S SL K F K L D Q G G S P S T V G K E G K A P T T S L E N Q V T L L 3761.928L812.14000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q S S N G S1S G F VV D0Q LG0-NSRC.oNtekcoDyenrottAL L V R S T T A T F A K P V P G A L G P A G C E K K S Q Q G R LKP S A S T I R P K Y Y F T V S P G S A G S A Y T G N S T T G D T E S E S E SA PF SL VK E Q S Y A G L T P T C P G W S D K V RV FT YH LP SN SS HT ER KA KY PL NS RS GG GV PALK T I N D S T A A G S S Y S K W F P F W S K T N E T E K G S KQG L E N K L G T K N R S D Y D N R Y V S P D I H K Y W D P A GVP T V L S G T G C S L V K L V M R K S V V C Y V G V E V S S PK F K L D Q G G S P S T V G K E G K A P T T S L E N Q V T L L K 4761.9a 28L812.14000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAPQ AA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV RP SV DR E G G T I P LS VT RP SY TV TG AG TY FN AT KT PE VS P GS A L G P A G C E K K S PQ QQ GG VR LL QL SI R Y T P A A G T D S P S EV E Q S Y A G L T P T C P G W S D K S V R F Y L S S H T K K P N R G G P SK F S S S T S G E A F L K V T H P N S T R A Y L S S G V A ILT I N D S T A A G S S Y S K W F P F W S K S N E T E K G S K TQL E N K L G T K N R S D Y D N R Y V S P D I H K Y W D P A G LVT V L S G T G C S L V K L V M R K S V V C M V G V E V S S P TF K L D Q G G S P S T V G K E G K A P T T S L E N Q V T L L K F 5761.928L812.15000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAAA AE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV RP SV DR EP G G T I P A VT RP SY TV TG AG TY FN AT KT PE VS PE GS A L G P A G C E K K S Q QQ GG VR LL QL AV RK Y T P A A G T D S P S V E Q S Y A G L T P T C P G W S D K S T V R F Y L S S H E K K P N R G G P S RF S S S T S G E A F L K V T H P N S T R A Y L S S G V A I KLI N D S T A A G S S Y S K W F P F W S K T N E T E K G S K T IQE N K L G T K Q R S D Y D N R Y V S P D I H K Y W D P A G L EVV L S G T G C S L V K L V M R K S V V C Y V G V E V S S P T VK L D Q G G S P S T V G K E G K A P T T S L E N Q V T L L K F K 6761.9a 28L812.15000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottAAE SL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV RP SV DR EP GQ G T I P A A RP SY TV TG AG TY FN AT KT PE VS PE GS AQ L G P A G C E K K S Q Q GG VR LL QL AV ER YF T P A A G T D S P S V E S Y A G L T P T C P G W S D K S T P V R F Y L S S H T K K P N R G G P S R YS S S T S G E A F L K V T H P N S T R A Y L S S G V A I K FLN D S T A A G S S Y S K W F P F W S K S N E T E K G S K T I NQN K L G T K Q R S D Y D N R Y V S P D I H K Y W D P A G L E NVL S G T G C S L V K L V M R K S V V C M V G V E V S S P T V LL D Q G G S P S T V G K E G K A P T T S L E N Q V T L L K F K L 7761.928L812.16000 2 / 5S0T-PI450LAPNL GS T G G LL DOW Y C K P S Q1V S S N G D S0S G F V Q LG0-NSRC.oNtekcoDyenrottASL SK GT SS TF EN YV PG TV TV SK GG GP TD SS SS TL QT PP TV RP SV DR EP GQ GG T I P A A S SY TV TG AG TY FN AT KT PE VS PE GS AQ LS G P A G C E K K S Q Q G VR LL QL AV ER LS TS P A A G T D S P S V E Y A G L T P T C P G W S D K S T P Y V R F Y L S S H E K K P N R G G P S R Y TS S T S G E A F L K V T H P N S T R A Y L S S G V A I K F SLD S T A A G S S Y S K W F P F W S K T N E T E K G S K T I N DQK L G T K R R S D Y D N R Y V S P D I H K Y W D P A G L E N KVS G T G C S L V K L V M R K S V V C Y V G V E V S S P T V L SD Q G G S P S T V G K E G K A P T T S L E N Q V T L L K F K L D 8761.9a 28L812.16000 2 / 5S0T-PI450LAPO W1LT QQ PV PE GG PA PF A L K00A Y G L G L Y PF SS KD -NSRC.oNtekcoDyenrottA QO ESNDI 627L P A M G S AFS T K G G N K Y S V V C T SS TF EN YV PG TV TV SKthgiRL A A Q Y A T GS LS NV HT PP VD AN VT PL S QR YT LY YH SS GG NW YL NC KD FL VV HV LV AKT T A T F A K P V PLG V P A P V S S G I C F V E S NV G G Y N T T E S E G W E T Y T T V S Y S V C V V SdP A A G T D S P S VnP N G S K V S T S T K S T G V VS S T S G E A F L KaQ M T K A L K V Q Q P P V D R KS T A A G S S Y S KsV G Y S C T S P L T E G E V Y CL G T K R R S D Y DnL Y T T Y G S E V G V G P Y T KG T G C S L V K L ViG N N D Y Q P P A L K A T W S YQ G G S P S T V G Ka nG T I L V G A F P S K A R N N Eh iaG F W S A W L Y F S D E S F Y KChS T G F T V P D T S V P I K Q GyE Y V T D D F K H P K A M V E NCvV G W F E F V V V V T P L E E La yeL S E R A Y S L G T N C T P R WvaQ A L R R W P C S V S P D D P DHeV A G K L H G G T V P P K E K QfH E C K F S S K L L S K C P H T Hose1.c 9n 2O8e8NQu22 1Eq 0 0De 0 S 7 I2 / S S. T-PBe Iu 4L4 r 5m 1te .0s al 1LnbN0oa A4tTCc P 0O W1LT QQ PV PE GG PA PF AP LS K00A Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAY K Y V H S V Y P S Y V Q K Q E S R A A Q Y A T S S V T P D NVQ V P L N C N T E L L K A G E G E G V N G T N F I D G T Y T V T A T E A E Y K L G DS ER TV DA TV S Q Y L Y S G N Y N K F V H G RV TP YA HP SV GS WS LG CI DC LF VV VEGE T P S H G S T G L T Q P P S K P W E T Y T T V S Y S V C VPR L Q Y M S Q Y M T D G P Y E S S N G S K V S T S T K S T GQP S G L V G V G W V D W F F Q L S M T K A L K V Q Q P P V DVQ V N F S G L S E R F Y I N S T L G Y S C T S P L T E G E VLG Q S F C G Q A L N Q D F N N L G Y T T Y G S E V G V G P YGK N E S S P V K G K L F V L G T Q N N D Y Q P P A L K A E WGA K W G F S Q C Q F S G S L S S H T I L V G A F P S K A R NGK T E D V L S S G K K M P C Q S T F W S A W L Y F S D E T FSS L V S N S G V P E L D A V L L V T G F T V P D T S V P I KEI E A D G L G K A N E F A V A S E Y V T D D F K H P K A Y VVT D I L Q S G V Q F M R V S N Y C G W F E F V V V V T P L ELK R D V Q K G S R N Y Y S A D T A C S E R A Y S L G T N C T PQE S S P W Q S A V T A D A T V S Y E A L R R W P C S V S P D DVI P P P R T G G W G T R S G K D V G A G K L H G G T V P P K EEP P Y T S Y G P Y G T R S S W K K R C K F S S K L L S K C P H 1.928823 10 0072 / ST-a PI4L51.01L 0A4P 0O W1LT QQ PV PE GG PA PF AP LS K00A Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAT L Y K Y V H S V Y P S Y V Q K Q E S R A A Q Y A T S S V T PLV A S K V N Q V P L N C N T E L L K A G E G E G V N G T N F I D G T Y T E A E Y K L T VA TG DS ER TV DA TV S Q Y L Y S G N Y N K F G RV TP YA HP SV GS WS LG CI DC LFGV S E T P S H G S T G L T Q P P S K P W E T Y T T V S Y S VPV V R L Q Y M S Q Y M T D G P Y E S S N G S K V S T S T K SQR K P S G L V G V G W V D W F F Q L S M T K A L K V Q Q P PVY C Q V N F S G L S E R F Y I N S T L G Y S C T S P L T E GLT K G Q S F C G Q A L N Q D F N N L G Y T T Y G S E V G V GGS Y K N E S S P V K G K L F V L G T Q N N D Y Q P P A L K AGN E A K W G F S Q C Q F S G S L S S H T I L V G A F P S K AGY K K T E D V L S S G K K M P C Q S T F W S A W L Y F S D ESQ G S L V S N S G V P E L D A V L L V T G F T V P D T S V PEE N I E A D G L G K A N E F A V A S E Y V T D D F K H P K AVE L T D I L Q S G V Q F M R V S N Y C G W F E F V V V V T PLR W K R D V Q K G S R N Y Y S A D T A C S E R A Y S L G T N CQP D E S S P W Q S A V T A D A T V S Y E A L R R W P C S V S PVK Q I P P P R T G G W G T R S G K D V G A G K L H G G T V P PET H P P Y T S Y G P Y G T R S S W K K R C K F S S K L L S K C 1.928824 10 0072 / ST-PI4L51.02L 0A4P 0OW1LT QQ PV PE GG PA PF AP LS K00A Y G L G L Y F S KD-NSRC.oNtekcoDyenrottAD N T L Y K Y V H S V Y P S Y V Q K Q E S R A A Q Y A T S S VVV H V V L E V A S K V N Q V P L N C N T E L L K A G E G E G V N G T N D Y T E A E Y K LS Q Y L Y S G N Y N F IG TT VA TG DS ER TV DA TV G RV TP YA HP SV GS WS LG CIGC V V S E T P S H G S T G L T Q P P S K P W E T Y T T V S YPT G V V R L Q Y M S Q Y M T D G P Y E S S N G S K V S T S TQV D R K P S G L V G V G W V D W F F Q L S M T K A L K V Q QVE V Y C Q V N F S G L S E R F Y I N S T L G Y S C T S P L TLP Y T K G Q S F C G Q A L N Q D F N N L G Y T T Y G S E V GGT W S Y K N E S S P V K G K L F V L G T Q N N D Y Q P P A LGR N N E A K W G F S Q C Q F S G S L S S H T I L V G A F P SGS F Y K K T E D V L S S G K K L P C Q S T F W S A W L Y F SSI K Q G S L V S N S G V P E L D A V L L V T G F T V P D T SEM V E N I E A D G L G K A N E F A V A S E Y V T D D F K H PVL E E L T D I L Q S G V Q F M R V S N Y C G W F E F V V V VLT P R W K R D V Q K G S R N Y Y S A D T A C S E R A Y S L G TQD D P D E S S P W Q S A V T A D A T V S Y E A L R R W P C S VVK E K Q I P P P R T G G W G T R S G K D V G A G K L H G G T VEP H T H P P Y T S Y G P Y G T R S S W K K R C K F S S K L L S 1.928825 10 0072 / ST-a PI4L51.02L 0A4P 0OW1LT QQ P Y V PE G A G P00G L G A P L F A Y PF -NSRC.oNtekcoDyenrottATK PF DV NH T L Y K Y V H S V Y P S Y V Q K Q E S RL A A Q Y A T S D L A V V N T L G E N N D Y T E A E Y K Q Y L Y S G N C LF VV VE VS KN QP LC NE LK AE GG V T I T V T D E T D T SG R T Y H S G WG F G T A G S R V A V V P A P V S SGS V C V V S E T P S H G S T G L T Q P P S K P W E T Y T T VPK S T G V V R L Q Y M S Q Y M T D G P Y E S S N G S K V S TQP P V D R K P S G L V G V G W V D W F F Q L S M T K A L K VVE G E V Y C Q V N F S G L S E R F Y I N S T L G Y S C T S PLV G P Y T K G Q S F C G Q A L N Q D F N N L G Y T T Y G S EGK A E W S Y K N E S S P V K G K L F V L G T Q N N D Y Q P PGK A R N N E A K W G F S Q C Q F S G S L S S H T I L V G A FGD E T F Y K K T E D V L S S G K K L P C Q S T F W S A W L YSV P I K Q G S L V S N S G V P E L D A V L L V T G F T V P DEK A Y V E N I E A D G L G K A N E F A V A S E Y V T D D F KVT P L E E L T D I L Q S G V Q F M R V S N Y C G W F E F V VLN C T P R W K R D V Q K G S R N Y Y S A D T A C S E R A Y S LQS P D D P D E S S P W Q S A V T A D A T V S Y E A L R R W P CVP P K E K Q I P P P R T G G W G T R S G K D V G A G K L H G GEK C P H T H P P Y T S Y G P Y G T R S S W K K R C K F S S K L 1.928826 10 0072 / ST-PI4L51.03L 0A4P 0OW1LS KK L D T QQ P S V P00A Y G E G L G P G AL -NSRC.oNtekcoDyenrottASY VN TK PF D N T L Y K Y V H S V Y P S Y V Q K Q E S RL A A Q Y A L V H L A V V N T L G E N N D Y T E A E Y K Q Y L Y S G CI DC LF VV VE VS KN QP LC NE LK A G V T I T V T D E T D T SG R T Y H SE G G F G T A G S R V A V V P A P VGS Y S V C V V S E T P S H G S T G L T Q P P S K P W E T Y TPS T K S T G V V R L Q Y M S Q Y M T D G P Y E S S N G S K VQQ Q P P V D R K P S G L V G V G W V D W F F Q L S M T K A LVL T E G E V Y C Q V N F S G L S E R F Y I N S T L G Y S C TLV G V G P Y T K G Q S F C G Q A L N Q D F N N L G Y T T Y GGA L K A T W S Y K N E S S P V K G K L F V L G T Q N N D Y QGP S K A R N N E A K W G F S Q C Q F S G S L S S H T I L V GGF S D E S F Y K K T E D V L S S G K K L P C Q S T F W S A WST S V P I K Q G S L V S N S G V P E L D A V L L V T G F T VEH P K A M V E N I E A D G L G K A N E F A V A S E Y V T D DVV V T P L E E L T D I L Q S G V Q F M R V S N Y C G W F E FLG T N C T P R W K R D V Q K G S R N Y Y S A D T A C S E R A YQS V S P D D P D E S S P W Q S A V T A D A T V S Y E A L R R WVT V P P K E K Q I P P P R T G G W G T R S G K D V G A G K L HEL S K C P H T H P P Y T S Y G P Y G T R S S W K K R C K F S S 1.928827 10 0072 / ST-a PI4L51.03L 0A4P 0OW1PF AP L F S KK I Y T Q00S D V Q P Y V P G QL -NSRC.oNtekcoDyenrottATG SN SY VN T P D N T L Y K Y V H S V Y P S Y V Q K Q E S RL A A Q G K F V H L A V V N T L G E N N D Y T E A E Y K Q Y L S WS LG CI DC LF VV VE VS KN QP LC N L A G V T I T V T D E T D T SG R T YE K E G G F G T A G S R V A V V P AGT V S Y S V C V V S E T P S H G S T G L T Q P P S K P W E TPS T S T K S T G V V R L Q Y M S Q Y M T D G P Y E S S N G SQK V Q Q P P V D R K P S G L V G V G W V D W F F Q L S M T KVS P L T E G E V Y C Q V N F S G L S E R F Y I N S T L G Y SLS E V G V G P Y T K G Q S F C G Q A L N Q D F N N L G Y T TGP P A L K A E W S Y K N E S S P V K G K L F V L G T Q N N DGA F P S K A R N N E A K W G F S Q C Q F S G S L S S H T I LGL Y F S D E T F Y K K T E D V L S S G K K L P C Q S T F W SSP D T S V P I K Q G S L V S N S G V P E L D A V L L V T G FEF K H P K A Y V E N I E A D G L G K A N E F A V A S E Y V TVV V V V T P L E E L T D I L Q S G V Q F M R V S N Y C G W FLS L G T N C T P R W K R D V Q K G S R N Y Y S A D T A C S E RQP C S V S P D D P D E S S P W Q S A V T A D A T V S Y E A L RVG G T V P P K E K Q I P P P R T G G W G T R S G K D V G A G KEK L L S K C P H T H P P Y T S Y G P Y G T R S S W K K R C K F 1.928828 10 0072 / ST-PI4L51.04L 0A4P 0OW1GG PA P L F AP L G S K00Y F S K I D T Q V QY -NSRC.oNtekcoDyenrottAYY AS TG SN S V T P D N T L Y K Y V H S V Y P S Y V Q K Q E S RL A H Y N K F V H L A V V N T L G E N N D Y T E A E Y K Q P SV GS WS LG CI DC LF VV VE VS KN Q L N L A G A T I T V T D E T D T SG RP C E K E G G F G T A G S R V A V VGY T T V S Y S V C V V S E T P S H G S T G L T Q P P S K P WPK V S T S T K S T G V V R L Q Y M S Q Y M T D G P Y E S S NQA L K V Q Q P P V D R K P S G L V G V G W V E W F F Q L S MVC T S P L T E G E V Y C Q V N F S G L S E R S Y I N S T L GLY G S E V G V G P Y T K G Q S F C G Q A L N R D F N N L G YGY Q P P A L K A T W S Y K N E S S P V K G K L F V L G T Q NGV G A F P S K A R N N E A K W G F S E C Q F S G S L S S H TGA W L Y F S D E S F Y K K T E D V L S S G K S M P C Q S T FST V P D T S V P I K Q G S L V S N S G V P E L D A V L L V TED D F K H P K A M V E N I E A D G L G K A N E F A V A S E YVE F V V V V T P L E E L T D I L Q S G V Q F M R V S N Y C GLA Y S L G T N C T P R W K R D V Q K G S R N Y Y S A D T A C SQR W P C S V S P D D P D E S S P W Q S A V T A D A T V S Y E AVL H G G T V P P K E K Q I P P P R T G G W G T R S G K D V G AES S K L L S K C P H T H P P Y T S Y G P Y G S R S S W K K R C 1.928829 10 0072 / ST-a PI4L51.04L 0A4P 0O W1PV PQ G L G PA P G F AP L0S K0G L Y F S KD -NSRC.oNtekcoDyenrottAA Q GY SA T GS S V T P D N T L Y GK Y V H GS V Y SP SS CY V Q K Q E SYT LY YH SS GG NW YL NC KD FL VV HV LV AK VQ VL NN TL LA GG EA NT NI DT YV TT ED AE ET YD K P A P V S S G I C F V E S N P C E K E G G F G T A G S R V A TVE T Y T T V S Y S V C V V S E T P S H G S T G L T Q P P S K PG S K V S T S T K S T G V V R L Q Y M S Q Y M T D G P Y E S ST K A L K V Q Q P P V D R K P S G L V G V G W V E W F F Q L SY S C T S P L T E G E V Y C Q V N F S G L S E R S Y I N S T LT T Y G S E V G V G P Y T K G Q S F C G Q A L N R D F N N L GN D Y Q P P A L K A E W S Y K N E S S P V K G K L F V L G T QI L V G A F P S K A R N N E A K W G F S E C Q F S G S L S S HW S A W L Y F S D E T F Y K K T E D V L S S G K S M P C Q S TG F T V P D T S V P I K Q G S L V S N S G V P E L D A V L L VV T D D F K H P K A Y V E N I E A D G L G K A N E F A V A S EW F E F V V V V T P L E E L T D I L Q S G V Q F M R V S N Y CE R A Y S L G T N C T P R W K R D V Q K G S R N Y Y S A D T A CL R R W P C S V S P D D P D E S S P W Q S A V T A D A T V S Y EG K L H G G T V P P K E K Q I P P P R T G G W G T R S G K D V GK F S S K L L S K C P H T H P P Y T S Y G P Y G S R S S W K K R 1.928821002 / STPIO W1IT QQ PV PQ GG PA PF AP LS K00V Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAR A A Q Y A T S S V T P D N T L Y K Y V H S V Y P S Y V Q K Q ELS QR YT LY YH SS GG NW YL NC KD FL VV HV LV AK VQ VL NN TL LA GG EA NT NI DT YV TT ED AE ET Y G V P A P V S S G I C F V E S N P C E K E G G F G T A G S R V DAG W E T Y T T V S Y S V C V V S E T P S H G S T G L T Q P P S KP N G S K V S T S T K S T G V V R L Q Y M S Q Y M T D G P Y E SQ M T K A L K V Q Q P P V D R K P S G L V G V G W V E W F F Q LV G Y S C T S P L T E G E V Y C Q V N F S G L S E R S Y I N S TL Y T T Y G S E V G V G P Y T K G Q S F C G Q A L N R D F N N LG N N D Y Q P P A L K A T W S Y K N E S S P V K G K L F V L G TG T I L V G A F P S K A R N N E A K W G F S E C Q F S G S L S SG F W S A W L Y F S D E S F Y K K T E D V L S S G K S L P C Q SS T G F T V P D T S V P I K Q G S L V S N S G V P E L D A V L LE Y V T D D F K H P K A M V E N I E A D G L G K A N E F A V A SV G W F E F V V V V T P L E E L T D I L Q S G V Q F M R V S N YL S E R A Y S L G T N C T P R W K R D V Q K G S R N Y Y S A D TQ A L R R W P C S V S P D D P D E S S P W Q S A V T A D A T V SV A G K L H G G T V P P K E K Q I P P P R T G G W G T R S G K DE C K F S S K L L S K C P H T H P P Y T S Y G P Y G S R S S W K 1.928820 11 0072 / ST-PI4L51.05L 0A4P 0O W1IT QQ PV PQ GG PA PF AP LS K00V Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAS R A A Q Y A T S S V T P D N T L Y K Y V H S V Y P S Y V Q KKT L V S Q G R Y V T L P Y Y A H S P S G V G N S W Y S L N G C K I D F C L V H L A V V N T L G E N N D Y T E A F VV VE VS KN QP LC NE LK AE GG AG TF IG TT VA TG DS ERGP W E T Y T T V S Y S V C V V S E T P S H G S T G L T Q P PPS N G S K V S T S T K S T G V V R L Q Y M S Q Y M T D G P YQS M T K A L K V Q Q P P V D R K P S G L V G V G W V E W F FVL G Y S C T S P L T E G E V Y C Q V N F S G L S E R S Y I NLG Y T T Y G S E V G V G P Y T K G Q S F C G Q A L N R D F NGQ N N D Y Q P P A L K A E W S Y K N E S S P V K G K L F V LGH T I L V G A F P S K A R N N E A K W G F S E C Q F S G S LGT F W S A W L Y F S D E T F Y K K T E D V L S S G K S L P CSV T G F T V P D T S V P I K Q G S L V S N S G V P E L D A VEE Y V T D D F K H P K A Y V E N I E A D G L G K A N E F A VVC G W F E F V V V V T P L E E L T D I L Q S G V Q F M R V SLA C S E R A Y S L G T N C T P R W K R D V Q K G S R N Y Y S AQY E A L R R W P C S V S P D D P D E S S P W Q S A V T A D A TVV G A G K L H G G T V P P K E K Q I P P P R T G G W G T R S GEK R C K F S S K L L S K C P H T H P P Y T S Y G P Y G S R S S 1.928821 11 0072 / ST-a PI4L51.05L 0A4P 0O W1IT QQ PV PQ GG PA PF AP LS K00V Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAQ E S R A A Q Y A T S S V T P D N T L Y K Y V H S V Y P S Y VET Y V D K A T L V S Q G R Y V T L P Y Y A H S P S G V G N S W Y S L N G C K F V H L A V V N T L G E N N D Y T I DC LF VV VE VS KN QP LC NE LK AE GG AG TF IG TT VA TGGS K P W E T Y T T V S Y S V C V V S E T P S H G S T G L T QPE S S N G S K V S T S T K S T G V V R L Q Y M S Q Y M T D GQQ L S M T K A L K V Q Q P P V D R K P S G L V G V G W V E WVS T L G Y S C T S P L T E G E V Y C Q V N F S G L S E R S YLN L G Y T T Y G S E V G V G P Y T K G Q S F C G Q A L N R DGG T Q N N D Y Q P P A L K A T W S Y K N E S S P V K G K L FGS S H T I L V G A F P S K A R N N E A K W G F S E C Q F S GGQ S T F W S A W L Y F S D E S F Y K K T E D V L S S G K S LSL L V T G F T V P D T S V P I K Q G S L V S N S G V P E L DEA S E Y V T D D F K H P K A M V E N I E A D G L G K A N E FVN Y C G W F E F V V V V T P L E E L T D I L Q S G V Q F M RLD T A C S E R A Y S L G T N C T P R W K R D V Q K G S R N Y YQV S Y E A L R R W P C S V S P D D P D E S S P W Q S A V T A DVK D V G A G K L H G G T V P P K E K Q I P P P R T G G W G T REW K K R C K F S S K L L S K C P H T H P P Y T S Y G P Y G S R 1.928822 11 0072 / ST-PI4L51.06L 0A4P 0O W1IT QQ PV PQ GG PA PF AP LS K00V Y G L G L Y F S KD -NSRC.oNtekcoDyenrottAQ K Q E S R A A Q Y A T S S V T P D N T L Y K Y V H S V Y P SED A S E E R T Y V D K A T L V S Q G R Y V T L P Y Y A H S P S G V G N S W Y N K F V H L A V V N T L G E N N D S LG CI DC LF VV VE VS KN QP LC NE LK AE GG AG TF IG TTGP P S K P W E T Y T T V S Y S V C V V S E T P S H G S T G LPP Y E S S N G S K V S T S T K S T G V V R L Q Y M S Q Y M TQF F Q L S M T K A L K V Q Q P P V D R K P S G L V G V G W VVI N S T L G Y S C T S P L T E G E V Y C Q V N F S G L S E RLF N N L G Y T T Y G S E V G V G P Y T K G Q S F C G Q A L NGV L G T Q N N D Y Q P P A L K A E W S Y K N E S S P V K G KGS L S S H T I L V G A F P S K A R N N E A K W G F S E C Q FGP C Q S T F W S A W L Y F S D E T F Y K K T E D V L S S G KSA V L L V T G F T V P D T S V P I K Q G S L V S N S G V P EEA V A S E Y V T D D F K H P K A Y V E N I E A D G L G K A NVV S N Y C G W F E F V V V V T P L E E L T D I L Q S G V Q FLS A D T A C S E R A Y S L G T N C T P R W K R D V Q K G S R NQA T V S Y E A L R R W P C S V S P D D P D E S S P W Q S A V TVS G K D V G A G K L H G G T V P P K E K Q I P P P R T G G W GES S W K K R C K F S S K L L S K C P H T H P P Y T S Y G P Y G 1.928823 11 0072 / ST-a PI4L51.06L 0A4P 0O W100-NSRC.oNtekcoDyenrottA 591AC VT KL Q Y Q V S V D H K Q K NF YV TT ED A E E S E T Y S G V D K ATD Q R A T G PP P F Y SE K V E W Q S P Y I F L S S N S T S RL D S F F G V NL NG L L S L T G L L S D P S S Q A CV Q F V L S H E A L T MY V S A S V R N Y E A YD SA A C R S T DV T S R K S A D Y C T G V E S S W K K GR 1.928821002 / STPIAttorney Docket No. CRSN-001WO VH Domains

[0267] In some embodiments, a binding protein provided herein comprises a first VH sequence selected from SEQ ID NOs: 295-296, 301-334, and 738-742 and a second VH sequence selected from SEQ ID NOs: 295-296, 301-334 and 738-742. In some embodiments, a binding protein provided herein comprises a first VH sequence selected from SEQ ID NOs: 295-296 and a second VH sequence selected from SEQ ID NOs: 301-334. In some embodiments, a binding protein provided herein comprises a first VH sequence comprising SEQ ID NO: 3 and a second VH sequence selected from SEQ ID NOs: 301-334.

[0268] In some embodiments, a binding protein provided herein comprises a first VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VH sequence selected from SEQ ID NOs: 295-296 and a second VH sequence selected from SEQ ID NOs: 301-334. In some embodiments, a binding protein provided herein comprises a first VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VH sequence comprising SEQ ID NO: 3 and a second VH sequence selected from SEQ ID NOs: 301-334. In some embodiments, a binding protein provided herein comprises a first VH sequence selected from SEQ ID NOs: 295-296 and a second VH sequence selected from SEQ ID NOs: 301-334, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, a binding protein provided herein comprises a first VH sequence comprising SEQ ID NO: 3 and a second VH sequence selected from SEQ ID NOs: 301-334, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the bispecific binding proteins described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining bispecific binding proteins. IPTS / 200128829.1 196Attorney Docket No. CRSN-001WO Table 5A. Sequences of VEGF Heavy Chain Variable Regions (VH) SEQ ID VH NO 295EV LVESGGGLV PGGSLRLSCAASGYTFTNYGMNWVR APGKGLEWVGWINTYW Y WSEQ ID VH NO S D S D S D S D S D S D S D S D S D S D S D S DIPTS / 200128829.1Attorney Docket No. CRSN-001WO YWGQGTTVTVSS QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPS QGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLRFDDTAVYYCARRDYRFDLGFD S D S D S D S D S D S D S D S D S D S D S D S D S D S D S YIPTS / 200128829.1Attorney Docket No. CRSN-001WO 329 EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWVRQAPGKEREWVSVITWS GGITYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAGDKHQSSWYDY WGQGTLVTVSS S Y S Y S Y S Y G W S Y S Y S Y S Y S DVL Domains

[0269] In some embodiments, a binding protein provided herein comprises a first VL sequence selected from SEQ ID NOs: 298-300, 335-349, and 743-744 and a second VL sequence selected from SEQ ID NOs: 298-300, 335-349, and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence selected from SEQ ID NOs: 298-300 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence comprising SEQ ID NO: 298 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein IPTS / 200128829.1 199Attorney Docket No. CRSN-001WO comprises a first VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VL sequence comprising SEQ ID NO: 298 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence comprising SEQ ID NO: 299 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VL sequence comprising SEQ ID NO: 299 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence comprising SEQ ID NO: 300 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VL sequence comprising SEQ ID NO: 300 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744.

[0270] In some embodiments, a binding protein provided herein comprises a first VL sequence selected from SEQ ID NOs: 298-300, and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, a binding protein provided herein comprises a first VL sequence comprising SEQ ID NO: 298 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. Table 6A. Sequences of VEGF Light Chain Variable Regions (VL) SEQ ID VL NO HHHTable 6B. Sequences of PD-1 Light Chain Variable Regions (VL) SEQ ID VL AIPTS / 200128829.1 00Attorney Docket No. CRSN-001WO SYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEI K EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLAI A I A I A I A I A I A I A I A I A I A I A I A I VAI A IIPTS / 200128829.1Attorney Docket No. CRSN-001WO VH-VL Combinations

[0271] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 456, and 457, respectively; (b) SEQ ID NOs: 451, 458, and 459, respectively; or (c) SEQ ID NOs: 443, 460, and 457, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 302 and 335, respectively; (b) SEQ ID NOs: 302 and 336, respectively; (c) SEQ ID NOs: 302 and 340, respectively; (d) SEQ ID NOs: 302 and 342, respectively; (e) SEQ ID NOs: 302 and 343, respectively; (f) SEQ ID NOs: 302 and 346, respectively; (g) SEQ ID NOs: 306 and 337, respectively; (h) SEQ ID NOs: 306 and 339, respectively; (i) SEQ ID NOs: 306 and 341, respectively; (j) SEQ ID NOs: 306 and 344, respectively; (k) SEQ ID NOs: 306 and 345, respectively; (l) SEQ ID NOs: 306 and 347, respectively; (m) SEQ ID NOs: 308 and 340, respectively; (n) SEQ ID NOs: 309 and 341, respectively; (o) SEQ ID NOs: 310 and 336, respectively; (p) SEQ ID NOs: 311 and 337, respectively; (q) SEQ ID NOs: 313 and 336, respectively; (r) SEQ ID NOs: 313 and 342, respectively; (s) SEQ ID NOs: 313 and 343, respectively; (t) SEQ ID NOs: 316 and 337, respectively; (u) SEQ ID NOs: 316 and 344, respectively; (v) SEQ ID NOs: 316 and 345, respectively; (w) SEQ ID NOs: 318 and 336, respectively; (x) SEQ ID NOs: 318 and 340, respectively; (y) SEQ ID NOs: 318 and 346, respectively; (z) SEQ ID NOs: 319 and 336, respectively; (aa) SEQ ID NOs: 319 and 340, respectively; (bb) SEQ ID NOs: 319 and 346, respectively; (cc) SEQ ID NOs: 320 and 337, respectively; (dd) SEQ ID NOs: 320 and 341, respectively; (ee) SEQ ID NOs: 320 and 347, respectively; (ff) SEQ ID NOs: 320 and 743, respectively; (gg) SEQ ID NOs: 321 and 337, respectively; (hh) SEQ ID NOs: 321 and 341, respectively; or (ii) SEQ ID NOs: 321 and 347, respectively. In some embodiments, the anti-PD1 VH and anti- PD1 VL have amino acid sequences of: (a) SEQ ID NOs: 302 and 335, respectively; (b) SEQ ID NOs: 302 and 336, respectively; (c) SEQ ID NOs: 302 and 340, respectively; (d) SEQ ID NOs: 302 and 342, respectively; (e) SEQ ID NOs: 302 and 343, respectively; (f) SEQ ID NOs: 302 and 346, respectively; (g) SEQ ID NOs: 306 and 337, respectively; (h) SEQ ID NOs: 306 and 339, respectively; (i) SEQ ID NOs: 306 and 341, respectively; (j) SEQ ID IPTS / 200128829.1 202Attorney Docket No. CRSN-001WO NOs: 306 and 344, respectively; (k) SEQ ID NOs: 306 and 345, respectively; (l) SEQ ID NOs: 306 and 347, respectively; (m) SEQ ID NOs: 308 and 340, respectively; (n) SEQ ID NOs: 309 and 341, respectively; (o) SEQ ID NOs: 310 and 336, respectively; (p) SEQ ID NOs: 311 and 337, respectively; (q) SEQ ID NOs: 313 and 336, respectively; (r) SEQ ID NOs: 313 and 342, respectively; (s) SEQ ID NOs: 313 and 343, respectively; (t) SEQ ID NOs: 316 and 337, respectively; (u) SEQ ID NOs: 316 and 344, respectively; (v) SEQ ID NOs: 316 and 345, respectively; (w) SEQ ID NOs: 318 and 336, respectively; (x) SEQ ID NOs: 318 and 340, respectively; (y) SEQ ID NOs: 318 and 346, respectively; (z) SEQ ID NOs: 319 and 336, respectively; (aa) SEQ ID NOs: 319 and 340, respectively; (bb) SEQ ID NOs: 319 and 346, respectively; (cc) SEQ ID NOs: 320 and 337, respectively; (dd) SEQ ID NOs: 320 and 341, respectively; (ee) SEQ ID NOs: 320 and 347, respectively; (ff) SEQ ID NOs: 320 and 743, respectively; (gg) SEQ ID NOs: 321 and 337, respectively; (hh) SEQ ID NOs: 321 and 341, respectively; or (ii) SEQ ID NOs: 321 and 347, respectively.

[0272] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 456, and 447, respectively; (b) SEQ ID NOs: 451, 458, and 453, respectively; or (c) SEQ ID NOs: 443, 460, and 447, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 303 and 336, respectively; (b) SEQ ID NOs: 325 and 347, respectively; or (c) SEQ ID NOs: 325 and 743, respectively. In some embodiments, the anti-PD1 VH and anti- PD1 VL have amino acid sequences of: (a) SEQ ID NOs: 303 and 336, respectively; (b) SEQ ID NOs: 325 and 347, respectively; or (c) SEQ ID NOs: 325 and 743, respectively.

[0273] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 461, and 447, respectively; (b) SEQ ID NOs: 451, 462, and 453, respectively; or (c) SEQ ID NOs: 443, 463, and 447, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: IPTS / 200128829.1 203Attorney Docket No. CRSN-001WO SEQ ID NOs: 326 and 347, respectively; or SEQ ID NOs: 326 and 743, respectively. In some embodiments, the anti-PD1 VH and anti-PD1 VL have amino acid sequences of: SEQ ID NOs: 326 and 347, respectively; or SEQ ID NOs: 326 and 743, respectively.

[0274] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 446, and 457, respectively; (b) SEQ ID NOs: 451, 452, and 459, respectively; or (c) SEQ ID NOs: 443, 455, and 457, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: SEQ ID NOs: 327 and 347, respectively; or SEQ ID NOs: 327 and 743, respectively. In some embodiments, the anti-PD1 VH and anti-PD1 VL have amino acid sequences of: SEQ ID NOs: 327 and 347, respectively; or SEQ ID NOs: 327 and 743, respectively.

[0275] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 461, and 457, respectively; (b) SEQ ID NOs: 451, 462, and 459, respectively; or (c) SEQ ID NOs: 443, 463, and 457, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 303 and 335, respectively; (b) SEQ ID NOs: 303 and 342, respectively; (c) SEQ ID NOs: 303 and 343, respectively; (d) SEQ ID NOs: 307 and 337, respectively; (e) SEQ ID NOs: 307 and 344, respectively; (f) SEQ ID NOs: 307 and 345, respectively; (g) SEQ ID NOs: 314 and 336, respectively; (h) SEQ ID NOs: 314 and 342, respectively; (i) SEQ ID NOs: 314 and 343, respectively; (j) SEQ ID NOs: 317 and 337, respectively; (k) SEQ ID NOs: 317 and 344, respectively; (l) SEQ ID NOs: 317 and 345, respectively; or (m) SEQ ID NOs: 324 and 347, respectively. In some embodiments, the anti-PD1 VH and anti- PD1 VL have amino acid sequences of: (a) SEQ ID NOs: 303 and 335, respectively; (b) SEQ ID NOs: 303 and 342, respectively; (c) SEQ ID NOs: 303 and 343, respectively; (d) SEQ ID NOs: 307 and 337, respectively; (e) SEQ ID NOs: 307 and 344, respectively; (f) SEQ ID NOs: 307 and 345, respectively; (g) SEQ ID NOs: 314 and 336, respectively; (h) SEQ ID IPTS / 200128829.1 204Attorney Docket No. CRSN-001WO NOs: 314 and 342, respectively; (i) SEQ ID NOs: 314 and 343, respectively; (j) SEQ ID NOs: 317 and 337, respectively; (k) SEQ ID NOs: 317 and 344, respectively; (l) SEQ ID NOs: 317 and 345, respectively; or (m) SEQ ID NOs: 324 and 347, respectively.

[0276] In some embodiments the CDR-H1, CDR-H2, and CDR-H3 of the VH within a PD-1 binding region (anti-PD1 VH) comprise the amino acid sequences of (a) SEQ ID NOs: 445, 446, and 447, respectively; (b) SEQ ID NOs: 451, 452, and 453, respectively; or (c) SEQ ID NOs: 443, 455, and 447, respectively, and the CDR-L1, CDR-L2, and CDR-HL of the VL within a PD-1 binding region (anti-PD1 VL) comprise the amino acid sequences of (a) SEQ ID NOs: 448, 449, and 450, respectively; (b) SEQ ID NO: 454, SAS, and SEQ ID NO: 450, respctively; or (c) SEQ ID NOs: 448, 449, or 450, respectively, and the anti-PD1 VH and anti-PD1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 301 and 335, respectively; (b) SEQ ID NOs: 301 and 336, respectively; (c) SEQ ID NOs: 301 and 342, respectively; (d) SEQ ID NOs: 301 and 343, respectively; (e) SEQ ID NOs: 301 and 348, respectively; (f) SEQ ID NOs: 305 and 337, respectively; (g) SEQ ID NOs: 305 and 344, respectively; (h) SEQ ID NOs: 305 and 345, respectively; (i) SEQ ID NOs: 312 and 335, respectively; (j) SEQ ID NOs: 312 and 336, respectively; (k) SEQ ID NOs: 312 and 342, respectively; (l) SEQ ID NOs: 312 and 343, respectively; (m) SEQ ID NOs: 315 and 337, respectively; (n) SEQ ID NOs: 315 and 344, respectively; (o) SEQ ID NOs: 315 and 345, respectively; (p) SEQ ID NOs: 322 and 346, respectively; (q) SEQ ID NOs: 323 and 347, respectively; or (r) SEQ ID NOs: 323 and 743, respectively. In some embodiments, the anti-PD1 VH and anti-PD1 VL have amino acid sequences of: (a) SEQ ID NOs: 301 and 335, respectively; (b) SEQ ID NOs: 301 and 336, respectively; (c) SEQ ID NOs: 301 and 342, respectively; (d) SEQ ID NOs: 301 and 343, respectively; (e) SEQ ID NOs: 301 and 348, respectively; (f) SEQ ID NOs: 305 and 337, respectively; (g) SEQ ID NOs: 305 and 344, respectively; (h) SEQ ID NOs: 305 and 345, respectively; (i) SEQ ID NOs: 312 and 335, respectively; (j) SEQ ID NOs: 312 and 336, respectively; (k) SEQ ID NOs: 312 and 342, respectively; (l) SEQ ID NOs: 312 and 343, respectively; (m) SEQ ID NOs: 315 and 337, respectively; (n) SEQ ID NOs: 315 and 344, respectively; (o) SEQ ID NOs: 315 and 345, respectively; (p) SEQ ID NOs: 322 and 346, respectively; (q) SEQ ID NOs: 323 and 347, respectively; or (r) SEQ ID NOs: 323 and 743, respectively.

[0277] In some embodiments, a binding protein provided herein comprises a first VH sequence selected from SEQ ID NO: 295 or SEQ ID NO: 296 and a second VH sequence selected from SEQ ID NOs: 301-334 and 738-742; and a first VL sequence selected from IPTS / 200128829.1 205Attorney Docket No. CRSN-001WO SEQ ID NOs: 298-300, and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VH sequence comprising SEQ ID NO: 295 and a second VH sequence selected from SEQ ID NOs: 301-334 and 738-742; and a first VL sequence comprising SEQ ID NOs: 298 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744.

[0278] In certain aspects, any of SEQ ID NO: 295 or SEQ ID NO: 296 can be combined with any of SEQ ID NOs: 298-300, and any of SEQ ID NOs: 301-334 and 738-742 can be combined with any of SEQ ID NOs: 335-349 and 743-744.

[0279] In some embodiments, a binding protein provided herein comprises a first VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VH sequence provided in selected from SEQ ID NO: 295 or SEQ ID NO: 296 and a second VH sequence selected from SEQ ID NOs: 301-334 and 738-742; and a first VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VL sequence provided in SEQ ID NOs: 298-300 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744. In some embodiments, a binding protein provided herein comprises a first VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VH sequence comprising SEQ ID NO: 295 and a second VH sequence selected from SEQ ID NOs 301-334 and 738-742; and a first VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VL sequence comprising SEQ ID NO: 298 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744.

[0280] In some embodiments, a binding protein provided herein comprises a first VH sequence provided in SEQ ID NO: 295 or SEQ ID NO: 296 and a second VH sequence selected from SEQ ID NOs: 301-334 and 738-742, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions; and a first VL sequence provided in SEQ ID NOs: 298-300 and a second VL sequence selected from SEQ ID NOs: 335-349 and 743-744, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some embodiments, a binding protein provided herein comprises a first VH sequence comprising SEQ ID NO: 295 and a second VH sequence selected from SEQ ID NOs: 301-334 and 738-742, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions; and a first VL sequence comprising SEQ ID NO: 298 and a second VL sequence selected from SEQ ID NOs: 335- 349 and 743-744, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or IPTS / 200128829.1 206Attorney Docket No. CRSN-001WO 20 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the binding proteins described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining binding proteins. Bispecific Formats

[0281] In some embodiments, the format of the bispecific binding proteins disclosed herein have any of the bispecific antibody formats described herein. In some embodiments, the format of the bispecific binding proteins disclosed herein is selected from the group consisting of (a) single chain Fv (scFv), (b) tandem scFv format of bispecific T cell engager (BiTE), (c) disulfide-linked diabody format of dual affinity retargeting (DART) bsAb, (d) tandem diabody (TandAb), (e) single-domain antibody (VHH), (f) conventional immunoglobulin G (IgG), (g) IgGs with additional binding units such as scFv, (h) IgGs with additional binding units such as VHH, (i) dual variable domain immunoglobulin (DVD-Ig), (j) quadromab bsAb, (k) knobs-into-holes (KiH) bsAb with a common light chain, (l) KiH- CrossMabCH1-CL, and (m) bsAb by controlled Fab arm exchange (cFAE). (see Shim et al. (2020) Biomolecules 26;10(3):360.) In some embodiments, the format of the bispecific binding proteins disclosed herein is selected from the group consisting of IgG-scFv, IgG- VHH, and DVD-Ig. In some embodiments, the format of the bispecific binding proteins disclosed herein is IgG-scFv. In some embodiments, the format of the bispecific binding proteins disclosed herein is IgG-VHH. In some embodiments, the format of the bispecific binding proteins disclosed herein is DVD-Ig. In some embodiments, the format of the bispecific binding proteins disclosed herein is kiH-CrossMabCH1-CL.

[0282] In some embodiments, bispecific binding proteins comprise an scFv which is characterized one or more stabilizing features, e.g., particular amino acid residues or sequences. In some embodiments, the one or more stabilizing features in the scFv are an engineered disulfide bond between the contact surface of the VH and VL domains. In some embodiments, the disulfide bond is at the position of H44-L100 (Kabat numbering). IPTS / 200128829.1 207Attorney Docket No. CRSN-001WO

[0283] In some embodiments, the binding protein comprises a heavy chain as disclosed in Table 4A or Table 4B and a light chain disclosed in Table 4A or Table 4B. In some embodiments, a binding protein provided herein comprises a first VH sequence as listed in Table 5A and second VH sequence as listed in Table 5B. In some embodiments, a binding protein provided herein comprises a first VL sequence as listed in Table 6A and second VL sequence as listed in Table 6B. In some embodiments, a binding protein provided herein comprises a heavy chain constant region as listed in Table 7. In some embodiments, a binding protein provided herein comprises a light chain constant region as listed in Table 8. In some embodiments, a binding protein provided herein comprises scFv or VHH sequence as listed in Table 9. In some embodiments, a binding protein provided herein comprises a first VH sequence as listed in Table 5A and second VH sequence as listed in Table 5B; a first VL sequence as listed in Table 6A and second VL sequence as listed in Table 6B; a heavy chain constant region as listed in Table 7; a light chain constant region as listed in Table 8; and a scFv or VHH sequence as listed in Table 9.

[0284] In some embodiments, the format of the bispecific binding proteins disclosed herein is IgG-scFv. In some embodiments, the bispecific format comprises a first VH sequence (VH1) comprising any one of SEQ ID NO: 295 or SEQ ID NO: 296, a heavy chain constant region (CH(1-3)) comprising any one of SEQ ID NOs: 350-352, and a first linker comprising at least 90% sequence identity to GGGGSGGGGSGGGGSGGGGS, a first VL sequence (VL1) comprising any one of SEQ ID NOs: 298-300, a second linker comprising at least 90% sequence identity to GGGGSGGGGSGGGGSGGGGS, a second VH (VH2) sequence comprising any one of SEQ ID NOs: 301-334 and 738-742, a second VL sequence (VL2) comprising any one of SEQ ID NOs: 335-349 and 743-744, and a light chain constant domain (CL) comprising SEQ ID NO: 353.

[0285] In some embodiments, the bispecific format comprises a first VH sequence (VH1) comprising any one of SEQ ID NOs: 301-334 and 738-742, a heavy chain constant region (CH(1-3)) comprising any one of SEQ ID NOs: 350-352, and a first linker comprising at least 90% sequence identity to GGGGSGGGGSGGGGSGGGGS, a first VL sequence (VL1) comprising any one of SEQ ID NOs: 298-300, a second linker comprising at least 90% sequence identity to GGGGSGGGGSGGGGSGGGGS, a second VH (VH2) sequence comprising any one of SEQ ID NO: 295 or SEQ ID NO: 296, a second VL sequence (VL2) comprising any one of SEQ ID NOs: 335-349 and 743-744, and a light chain constant domain (CL) comprising SEQ ID NO: 353. IPTS / 200128829.1 208Attorney Docket No. CRSN-001WO

[0286] In some embodiments, the bispecific format comprises a first VH sequence (VH1) comprising any one of SEQ ID NOs: 295-296, 301-334, and 738-742, a heavy chain constant region (CH(1-3)) comprising any one of SEQ ID NOs: 350-352, and a first linker comprising at least 90% sequence identity to GGGGSGGGGSGGGGSGGGGS, a scFv or VHH comprising any one of SEQ ID NOs: 354-430, a first VL sequence comprising any one of SEQ ID Nos: 298-300, and a light chain constant domain (CL) comprising SEQ ID NO: 353. Table 7. Sequences of Exemplary Heavy Chain Constant Regions 1-3 SEQ ID CH1-3 NO A P V S K K A P V S K K A P V S K KTable 8. Sequence of Exemplary Light Constant Region SEQ ID CL NO STable 9. Exemplary scFv and VHH Sequences SEQ scFV G T T AIPTS / 200128829.1Attorney Docket No. CRSN-001WO QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSQGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDLGFDYWGQGT TVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASKGVST A G T T A G T T A G T T A G T T A Y G R Y Y G A A G T T A G T T A G T T AIPTS / 200128829.1 210Attorney Docket No. CRSN-001WO VYYCQHSRDLPLTFGGGTKVEIKR QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQCLEWMGGINPSQGGT T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T TIPTS / 200128829.1Attorney Docket No. CRSN-001WO SGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFA VYYCQHSRDLPLTFGGGTKVEIKR QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSQGGT T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G TIPTS / 200128829.1Attorney Docket No. CRSN-001WO TVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPSTLSLSPGERATLSCRASKGVST SGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFA VYYCQHSRDLPLTFGCGTKVEIKR G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A GIPTS / 200128829.1Attorney Docket No. CRSN-001WO TNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDLGFDYWGQGT TVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPSTLSLSPGERATLSCRASKGVST SGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFA G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T A G T T AIPTS / 200128829.1 214Attorney Docket No. CRSN-001WO QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQCLEWMGGINPSQGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDLGFDYWGQGT TVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPATLSVSPGERATLSCRASKGVST A G T T A G T T A G T T A G T T A G T T A G T T A G T T A Y G A A Y G A AIPTS / 200128829.1 215Attorney Docket No. CRSN-001WO RRDYRFDLGFDYWGQGTTVTVSS EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYG A A Y G A A G T T A G T T A G T T A G T T A G T T A G T T A E G D T E G DIPTS / 200128829.1Attorney Docket No. CRSN-001WO ISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQYSTVPWTFGCGTKVEIKR 424EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWVRQAPGKEREWVSVITWSGGIL I L I L I L I L I L Y V L Qc o ca ons

[0287] Binding proteins (e.g., PD-1 binding proteins or bispecific PD-1 / VEGF binding proteins) described herein typically comprise an immunoglobulin Fc region. Fc regions typically comprise one or more Fc polypeptides, such as a first Fc polypeptide and a second Fc polypeptide. An IgG Fc polypeptide typically contains two constant heavy domains (CH2 and CH3) and a hinge region connected to the CH2 domain. Typical Fc regions comprise two Fc polypeptides which dimerize with one another; however, an Fc region may have a single Fc polypeptide or more than two Fc polypeptides, e.g., as may be present in some antibody formats.

[0288] In some embodiments, the binding proteins described herein comprise an IgG1 Fc region (e.g., human IgG1 Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that is substantially similar to that of the Fc region within a wild type IgG1 Fc. In some embodiments, the wild type IgG1 Fc is a human IgG1 Fc, in which each Fc polypeptide comprises an amino acid sequence of SEQ ID NO: 792, 911, or 1022. In some embodiments, IPTS / 200128829.1 217Attorney Docket No. CRSN-001WO the binding proteins described herein comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild-type IgG1 Fc.

[0289] In certain embodiments, human IgG1 Fc regions include an SRDEL allotype or an SREEM allotype.

[0290] In some embodiments, the binding proteins described herein comprise an IgG2 Fc region (e.g., human IgG2 Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that is substantially similar to that of the Fc region within a wild type IgG2 Fc. In some embodiments, the wild type IgG2 Fc is a human IgG2 Fc, in which each Fc polypeptide comprises an amino acid sequence of SEQ ID NO: 793 or 912. In some embodiments, the binding proteins described herein comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild-type IgG2 Fc.

[0291] In some embodiments, the binding proteins described herein comprise an IgG4 Fc region (e.g., human IgG4 Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that is substantially similar to that of the Fc region within a wild type IgG4 Fc. In some embodiments, the wild type IgG4 Fc is a human IgG4 Fc, in which each Fc polypeptide comprises an amino acid sequence of SEQ ID NO: 794 or 913. In some embodiments, the binding proteins described herein comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild-type IgG4 Fc.

[0292] In some embodiments, the binding protein comprises a modified Fc comprising one or more modifications. In some embodiments, the one or more modifications are located in a Fc from IgG1 (e.g., human IgG1 (hIgG1). In some embodiments, the one or more modifications are located in a Fc from IgG4 (e.g., human IgG4 (hIgG4). In some embodiments, the one or more modifications are located in a Fc from IgG2. In some embodiments, the one or more modifications promote selective binding of Fc-gamma receptors. In any embodiment, a constant heavy chain region can include a C-terminal lysine. IPTS / 200128829.1 218Attorney Docket No. CRSN-001WO

[0293] Amino acid sequences of exemplary Fc regions are provided in Tables 10A and 10B. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. Table 10A. Exemplary Fc Polypeptide Sequences Name SEQ Fc polypeptide sequence ID L T R R Q T K L T V V L M L L T E S T P S L T E S T P SIPTS / 200128829.1 219Attorney Docket No. CRSN-001WO IgG4-SPLE796ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNT KVDKRVESKYGPPCPPCPAPEELGGPSVFLFPPKPKDTLMISRTPE S T P S L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q TIPTS / 200128829.1Attorney Docket No. CRSN-001WO G237A)TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R RIPTS / 200128829.1Attorney Docket No. CRSN-001WO VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L TIPTS / 200128829.1Attorney Docket No. CRSN-001WO LALA / LSKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1Attorney Docket No. CRSN-001WO hIgG1-819ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALD265A / DHS TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T E S T P SIPTS / 200128829.1Attorney Docket No. CRSN-001WO LSLG hIgG4-825ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALT E S T P S L T E S T P S L T E S T P S L T E S T P S L T E S T P S L T E S TIPTS / 200128829.1Attorney Docket No. CRSN-001WO LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHSHYTQKSLS LSLG L T E S T P S L T E S T P S L T V V L M L L T V V L M L L T V V L M L L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 227Attorney Docket No. CRSN-001WO hIgG1-842ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALLALAPG / L TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT A KVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1Attorney Docket No. CRSN-001WO SLSLSPG hIgG1-848ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R QIPTS / 200128829.1Attorney Docket No. CRSN-001WO VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQK SLSLSPG L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO DPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLQVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 231Attorney Docket No. CRSN-001WO hIgG1-865ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALN297A / DW TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1Attorney Docket No. CRSN-001WO SLSLSPG hIgG1 / YD871ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R QIPTS / 200128829.1Attorney Docket No. CRSN-001WO VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLQVLHVDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 235Attorney Docket No. CRSN-001WO hIgG1-888ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALLALA / DDR TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT VV KVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T E S T P SIPTS / 200128829.1Attorney Docket No. CRSN-001WO LSLG IgG4-894ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALT E S T P S L T E S T P S L T V V L M L L T R R Q T K L T R R Q T K L T R R QIPTS / 200128829.1Attorney Docket No. CRSN-001WO VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQK SLSLSPG L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO M252Y / S25 EPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR 4T / T256E VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ (YTE) VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 239Attorney Docket No. CRSN-001WO Table 10B. Exemplary Fc polypeptide Sequences Name SEQ Fc polypeptide sequence ID L T R R Q T K L T V V L M L L T E S T P S L T E S T P S L T E S TIPTS / 200128829.1 0Attorney Docket No. CRSN-001WO LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP with C- VLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS L L K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R QIPTS / 200128829.1Attorney Docket No. CRSN-001WO G237A) VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT with C- TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK L L P K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO with C- EPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR terminal VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPP RDELTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q TIPTS / 200128829.1Attorney Docket No. CRSN-001WO TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQK SLSLSPGK L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 244Attorney Docket No. CRSN-001WO hIgG1-DHS936ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPK DKTHT PP PAPELL P VFLFPPKPKDTLMI R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 245Attorney Docket No. CRSN-001WO hIgG1-941ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALLALAGA / D TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPK DKTHT PP PAPEAA AP VFLFPPKPKDTLMI R R Q T K L T R R Q T K L T E S T P S L T E S T P S L T E S T P S L T EIPTS / 200128829.1Attorney Docket No. CRSN-001WO lysineVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT LPP EEMTKN V LT LVK FYP DIAVEWE N PENNYKTTPP S L T E S T P S L T E S T P S L T E S T P S L T E S T P S L T E S T PIPTS / 200128829.1Attorney Docket No. CRSN-001WO VLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHSHYTQKSLS LSLGK L T V V L M L L T V V L M L L T V V L M L L T R R Q T K L T R R Q T KIPTS / 200128829.1 248Attorney Docket No. CRSN-001WO hIgG1-957ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALD265A / LA TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPK DKTHT PP PAPELL P VFLFPPKPKDTLMI R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO with C- TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR terminal VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPP RDELTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q TIPTS / 200128829.1Attorney Docket No. CRSN-001WO lysineTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHAHYTQKSLSLSPGK L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 251Attorney Docket No. CRSN-001WO hIgG1-973ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALLAGA / TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPK DKTHT PP PAPELA AP VFLFPPKPKDTLMI R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO with C- DPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR terminal VVSVLQVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPP RDELTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q TIPTS / 200128829.1Attorney Docket No. CRSN-001WO terminal TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK lysine SLSLSPGK L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1 5Attorney Docket No. CRSN-001WO hIgG1-989ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALLALAPG / D TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPK DKTHT PP PAPEAA P VFLFPPKPKDTLMI R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO terminal DPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR lysine VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPP RDELTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R QIPTS / 200128829.1Attorney Docket No. CRSN-001WO lysineVYTLPPSRDELTKNQVSLTCLVKGFYPSDIVVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK L L P K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1Attorney Docket No. CRSN-001WO A378V) with C- L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q TIPTS / 200128829.1Attorney Docket No. CRSN-001WO lysineTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK L T R R Q T K L T R R Q T K L T E S T P S L T E S T P S L T E S T P SIPTS / 200128829.1Attorney Docket No. CRSN-001WO IgG2-1015ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALQ311R / M42 TSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNT KVDKTVERK VE PP PAPPVA P VFLFPPKPKDTLMI RTPEV V L M L L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO L TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHRDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ with C- VYTLPP RDELTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T K L T RIPTS / 200128829.1Attorney Docket No. CRSN-001WO M428L / N43 TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR 4A (LA) VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPP REEMTKN V LT LVK FYP DIAVEWE N PENNYKT K L T R R Q T K L T R R Q T K L T R R Q T K L T R R Q T KIPTS / 200128829.1Attorney Docket No. CRSN-001WO

[0294] In some embodiments, any binding protein described herein may comprise a Fc comprising one or more modifications with any one of the Fc modifications described herein. In some embodiments, any binding protein described herein can comprise any one of the Fc sequences in Tables 10A-10B (SEQ ID NOs: 792-1029). In some embodiments, the CH(1-3) domain of a binding protein in Table 7 is substituted with any one of the Fc sequences in Tables 10A-10B (SEQ ID NOs: 792-1029).

[0295] In some embodiments, one or more modifications in the modified Fc is selected from the group consisting of: S298A, E333A, K334A, K326A, F243L, R292P, Y300L, V305I, P396L, F243L, R292P, Y300L, L235V, P396L, F243L, S239D, I332E, A330L, S267E, L328F, D265S, S239E, K326A, A327H, G237F, K326E, G236A, D270L, H268D, S324T, L234F, N325L, V266L, and S267D. In some embodiments, one or more modifications in the modified Fc is selected from the group consisting of S228P, M252Y, S254T, T256E, T256D, T250Q, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, and N434W.

[0296] In some embodiments, the modified Fc comprises a specific combination of amino acid substitutions selected from the group consisting of: L234A / L235A; V234A / G237A; L235A / G237A / E318A; S228P / L236E; H268Q / V309L / A330S / A331S; C220S / C226S / C229S / P238S; C226S / C229S / E3233P / L235V / L235A; L234F / L235E / P331S; C226S / P230S; L234A / G237A; L234A / L235A / G237A; and L234A / L235A / P329G.

[0297] In some embodiments, the modified Fc comprises a specific combination of amino acid substitutions selected from the group consisting of M428L / N434S (LS); M252Y / S254T / T256E (YTE); T250Q / M428L; T307A / E380A / N434A; T256D / T307Q (DQ); T256D / T307W (DW); M252Y / T256D (YD); T307Q / Q311V / A378V (QVV); T256D / H285D / T307R / Q311V / A378V (DDRVV); L309D / Q311H / N434S (DHS); S228P / L235E (SPLE); L234A / L235A (LALA); M428L / N434A (LA); L234A / G237A (LAGA); L234A / L235A / G237A (LALAGA); L234A / L235A / P329G (LALAPG); N297A / YTE; D265A / YTE; LALA / YTE; LAGA / YTE; LALAGA / YTE; LALAPG / YTE; N297A / LS; D265A / LS; LALA / LS; LAGA / LS; LALAGA / LS; LALAPG / LS; N297A / DHS; D265A / DHS; LALA / DHS; LAGA / DHS; LALAGA / DHS; LALAPG / DHS; SP / YTE; SPLE / YTE; SP / LS; SPLE / LS; SP / DHS; SPLE / DHS; N297A / LA; D265A / LA; LALA / LA; LAGA / LA; LALAGA / LA; LALAPG / LA; N297A / N434A; D265A / N434A; LALA / N434A; IPTS / 200128829.1 263Attorney Docket No. CRSN-001WO LAGA / N434A; LALAGA / N434A; LALAPG / N434A; N297A / N434W; D265A / N434W; LALA / N434W; LAGA / N434W; LALAGA / N434W; LALAPG / N434W; N297A / DQ; D265A / DQ; LALA / DQ; LAGA / DQ; LALAGA / DQ; LALAPG / DQ; N297A / DW; D265A / DW; LALA / DW; LAGA / DW; LALAGA / DW; LALAPG / DW; N297A / YD; D265A / YD; LALA / YD; LAGA / YD; LALAGA / YD; LALAPG / YD; N297A / QVV; D265A / QVV; LALA / QVV; LAGA / QVV, LALAGA / QVV; LALAPG / QVV; N297A / DDRVV; D265A / DDRVV; LALA / DDRVV; LAGA / DDRVV; LALAGA / DDRVV; and LALAPG / DDRVV. In some embodiments, the modified Fc comprises a specific combination of amino acid substitutions selected from the group consisting of M428L / N434S (LS) and M252Y / S254T / T256E (YTE). In some embodiments, the modified Fc comprises M428L / N434S (LS) (e.g., SEQ ID NO: 810, 827, 834, 904, 929, 946, 953, or 1023) modifications. In some embodiments, the modified Fc comprises M252Y / S254T / T256E (YTE) modifications (e.g., SEQ ID NO: 803, 824, 833, 905, 922, 952, or 1024).

[0298] In some embodiments, the bispecific binding proteins described herein includes modifications to improve its ability to mediate effector function. Such modifications are known in the art and include afucosylation, or engineering of the affinity of the Fc towards an activating receptor, mainly FCGR3a for antibody-dependent cellular cytotoxicity (ADCC), and towards C1q for complement-dependent cytotoxicity (CDC).

[0299] In some embodiments, modifications to Fc regions reduce or abrogate effector functions, e.g., Fcγ receptor-mediated effector functions. Non-limiting examples of effector- reducing mutations or sets of mutations include, e.g., aglycosylation mutations (e.g., N297A or N297Q or N297G), L234A / L235A (for IgG1 Fc regions), H268Q / V309L / A330S / P331S (for IgG2 Fc regions), and V234A / G237A / P238S / H268A / V309L / A330S / P331S (for IgG2 Fc regions). In some embodiments, effector function is reduced by modifying the attached sugar structures. Non-limiting examples of effector-reducing sugar modifications include increasing sialylation or galactosylation of the sugar chains.

[0300] In some aspects, the bispecific binding proteins provided herein comprises a Fc domain (e.g., IgG1) with reduced fucose content at position Asn 297 (EU numbering) compared to a naturally occurring Fc domain. Such Fc domains are known to have improved ADCC. In some aspects, such binding proteins do not comprise any fucose at position Asn 297.

[0301] In some embodiments, the bispecific binding proteins described herein comprises an Fc region with one or more amino acid substitutions which improve ADCC, such as a IPTS / 200128829.1 264Attorney Docket No. CRSN-001WO substitution at one or more of positions 298, 333, and 334 of the Fc region. In some embodiments, the bispecific binding proteins provided herein comprises an Fc region with one or more amino acid substitutions at positions 239, 332, and 330.

[0302] In some embodiments, the Fc comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B. In some embodiments, the Fc comprises the amino acid sequence according to any one of SEQ ID NOs in Table 10A or 10B.

[0303] In some embodiments, the bispecific binding proteins described herein comprise an Fc region with at least one galactose residue in the oligosaccharide attached to the Fc region. Such variants may have improved CDC function.

[0304] In some embodiments, the bispecific binding proteins described herein comprise one or more alterations that improves or diminishes C1q binding and / or CDC.

[0305] In certain embodiments, the Fc region comprises one or more amino acid substitutions, wherein the one or more substitutions result in an increase in one or more of antibody half-life, ADCC activity, ADCP activity, or CDC activity compared with the Fc without the one or more substitutions. In certain embodiments, the one or more amino acid substitutions results in increased antibody half-life at pH 6.0 compared to an antibody comprising a wild-type Fc region. In certain embodiments, the binding protein has an IPTS / 200128829.1 265Attorney Docket No. CRSN-001WO increased half-life that is about 10,000-fold, 1,000-fold, 500-fold, 100-fold, 50-fold, 20-fold, 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4.5-fold, 4-fold, 3.5-fold, 3-fold, 2.5-fold, 2- fold, 1.95-fold, 1.9-fold, 1.85-fold, 1.8-fold, 1.75-fold, 1.7-fold, 1.65-fold, 1.6-fold, 1.55-fold, 1.50-fold, 1.45-fold, 1.4-fold, 1.35-fold, 1.3-fold, 1.25-fold, 1.2-fold, 1.15-fold, 1.1-fold, or 1.05-fold longer compared to an antibody comprising a wild-type Fc region.

[0306] In certain embodiments, the Fc region comprises one or more amino acid substitutions, wherein the one or more substitutions result in a decrease in one or more of ADCC activity, ADCP activity, or CDC activity compared with the Fc without the one or more substitutions.

[0307] In certain embodiments, the Fc region binds an Fcγ Receptor selected from the group consisting of: FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb. In certain embodiments, the Fc region binds an Fcγ Receptor with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region.

[0308] In some embodiments, the bispecific binding proteins described herein comprise an extended half-life (i.e., serum half-life). In some embodiments, the bispecific binding proteins described herein comprise a half-life of at least about 14, 28, 42, 56, 70, 84, 96, or more than 96 weeks. In some embodiments, the binding protein described herein comprises a half-life in a range of about 14 days to about 96 days, about 14 days to about 84 days, about 14 days to about 70 days, about 14 days to about 56 days, about 14 days to about 42 days, about 14 days to about 28 days, of about 28 days to about 96 days, about 28 days to about 84 days, about 28 days to about 70 days, about 28 days to about 56 days, about 28 days to about 42 days, of about 42 days to about 96 days, about 42 days to about 84 days, about 42 days to about 70 days, or about 42 days to about 56 days. In some embodiments, the bispecific binding proteins described herein comprise a half-life in a range of about 42 days to about 56 days. In some embodiments, the bispecific binding proteins described herein comprise a half- life of at least about 50 days. In some embodiments, the bispecific binding proteins described herein comprise a half-life of about 50 days. Methods of measuring half-life are known in the art. In some embodiments, the half-life is measured in a non-human primate. In some embodiments, the half-life is measured in a human. In some embodiments, the half-life is measured following intravenous administration. In some embodiments, the half-life is measured following subcutaneous administration.

[0309] In some embodiments, the bispecific binding proteins described herein have a half-life that is at least 20% longer than a comparator antibody. In some embodiments, the IPTS / 200128829.1 266Attorney Docket No. CRSN-001WO comparator antibody comprises the same complementarity determining regions and variable regions but different Fc regions. In some embodiments, the half-life of the bispecific binding proteins described herein is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% longer than the half-life of the comparator antibody. In some embodiments, the half-life of the bispecific binding proteins described herein is longer than the half-life of the comparator antibody by at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold. Binding

[0310] The affinity of a molecule X for its partner Y can be represented by the dissociation equilibrium constant (KD). The kinetic components that contribute to the dissociation equilibrium constant are described in more detail below. Affinity can be measured by common methods known in the art, including those described herein, such as surface plasmon resonance (SPR) technology (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®).

[0311] With regard to the binding of an antibody to a target molecule, the terms “bind,” “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction (e.g., with a non-target molecule). Specific binding can be measured, for example, by measuring binding to a target molecule (i.e., VEGF or PD-1) and comparing it to binding to a non-target molecule. Specific binding can also be determined by competition with a control molecule that mimics the epitope recognized on the target molecule. In that case, specific binding is indicated if the binding of the antibody to the target molecule is competitively inhibited by the control molecule. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 50% of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 40% of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 40% of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 20% of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 10% of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 1% IPTS / 200128829.1 267Attorney Docket No. CRSN-001WO of the affinity for VEGF or PD-1. In some embodiments, the affinity of a binding protein disclosed here in for a non-target molecule is less than about 0.1% of the affinity for VEGF or PD-1.

[0312] When used herein in the context of two or more binding proteins, the term “competes with” or “cross-competes with” indicates that the two or more binding proteins compete for binding to an antigen (e.g., VEGF). In one exemplary assay, VEGF is coated on a surface and contacted with a first anti-VEGF antibody, after which a second anti-VEGF antibody is added. In another exemplary ass...

Claims

Attorney Docket No. CRSN-001WO CLAIMS 1. A programmed death receptor 1 (PD-1) binding protein a comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 456, 461, or 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 457 or 447; (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 458, 462, or 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 459 or 453; or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 460, 463, or 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 457 or 447, provided that: (i) if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 446, then CDR-H3 does not comprise the amino acid sequence of 447; (ii) if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 452, then CDR-H3 does not comprise the amino acid sequence of 453; and (iii) if CDR-H2 comprises the amino acid sequence of SEQ ID NO: 455, then CDR-H3 does not comprise the amino acid sequence of 447.

2. The PD-1 binding protein of claim 1, wherein the CDR-H1, CDR-H2, and CDR- H3 comprise the amino acid sequences of (a) SEQ ID NOs 445, 456, and 457, respectively; (b) SEQ ID NOs 451, 458, and 459, respectively; or (c) SEQ ID NOs 443, 460, and 457, respectively.

3. The PD-1 binding protein of claim 2, further comprising an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; IPTS / 200128829.1 332Attorney Docket No. CRSN-001WO CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

450.

4. The PD-1 binding protein of claim 3, wherein the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 302 and 335, respectively; (b) SEQ ID NOs: 302 and 336, respectively; (c) SEQ ID NOs: 302 and 340, respectively; (d) SEQ ID NOs: 302 and 342, respectively; (e) SEQ ID NOs: 302 and 343, respectively; (f) SEQ ID NOs: 302 and 346, respectively; (g) SEQ ID NOs: 306 and 337, respectively; (h) SEQ ID NOs: 306 and 339, respectively; (i) SEQ ID NOs: 306 and 341, respectively; (j) SEQ ID NOs: 306 and 344, respectively; (k) SEQ ID NOs: 306 and 345, respectively; (l) SEQ ID NOs: 306 and 347, respectively; (m) SEQ ID NOs: 308 and 340, respectively; (n) SEQ ID NOs: 309 and 341, respectively; (o) SEQ ID NOs: 310 and 336, respectively; (p) SEQ ID NOs: 311 and 337, respectively; (q) SEQ ID NOs: 313 and 336, respectively; (r) SEQ ID NOs: 313 and 342, respectively; (s) SEQ ID NOs: 313 and 343, respectively; (t) SEQ ID NOs: 316 and 337, respectively; (u) SEQ ID NOs: 316 and 344, respectively; (v) SEQ ID NOs: 316 and 345, respectively; (w) SEQ ID NOs: 318 and 336, respectively; IPTS / 200128829.1 333Attorney Docket No. CRSN-001WO (x) SEQ ID NOs: 318 and 340, respectively; (y) SEQ ID NOs: 318 and 346, respectively; (z) SEQ ID NOs: 319 and 336, respectively; (aa) SEQ ID NOs: 319 and 340, respectively; (bb) SEQ ID NOs: 319 and 346, respectively; (cc) SEQ ID NOs: 320 and 337, respectively; (dd) SEQ ID NOs: 320 and 341, respectively; (ee) SEQ ID NOs: 320 and 347, respectively; (ff) SEQ ID NOs: 320 and 743, respectively; (gg) SEQ ID NOs: 321 and 337, respectively; (hh) SEQ ID NOs: 321 and 341, respectively; or (ii) SEQ ID NOs: 321 and 347, respectively.

5. The PD-1 binding protein of claim 4, wherein the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences of: (a) SEQ ID NOs: 302 and 335, respectively; (b) SEQ ID NOs: 302 and 336, respectively; (c) SEQ ID NOs: 302 and 340, respectively; (d) SEQ ID NOs: 302 and 342, respectively; (e) SEQ ID NOs: 302 and 343, respectively; (f) SEQ ID NOs: 302 and 346, respectively; (g) SEQ ID NOs: 306 and 337, respectively; (h) SEQ ID NOs: 306 and 339, respectively; (i) SEQ ID NOs: 306 and 341, respectively; (j) SEQ ID NOs: 306 and 344, respectively; (k) SEQ ID NOs: 306 and 345, respectively; (l) SEQ ID NOs: 306 and 347, respectively; (m) SEQ ID NOs: 308 and 340, respectively; (n) SEQ ID NOs: 309 and 341, respectively; (o) SEQ ID NOs: 310 and 336, respectively; (p) SEQ ID NOs: 311 and 337, respectively; (q) SEQ ID NOs: 313 and 336, respectively; (r) SEQ ID NOs: 313 and 342, respectively; (s) SEQ ID NOs: 313 and 343, respectively; IPTS / 200128829.1 334Attorney Docket No. CRSN-001WO (t) SEQ ID NOs: 316 and 337, respectively; (u) SEQ ID NOs: 316 and 344, respectively; (v) SEQ ID NOs: 316 and 345, respectively; (w) SEQ ID NOs: 318 and 336, respectively; (x) SEQ ID NOs: 318 and 340, respectively; (y) SEQ ID NOs: 318 and 346, respectively; (z) SEQ ID NOs: 319 and 336, respectively; (aa) SEQ ID NOs: 319 and 340, respectively; (bb) SEQ ID NOs: 319 and 346, respectively; (cc) SEQ ID NOs: 320 and 337, respectively; (dd) SEQ ID NOs: 320 and 341, respectively; (ee) SEQ ID NOs: 320 and 347, respectively; (ff) SEQ ID NOs: 320 and 743, respectively; (gg) SEQ ID NOs: 321 and 337, respectively; (hh) SEQ ID NOs: 321 and 341, respectively; or (ii) SEQ ID NOs: 321 and 347, respectively.

6. The PD-1 binding protein of claim 1, wherein the CDR-H1, CDR-H2, and CDR- H3 comprise the amino acid sequences of (a) SEQ ID NOs 445, 456, and 447, respectively; (b) SEQ ID NOs 451, 458, and 453, respectively; or (c) SEQ ID NOs 443, 460, and 447, respectively.

7. The PD-1 binding protein of claim 6, further comprising an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

450. IPTS / 200128829.1 335Attorney Docket No. CRSN-001WO 8. The PD-1 binding protein of claim 7, wherein the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 303 and 336, respectively; (b) SEQ ID NOs: 325 and 347, respectively; or (c) SEQ ID NOs: 325 and 743, respectively.

9. The PD-1 binding protein of claim 8, wherein the anti-PD-1 VHand anti-PD-1 VLhave amino acid sequences of: (a) SEQ ID NOs: 303 and 336, respectively; (b) SEQ ID NOs: 325 and 347, respectively; or (c) SEQ ID NOs: 325 and 743, respectively.

10. The PD-1 binding protein of claim 1, wherein the CDR-H1, CDR-H2, and CDR- H3 comprise the amino acid sequences of (a) SEQ ID NOs 445, 461, and 447, respectively; (b) SEQ ID NOs 451, 462, and 453, respectively; or (c) SEQ ID NOs 443, 463, and 447, respectively.

11. The PD-1 binding protein of claim 10, further comprising an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

450.

12. The PD-1 binding protein of claim 11, wherein the anti-PD-1 VHand anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 326 and 347, respectively; or (b) SEQ ID NOs: 326 and 743, respectively.

13. The PD-1 binding protein of claim 12, wherein the anti-PD-1 VHand anti-PD-1 VL have amino acid sequences of: (a) SEQ ID NOs: 326 and 347, respectively; or IPTS / 200128829.1 336Attorney Docket No. CRSN-001WO (b) SEQ ID NOs: 326 and 743, respectively.

14. The PD-1 binding protein of claim 1, wherein the CDR-H1, CDR-H2, and CDR- H3 comprise the amino acid sequences of (a) SEQ ID NOs 445, 446, and 457, respectively; (b) SEQ ID NOs 451, 452, and 459, respectively; or (c) SEQ ID NOs 443, 455, and 457, respectively.

15. The PD-1 binding protein of claim 14, further comprising an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (e) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (f) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

450.

16. The PD-1 binding protein of claim 14, wherein the anti-PD-1 VH and anti-PD-1 VLhave amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 327 and 347, respectively; or (b) SEQ ID NOs: 327 and 743, respectively.

17. The PD-1 binding protein of claim 15, wherein the anti-PD-1 VH and anti-PD-1 VLhave amino acid sequences of: (a) SEQ ID NOs: 327 and 347, respectively; or (b) SEQ ID NOs: 327 and 743, respectively.

18. The PD-1 binding protein of claim 1, wherein the CDR-H1, CDR-H2, and CDR- H3 comprise the amino acid sequences of (a) SEQ ID NOs 445, 461, and 457, respectively; (b) SEQ ID NOs 451, 462, and 459, respectively; or (c) SEQ ID NOs 443, 463, and 457, respectively.

19. The PD-1 binding protein of claim 18, further comprising an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementarity-determining regions: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; IPTS / 200128829.1 337Attorney Docket No. CRSN-001WO CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

450.

20. The PD-1 binding protein of claim 19, wherein the anti-PD-1 VH and anti-PD-1 VLhave amino acid sequences that are at least 85% identical to that of: (a) SEQ ID NOs: 303 and 335, respectively; (b) SEQ ID NOs: 303 and 342, respectively; (c) SEQ ID NOs: 303 and 343, respectively; (d) SEQ ID NOs: 307 and 337, respectively; (e) SEQ ID NOs: 307 and 344, respectively; (f) SEQ ID NOs: 307 and 345, respectively; (g) SEQ ID NOs: 314 and 336, respectively; (h) SEQ ID NOs: 314 and 342, respectively; (i) SEQ ID NOs: 314 and 343, respectively; (j) SEQ ID NOs: 317 and 337, respectively; (k) SEQ ID NOs: 317 and 344, respectively; (l) SEQ ID NOs: 317 and 345, respectively; or (m) SEQ ID NOs: 324 and 347, respectively.

21. The PD-1 binding protein of claim 20, wherein the anti-PD-1 VH and anti-PD-1 VLhave amino acid sequences of: (a) SEQ ID NOs: 303 and 335, respectively; (b) SEQ ID NOs: 303 and 342, respectively; (c) SEQ ID NOs: 303 and 343, respectively; (d) SEQ ID NOs: 307 and 337, respectively; (e) SEQ ID NOs: 307 and 344, respectively; (f) SEQ ID NOs: 307 and 345, respectively; (g) SEQ ID NOs: 314 and 336, respectively; (h) SEQ ID NOs: 314 and 342, respectively; IPTS / 200128829.1 338Attorney Docket No. CRSN-001WO (i) SEQ ID NOs: 314 and 343, respectively; (j) SEQ ID NOs: 317 and 337, respectively; (k) SEQ ID NOs: 317 and 344, respectively; (l) SEQ ID NOs: 317 and 345, respectively; or (m) SEQ ID NOs: 324 and 347, respectively.

22. The PD-1 binding protein of any one of claims 3, 7, 11, 15, or 19, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence at least 85% identical to that within any one of SEQ ID NO: 464-470; and (b) the anti-PD-1 VL has a framework having an amino acid sequence at least 85% identical to that within any one of SEQ ID NO: 471-476.

23. The PD-1 binding protein of claim 22, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within any one of SEQ ID NO: 464-470; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within any one of SEQ ID NO: 471-476.

24. The PD-1 binding protein of any one of claims 3, 7, 11, 15, or 19, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

471.

25. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

472.

26. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

471.

27. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and IPTS / 200128829.1 339Attorney Docket No. CRSN-001WO (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

473.

28. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 464; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

472.

29. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

473.

30. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 464; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

474.

31. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 464; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

475.

32. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

471.

33. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 467; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

474.

34. The PD-1 binding protein of claim 23, wherein IPTS / 200128829.1 340Attorney Docket No. CRSN-001WO (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

475.

35. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

471.

36. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

474.

37. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

475.

38. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 466; and (b) the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO:

471.

39. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 470; and (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

474.

40. The PD-1 binding protein of claim 23, wherein (a) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 469; and IPTS / 200128829.1 341Attorney Docket No. CRSN-001WO (b) the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

476.

41. The PD-1 binding protein of claim 22, wherein: (i) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution, (ii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (iii)the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution, (iv) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution, (v) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution, (vi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (vii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (viii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and IPTS / 200128829.1 342Attorney Docket No. CRSN-001WO the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (ix) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (x) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (xii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (xiii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xiv) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xv) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 466 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, or (xvi) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 470 except for one amino acid substitution; and IPTS / 200128829.1 343Attorney Docket No. CRSN-001WO the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, wherein the one amino acid substition in the VH is from a non-cysteine residue to a cysteine residue and the one amino acid substition in the VLis from a non-cysteine residue to a cysteine residue.

42. The PD-1 binding protein of claim 41, wherein the one amino acid substition in the anti- PD-1 VH is at residue H44 and the one amino acid substition in the anti-PD-1 VL is at residue L100, wherein numbering is according to Kabat.

43. A PD-1 binding protein comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 447, respectively; (2) SEQ ID NOs 451, 458, and 453, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and (b) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively.

44. The PD-1 binding protein of claim 43, wherein (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 325; and (b) the anti-PD-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

347.

45. The PD-1 binding protein of claim 44, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 325; and (b) the anti-PD-1 VLhas an amino acid sequence of SEQ ID NO:

347.

46. A PD-1 binding protein comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 457, respectively; (2) SEQ ID NOs 451, 458, and 459, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and IPTS / 200128829.1 344Attorney Docket No. CRSN-001WO (b) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively.

47. The PD-1 binding protein of claim 46, wherein (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 320; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO:

347.

48. The PD-1 binding protein of claim 47, wherein (a) the anti-PD-1 VHhas an amino acid sequence of SEQ ID NO: 320; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO:

347.

49. A PD-1 binding protein comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 457, respectively; (2) SEQ ID NOs 451, 462, and 459, respectively; or (3) SEQ ID NOs 443, 463, and 457, respectively, and (b) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively.

50. The PD-1 binding protein of claim 49, wherein (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 324; and (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO:

347.

51. The PD-1 binding protein of claim 50, wherein (a) the anti-PD-1 VHhas an amino acid sequence of SEQ ID NO: 324; and (b) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO:

347.

52. A PD-1 binding protein comprising IPTS / 200128829.1 345Attorney Docket No. CRSN-001WO (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 447, respectively; (2) SEQ ID NOs 451, 462, and 453, respectively; or (3) SEQ ID NOs 443, 463, and 447, respectively, and (b) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively.

53. The PD-1 binding protein of claim 52, wherein (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 326; and (b) the anti-PD-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

347.

54. The PD-1 binding protein of claim 53, wherein (c) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 326; and (d) the anti-PD-1 VL has an amino acid sequence of SEQ ID NO:

347.

55. A PD-1 binding protein comprising (a) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 446, and 457, respectively; (2) SEQ ID NOs 451, 452, and 459, respectively; or (3) SEQ ID NOs 443, 455, and 457, respectively, and (b) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively.

56. The PD-1 binding protein of claim 55, wherein (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 327; and IPTS / 200128829.1 346Attorney Docket No. CRSN-001WO (b) the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO:

347.

57. The PD-1 binding protein of claim 56, wherein (a) the anti-PD-1 VHhas an amino acid sequence of SEQ ID NO: 327; and (b) and the anti-PD-1 VL has an amino acid sequence of SEQ ID NO:

347.

58. A programmed death receptor 1 (PD-1) binding protein comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein: [0226] (1) the anti-PD-1 VH comprises complementary determining regions (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 453; or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; (2) the anti-PD-1 VLcomprises complementary determining regions (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein (i) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 472, IPTS / 200128829.1 347Attorney Docket No. CRSN-001WO (ii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471, (iii)the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473, (iv) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 472, (v) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473, (vi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 474, (vii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, (viii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471, (ix) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 474, (x) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 467; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, (xi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471, (xii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474, IPTS / 200128829.1 348Attorney Docket No. CRSN-001WO (xiii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 475, (xiv) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475, (xv) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 466; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471, or (xvi) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 470; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO:

474.

59. A programmed death receptor 1 (PD-1) binding protein comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein [0227] (1) the anti-PD-1 VH comprises complementary determining regions (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 453; or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447, (2) the anti-PD-1 VL comprises complementary determining regions (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; IPTS / 200128829.1 349Attorney Docket No. CRSN-001WO CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein (i) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution, (ii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (iii)the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 465 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution, (iv) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 472 except for one amino acid substitution, (v) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 473 except for one amino acid substitution, (vi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (vii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 464 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (viii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and IPTS / 200128829.1 350Attorney Docket No. CRSN-001WO the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (ix) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (x) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 467 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xi) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, (xii) the anti-PD-1 VH has a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, (xiii) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xiv) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 468 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 475 except for one amino acid substitution, (xv) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 466 except for one amino acid substitution; and the anti-PD-1 VLhas a framework having an amino acid sequence of that within SEQ ID NO: 471 except for one amino acid substitution, or (xvi) the anti-PD-1 VHhas a framework having an amino acid sequence of that within SEQ ID NO: 470 except for one amino acid substitution; and IPTS / 200128829.1 351Attorney Docket No. CRSN-001WO the anti-PD-1 VL has a framework having an amino acid sequence of that within SEQ ID NO: 474 except for one amino acid substitution, [0228] wherein the one amino acid substition in the VH is from a non- cysteine residue to a cysteine residue and the one amino acid substition in the VL is from a non-cysteine residue to a cysteine residue.

60. The PD-1 binding protein of claim 59, wherein the one amino acid substition in the anti- PD-1 VH is at residue H44 and the one amino acid substition in the anti-PD-1 VL is at residue L100, wherein numbering is according to Kabat.

61. A programmed death receptor 1 (PD-1) binding protein comprising an anti-PD1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) and an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL), wherein: (1) the anti-PD-1 VHcomprises complementary determining regions (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 445; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 446; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 451; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 452; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 453; or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 455; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 447; (2) the anti-PD-1 VL comprises complementary determining regions (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 454; CDR-L2 comprising the amino acid sequence of LAS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 448; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 449; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 450, and wherein the anti-PD-1 VH and anti-PD-1 VL have amino acid sequences that are at least 85% identical to that of: IPTS / 200128829.1 352Attorney Docket No. CRSN-001WO (a) SEQ ID NOs: 301 and 335, respectively; (b) SEQ ID NOs: 301 and 336, respectively; (c) SEQ ID NOs: 301 and 342, respectively; (d) SEQ ID NOs: 301 and 343, respectively; (e) SEQ ID NOs: 301 and 348, respectively; (f) SEQ ID NOs: 305 and 337, respectively; (g) SEQ ID NOs: 305 and 344, respectively; (h) SEQ ID NOs: 305 and 345, respectively; (i) SEQ ID NOs: 312 and 335, respectively; (j) SEQ ID NOs: 312 and 336, respectively; (k) SEQ ID NOs: 312 and 342, respectively; (l) SEQ ID NOs: 312 and 343, respectively; (m) SEQ ID NOs: 315 and 337, respectively; (n) SEQ ID NOs: 315 and 344, respectively; (o) SEQ ID NOs: 315 and 345, respectively; (p) SEQ ID NOs: 322 and 346, respectively; (q) SEQ ID NOs: 323 and 347, respectively; or (r) SEQ ID NOs: 323 and 743, respectively.

62. The PD-1 binding protein of claim 61, wherein the anti-PD-1 VHand anti-PD-1 VLhave amino acid sequences of: (a) SEQ ID NOs: 301 and 335, respectively; (b) SEQ ID NOs: 301 and 336, respectively; (c) SEQ ID NOs: 301 and 342, respectively; (d) SEQ ID NOs: 301 and 343, respectively; (e) SEQ ID NOs: 301 and 348, respectively; (f) SEQ ID NOs: 305 and 337, respectively; (g) SEQ ID NOs: 305 and 344, respectively; (h) SEQ ID NOs: 305 and 345, respectively; (i) SEQ ID NOs: 312 and 335, respectively; (j) SEQ ID NOs: 312 and 336, respectively; (k) SEQ ID NOs: 312 and 342, respectively; (l) SEQ ID NOs: 312 and 343, respectively; (m) SEQ ID NOs: 315 and 337, respectively; IPTS / 200128829.1 353Attorney Docket No. CRSN-001WO (n) SEQ ID NOs: 315 and 344, respectively; (o) SEQ ID NOs: 315 and 345, respectively; (p) SEQ ID NOs: 322 and 346, respectively; (q) SEQ ID NOs: 323 and 347, respectively; or (r) SEQ ID NOs: 323 and 743, respectively.

63. The PD-1 binding protein of claim of any one of claims 1-62, further comprising an Fc region.

64. The PD-1-binding protein of claim 63, wherein the Fc region comprises a means for extending the half-life of the PD-1 binding protein.

65. The PD-1 binding protein of claim 64, wherein the half-life extending means comprises an Fc modification.

66. The PD-1-binding protein of claim 65, wherein the Fc modification is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).

67. The PD-1 binding protein of claim 66, wherein the Fc modification is M252Y / S254T / T256E (YTE) or M428L / N434S (LS).

68. The PD-1 binding protein of claim 67, wherein the Fc modification is M428L / N434S (LS).

69. The PD-1 binding protein of any one of claims 63-68, wherein the Fc region is an IgG1, IgG2, or IgG4 Fc region.

70. The PD-1 binding protein of any one of claims 1-69, wherein the PD-1 binding protein is an antibody or antigen-binding fragment thereof.

71. The PD-1 binding protein of claim 70, wherein the PD-1 binding protein is a human or humanized antibody or antigen-binding fragment thereof.

72. The PD-1 binding protein of claim 70 or 71, wherein the antigen-binding fragment is a Fab, a F(ab’)2, a Fab’, a single-chain Fv (scFv), an Fv fragment, a Fd fragment, or a diabody.

73. A bispecific protein comprising a PD-1 binding protein of any one of claims 1-72, further comprising a VEGF-binding region comprising an anti-VEGF immunoglobulin heavy chain variable domain (anti-VEGF VH) comprising complementary determining regions (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 433; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 434; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 435; IPTS / 200128829.1 354Attorney Docket No. CRSN-001WO (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 439; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 440; and CDR-H3 comprising the amino acid sequence of SEQ ID NO: 441; or (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 443; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 444; and CDR-H3 comprising the amino acid sequence of SEQ ID NO:

435.

74. The bispecific protein of claim 73, further comprising an anti-VEGF immunoglobulin light chain variable domain (anti-VEGF VL) comprising complementarity-determining regions: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 436; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 437; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 438; (b) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 442; CDR-L2 comprising the amino acid sequence of FTS; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 438; or (c) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 436; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 437; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

438.

75. The bispecific protein of claim 73 or 74, wherein the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

76. The bispecific protein of claim 75, wherein the anti-VEGF VHhas an amino acid sequence of SEQ ID NO: 431; and the anti-VEGF-1 VL has an amino acid of SEQ ID NO:

432.

77. A bispecific protein comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 447, respectively; (2) SEQ ID IPTS / 200128829.1 355Attorney Docket No. CRSN-001WO NOs 451, 458, and 453, respectively; or (3) SEQ ID NOs 443, 460, and 447, respectively, and (ii) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti- VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti- VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

78. The bispecific protein of claim 77, wherein the (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 325; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

79. The bispecific protein of claim 78, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 325; and the anti- PD-1 VLhas an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti- VEGF-1 VLhas an amino acid sequence of SEQ ID NO:

432. IPTS / 200128829.1 356Attorney Docket No. CRSN-001WO 80. A bispecific protein comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 456, and 457, respectively; (2) SEQ ID NOs 451, 458, and 459, respectively; or (3) SEQ ID NOs 443, 460, and 457, respectively, and (ii) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti- VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti- VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

81. The bispecific protein of claim 80, wherein the (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 320; and the anti-PD-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and IPTS / 200128829.1 357Attorney Docket No. CRSN-001WO (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

82. The bispecific protein of claim 81, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 320; and the anti- PD-1 VLhas an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti- VEGF-1 VLhas an amino acid sequence of SEQ ID NO:

432.

83. A bispecific protein comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 457, respectively; (2) SEQ ID NOs 451, 462, and 459, respectively; or (3) SEQ ID NOs 443, 463, and 457, respectively, and (ii) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti- VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and IPTS / 200128829.1 358Attorney Docket No. CRSN-001WO (ii) an anti-VEGF immunoglobulin light chain variable domain (anti- VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

84. The bispecific protein of claim 83, wherein the (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 324; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

85. The bispecific protein of claim 84, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 324; and the anti- PD-1 VL has an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti- VEGF-1 VL has an amino acid sequence of SEQ ID NO:

432.

86. A bispecific protein comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 461, and 447, respectively; (2) SEQ ID NOs 451, 462, and 453, respectively; or (3) SEQ ID NOs 443, 463, and 447, respectively, and (ii) an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and IPTS / 200128829.1 359Attorney Docket No. CRSN-001WO (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti- VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti- VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

87. The bispecific protein of claim 86, wherein the (a) the anti-PD-1 VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 326; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

88. The bispecific protein of claim 87, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 326; and the anti- PD-1 VLhas an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti- VEGF-1 VLhas an amino acid sequence of SEQ ID NO:

432.

89. A bispecific protein comprising a PD-1 binding region and a VEGF-binding region, wherein (a) the PD-1 binding region comprises (i) an anti-PD-1 immunoglobulin heavy chain variable domain (anti-PD-1 VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs 445, 446, and 457, respectively; (2) SEQ ID IPTS / 200128829.1 360Attorney Docket No. CRSN-001WO NOs 451, 452, and 459, respectively; or (3) SEQ ID NOs 443, 455, and 457, respectively, and (ii) (an anti-PD1 immunoglobulin light chain variable domain (anti-PD-1 VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs 448, 449, and 450, respectively; (2) SEQ ID NO: 454, LAS, and SEQ ID NO: 450, respectively; or (3) SEQ ID NOs 448, 449, and 450 respectively; and (b) the VEGF-binding region comprises (i) an anti-VEGF immunoglobulin heavy chain variable domain (anti- VEGF VH) comprising complementary determining regions CDR-H1, CDR-H2, and CDR-H3 which comprise the amino acid sequences of (1) SEQ ID NOs: 433, 434, and 435, respectively; (2) SEQ ID NOs: 439, 440, and 441, respectively; or (3) SEQ ID NOs: 443, 444, and 435, respectively, and (ii) an anti-VEGF immunoglobulin light chain variable domain (anti- VEGF VL) comprising complementary determining regions CDR-L1, CDR-L2, and CDR-L3 which comprise the amino acid sequences of (1) SEQ ID NOs: 436, 437, and 438, respectively; (2) SEQ ID NO: 442, FTS, and SEQ ID NO: 438, respectively; or (3) SEQ ID NOs: 436, 437, and 438, respectively.

90. The bispecific protein of claim 89, wherein the (a) the anti-PD-1 VHhas an amino acid sequence at least 85% identical to that of SEQ ID NO: 327; and the anti-PD-1 VL has an amino acid sequence at least 85% identical to that of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence at least 85% identical to that of SEQ ID NO: 431; and the anti-VEGF-1 VLhas an amino acid sequence at least 85% identical to that of SEQ ID NO:

432.

91. The bispecific protein of claim 90, wherein (a) the anti-PD-1 VH has an amino acid sequence of SEQ ID NO: 327; and the anti- PD-1 VLhas an amino acid sequence of SEQ ID NO: 347; and (b) the anti-VEGF VH has an amino acid sequence of SEQ ID NO: 431; and the anti- VEGF-1 VLhas an amino acid sequence of SEQ ID NO:

432. IPTS / 200128829.1 361Attorney Docket No. CRSN-001WO 92. The bispecific protein of claim of any one of claims 73-91, further comprising an Fc region.

93. The bispecific protein of claim 92, wherein the Fc region comprises a means for extending the half-life of the PD-1 binding protein.

94. The bispecific protein of claim 93, wherein the half-life extending means comprises an Fc modification.

95. The bispecific protein of claim 94, wherein the Fc modification is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).

96. The bispecific protein of claim 95, wherein the Fc modification is M252Y / S254T / T256E (YTE) or M428L / N434S (LS).

97. The bispecific protein of claim 96, wherein the Fc modification is M428L / N434S (LS).

98. The bispecific protein of any one of claims 92-97, wherein the Fc region is an IgG1, IgG2, or IgG4 Fc region.

99. The bispecific protein of any one of claims 73-98, wherein the bispecific protein is an antibody or antigen-binding fragment thereof.

100. The bispecific protein of claim 99, wherein the bispecific protein is a human or humanized antibody or antigen-binding fragment thereof.

101. The bispecific protein of claim 99 or 100, wherein the antigen-binding fragment is a Fab, a F(ab’)2, a Fab’, a single-chain Fv (scFv), an Fv fragment, a Fd fragment, or a diabody.

102. The bispecific protein of any one of claims 73-101, comprising two PD-1 binding regions and two VEGF binding regions.

103. The bispecific protein of any one of claims 73-101, comprising two PD-1 binding regions and one VEGF binding region.

104. The bispecific protein of any one of claims 73-101, comprising one PD-1 binding region and two VEGF binding regions.

105. The bispecific protein of any one of claims 102-104, wherein each PD-1 binding region is an scFv.

106. The bispecific protein of claim 105, wherein each VEGF binding region comprises an anti-VEGF VHon a first polypeptide chain and an anti-VEGF VLon a second polypeptide chain, an anti-VEGF VH and an anti-VEGF VL within a Fab, or an anti-VEGF VH and an anti-VEGF VLwithin a CrossFab. IPTS / 200128829.1 362Attorney Docket No. CRSN-001WO 107. The bispecific protein of any one of claims 102-104, wherein each VEGF binding region is an scFv.

108. The bispecific protein of claim 107, wherein each PD-1 binding region comprises an anti-PD1 VHon a first polypeptide chain and an anti-PD1 VLon a second polypeptide chain, an anti-PD1 VH and an anti-PD1 VL within a Fab, or an anti-PD1 VH and an anti- PD1 VLwithin a CrossFab.

109. The bispecific protein of any one of claims 102-104, wherein each PD-1 binding region is a VHH.

110. The bispecific protein of claim 109, wherein each VEGF binding region comprises an anti-VEGF VHon a first polypeptide chain and an anti-VEGF VLon a second polypeptide chain, an anti-VEGF VH and an anti-VEGF VL within a Fab, or an anti-VEGF VH and an anti-VEGF VLwithin a CrossFab.

111. A bispecific protein comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 92 and a second polypeptide chain having the sequence of SEQ ID NO:

239.

112. A bispecific protein comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 73 and a second polypeptide chain having the sequence of SEQ ID NO:

220.

113. A bispecific protein comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 91 and a second polypeptide chain having the sequence of SEQ ID NO:

238.

114. A bispecific protein comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 94 and a second polypeptide chain having the sequence of SEQ ID NO:

241.

115. A bispecific protein comprising at least one PD-1 binding region and at least one VEGF-binding region, comprising a first polypeptide chain having the sequence of SEQ ID NO: 96 and a second polypeptide chain having the sequence of SEQ ID NO:

243.

116. A dimer of the bispecific protein of any one of claims 111-115.

117. An isolated nucleic acid encoding one or more chains of the PD-1 binding protein of any one of claims 1-72 or of the bispecific protein of any one of claims 73-116.

118. An expression vector comprising the isolated nucleic acid of claim 117.

119. A host cell comprising the isolated nucleic acid of claim 117 or the expression vector of claim 118. IPTS / 200128829.1 363Attorney Docket No. CRSN-001WO 120. A set of isolated nucleic acids collectively encoding the PD-1 binding protein of any one of claims 1-72 or of the bispecific protein of any one of claims 73-116.

121. A set of expression vectors collectively comprising the set of isolated nucleic acids of claim 120.

122. A host cell comprising the set of isolated nucleic acids of claim 120 or the set of expression vectors of claim 121.

123. A pharmaceutical composition comprising the PD-1 binding protein of any one of claims 1-72 or of the bispecific protein of any one of claims 73-116 and a pharmaceutically acceptable carrier.

124. A method comprising a step of administering to a subject in need thereof an effective amount of the PD-1 binding protein of any one of claims 1-72, the bispecific protein of any one of claims 73-116, or the pharmaceutical composition of claim 123.

125. The method of claim 124, wherein the subject has or is at risk of having a disease or condition associated with aberrant PD-1 and / or VEGF expression or signaling.

126. The method of claim 125, wherein the disease or condition is a cancer.

127. The method of claim 126, wherein the cancer is a lung cancer.

128. The method of claim 127, wherein the lung cancer is non-small cell lung cancer.

129. The method of claim 126, wherein the cancer is a gastrointestinal cancer.

130. The method of claim 129, wherein the gastrointestinal cancer is colorectal cancer, biliary cancer, gastric cancer, or hepatocellular cancer.

131. The method of claim 126, wherein the cancer is a reproductive cancer.

132. The method of claim 131, wherein the reproductive cancer is cervical cancer, endometrial cancer, or ovarian cancer.

133. The method of any one of claims 124-132, wherein the step of administering comprises systemic administration of the PD-1 binding protein, the bispecific protein, or the pharmaceutical composition.

134. The method of claim 133, wherein systemic administration comprises intravenous administration of the PD-1 binding protein, the bispecific protein, or the pharmaceutical composition.

135. The method of claim 133, wherein systemic administration comprises subcutaneous administration of the PD-1 binding protein, the bispecific protein, or the pharmaceutical composition. IPTS / 200128829.1 364

Images